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Abstract.
The primary aim of this thesis was to characterise the metabolism of apoB containing 
lipoproteins in various dyslipidaemic states, using stable isotope methodology and 
multicompartmental modelling techniques. Human apoB kinetics have been 
extensively studied in normolipidaemic subjects, both using radio-isotope 
methodology and, more recently, using stable isotope techniques. Radio-isotopes have 
also been widely used to study various dyslipidaemias, but the use of stable isotopes 
in such conditions is more limited.
To provide a basis on which to understand lipid and lipoprotein metabolism in 
dyslipidaemias, a non-kinetic study of 95 normolipidaemic individuals was 
performed. Eighty of these subjects were healthy (41 males and 39 females) with the 
remaining 15 being sufferers of coronary heart disease (CHD). The relationships 
between the subtractions of VLDL, LDL and HDL and indices of obesity, insulin 
resistance and lipase activity were established. In particular, differences between the 
sexes and between the healthy group and the CHD sufferers were noted. The main 
observation of this study was that even within the normal range of plasma lipid levels 
(cholesterol<6.0mmol/l, triglyceride<2.0mmol/l) several subgroups of differing lipid 
patterns appear to exist. Plasma triglyceride appeared to play a strong role in 
determining measured lipoprotein profiles and hence risk for CHD. Those subjects 
with marginally higher triglyceride levels tended to have lower levels of HDL 
cholesterol and higher levels of the small, dense species of LDL (primarily LDLIII). 
Thus they could be described as having the Atherogenic Lipoprotein Phenotype 
despite having plasma triglyceride levels within the normal range. The likely causes 
of the marginal increase in triglycerides were highlighted by further comparing the 
subgroups. Relatively obese individuals, as determined by increased body mass 
indices and waistihip ratios, and those with a tendency towards insulin resistance, as 
determined by increased fasting glucose and insulin levels, had higher triglyceride 
levels and a trend towards developing the atherogenic lipoprotein phenotype. Those 
individuals most strongly exhibiting these features were the 15 subjects already 
suffering from CHD. The influence of sex on the lipoproteins appears to be mediated 
through the lipolytic enzymes, in particular hepatic lipase which has a higher activity 
in men than women. From this study a metabolic model was drawn, with particular 
reference to the factors that may influence lipoprotein secretion and their further 
metabolism. This in turn directed the kinetic studies to look in particular at the nature 
of the apoB containing lipoprotein being predominantly secreted, i.e. triglyceride-rich 
VLDL! or relatively cholesterol-rich VLDL2.
Kinetic studies of the metabolism of apoB containing lipoproteins were then 
performed in certain dyslipidaemic states. Subjects with heterozygous familial 
hypercholesterolaemia (FH) were compared to subjects heterozygous for familial 
defective apoB-100 (FDB), as in both conditions there is a disruption of receptor- 
mediated LDL catabolism. Both exhibited the expected reduced catabolic rate of 
LDL, but in addition there was reduced transfer of the lipoproteins down the 
delipidation chain, possibly as a result of the nature of the lipoproteins being produced 
by the liver or due to a disruption of receptor-lipase interaction. In FH there was a
reduced catabolism of LDL precursors that was not seen in FDB, probably reflecting 
normal apoE-mediated clearance in FDB.
Two rare and very different subjects were then studied. A hypobetalipoproteinaemic 
subject, with very low levels of plasma cholesterol and apoB, showed greatly reduced 
hepatic lipoprotein production, in particular VLDL production, possibly as a 
consequence of a genetic defect in apoB. In contrast, in a unique study of an 
analbuminaemic subject, massive overproduction of VLDL2 was shown to be the 
cause of the grossly elevated plasma cholesterol and apoB levels. This secondary 
hyperlipidaemia reflects a compensatory response to negligible plasma albumin 
levels, identifying a further factor that is influential in apoB metabolism.
The kinetics of apoB in mixed hyperlipidaemia were studied in seven individuals with 
plasma cholesterol levels of 6.0-9.0mmol/l and triglyceride of 2.0-4.0mmol/l. These 
subjects, with only moderate elevations in their plasma lipids, showed an increase in 
total apoB production, specifically VLDLj production, a decrease in the transfer of 
apoB down the delipidation chain, and decreases in the catabolism of VLDL! and 
LDL. Further analysis suggested that it is the production of VLDLj as the 
predominant lipoprotein (manifest as elevated plasma triglycerides) that influences the 
further metabolism of the apoB.
Finally, the mechanisms of action of two HMG-CoA reductase inhibitors, simvastatin 
and atorvastatin, were compared in the mixed hyperlipidaemic group. This type of 
dyslipidaemia is more usually treated with one of the fibrate class of drug but the 
triglyceride-lowering action of the HMG-CoA reductase inhibitors was particularly 
under study here. In addition to the expected increase in LDL catabolism, these drugs 
(notably atorvastatin) had surprising effects on VLDLj metabolism. Treatment caused 
an increase in both VLDLj production and catabolism, seemingly resulting in ‘futile 
cycling’ of triglyceride. In addition, atorvastatin caused a shift in the LDL subfraction 
profiles from those of mainly small, dense LDL to a predominance of the larger, less 
dense species. This is presumably due to the triglyceride-lowering action of 
atorvastatin, an effect that has previously only been reported for the fibrates.
The results of the above studies were drawn together in a scheme describing the 
regulation of apoB metabolism. It was suggested that obesity and insulin resistance 
cause the liver to become relatively triglyceride-rich, whilst analbuminaemia may 
increase the cholesterol ester content. The intrahepatic lipid content in turn determines 
the amount and type of lipoprotein secreted - triglyceride-rich VLDLj or relatively 
cholesterol-rich VLDL2. The VLDL particles have different metabolic properties with 
VLDLj being relatively slowly metabolised to form predominantly small, dense LDL, 
whilst VLDL2 is more rapidly metabolised to the larger species of LDL. Hepatic 
lipase also has an effect on the LDL subfractions by catalyzing the interconversion 
from LDLI to LDLIII. The different LDL species are then catabolised at different 
rates with LDLI being cleared more avidly by the receptor than LDLIII.
In conclusion, this work characterises the metabolism of apoB containing lipoproteins 
in a number of dyslipidaemic states, and in so doing highlights points of regulation of 
apoB kinetics namely, intrahepatic lipid availability, the nature of the particle
secreted, and the subsequent metabolism of the lipoproteins. It is clear that stable 
isotope methodology and multicompartmental modelling techniques have tremendous 
potential in the further elucidation of the causes of dyslipidaemia and the mechanism 
of action of lipid-lowering therapy.
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1Chapter 1 Introduction.
1.1 Hyperlipidaemia. Atherosclerosis and Coronary Heart Disease.
Coronary heart disease (CHD) is currently responsible for the majority of morbidity 
and mortality in most developed countries, with mortality rates from CHD in the 
United Kingdom, in particular Scotland, being amongst the highest in the world.
Over one hundred years ago Marchand coined the term atheroma or atherosclerosis to 
describe the pathological feature now familiar to us as the major cause of CHD 
(Aschoff 1924). He took the term from the Greek, athere meaning gruel, oma 
meaning mass and skleros meaning hard. In 1847 his contemporary, Vogel, described 
the principal histological characteristic of these lesions, that of lipid accumulation, 
predominantly cholesterol, in the arterial wall.
Keele (1952) credits Leonardo da Vinci (1452-1519) as giving us the first theory on 
the pathogenesis of atherosclerosis when, whilst illustrating an autopsy of an elderly 
man, he suggested it may be caused by ‘excessive nourishment’ from the blood. This 
euphemistic term for hyperlipidaemia serves to remind us that lipids are not purely 
pathological but do have a physiological function in the ‘nourishment’ of cells. It is, 
however, ironic that Marchand’s terminology for this excessive nourishment could be 
equally well applied to the traditional diet of many Scots, namely porridge: a mass of 
hard gruel.
1.1.1 Epidemiology and Risk Factors.
Research throughout this century has further elaborated on the link between lipids and 
atherosclerosis formation, confirming the direct relationship between elevated plasma 
cholesterol levels and CHD development. Large epidemiological studies have done 
much to identify risk factors for CHD. Perhaps one of the most famous of these is the 
Framingham Study - a prospective, observational study, set up in 1948, and now 
studying the off-spring of the original subjects (Wilson and Castelli 1989). This study 
was responsible for the identification of many of the now accepted risk factors for 
CHD, such as hypercholesterolaemia, hypertension, cigarette smoking and a low level 
of high density lipoprotein (HDL) cholesterol. It also highlighted the fact that these 
factors are not additive but multiplicative in increasing the risk for CHD development. 
Male sex and increasing age were observed to have higher associated incidences of 
CHD, with the incidence for women catching up with that for men post-menopausally.
From this study came interesting observations on the various cholesterol levels at 
which CHD was more common. Approximately 50% of CHD events occurred at 
cholesterol levels of 5.28-6.80mmol/l - a sobering observation given the average 
cholesterol level in Scotland of 6.4mmol/l. Only 20% of events in men and 45% of 
events in women occurred at levels above 6.80mmol/l. CHD events below 5.28mmol/l 
were 25% and 10% in men and women respectively. From this and other studies has 
emerged the threshold cholesterol value of 5.20mmol/l. An individual cholesterol 
level below this value is said to be ideal for minimising the risk of CHD development.
2However, the Multiple Risk Factor Intervention Trial, MRFIT, demonstrated that 
there is not a critical level of serum cholesterol above which CHD will develop, but 
that the risk is ‘continuous and graded’ (Stamler et al 1986).
The MRFIT also observed racial differences in predisposition to CHD and 
cerebrovascular disease, studying diastolic blood pressure (DBP) in black and white 
males (Neaton et al 1984). An increase in DBP was associated with an increased 
incidence of CHD in whites that was greater than that in blacks, whereas for 
cerebrovascular disease the converse was true. An earlier study, the Seven Countries 
Study (Keys 1970), illustrated the large variations in CHD incidence between 
populations. However, despite this variation the all cause death rate for each country 
reflected the CHD death rate. Population differences in CHD incidence open the way 
for ‘nature versus nurture’ debates of the relative importance of endogenous and 
exogenous risk factors. Extensive research by Goldstein and co-workers in the 1970’s 
has done much to characterise the familial aggregation of lipid phenotypes and CHD 
(Hazzard et al 1973). A family history of premature CHD is now considered an 
independent risk factor.
Further studies have identified a range of other risk factors including obesity, 
inactivity, glucose intolerance and hypertriglyceridaemia. The more recently 
identified risk factors include certain lipoprotein and apolipoprotein characteristics, 
and most recently elevations in coagulation factors such as fibrinogen.
1.1.2 Treatment Strategies - populations versus the high risk individual.
Strategies for the primary and secondary prevention of CHD by correction of 
hyperlipidaemia include both lifestyle modification and pharmacological intervention. 
Because of the multiplicative nature of risk factors it is essential that all modifiable 
risks are addressed. Guidelines published by the British Hyperlipidaemia Association 
(BHA) in 1993 stress the need for lifestyle modification prior to the introduction of 
lipid-lowering agents (Betteridge et al 1993). In some individuals lifestyle 
modification is all that is required to correct their lipid profile, thus avoiding the need 
for lifelong drug therapy with the inevitable potential for side effects. Lifestyle 
modifications include weight loss if over-weight, cessation of smoking, moderation of 
alcohol intake and adherence to a cholesterol-lowering diet, as follows -
Table 1.1 The Cholesterol-lowering Diet (BHA 1993).
% total calories
Total fat <30
Saturated fat <10
Monounsaturated fat <10
Polyunsaturated fat <10
Carbohydrate 50-60
Protein 10-20
Fibre 35g/day
Cholesterol <300mg/day
3These modifications should be followed for three to six months before 
pharmacological intervention is considered, and continued on the introduction of 
therapy.
Such modifications are readily applicable to whole populations without the need for 
consideration of cost effectiveness. (Some would argue that we all should be adhering 
to the healthy lifestyle irrespective of our lipid profile). Commencement of lipid- 
lowering therapy, however, cannot be applied to whole populations but must be 
tailored to the individual. For each individual all risk factors must be taken into 
account in order to calculate his overall risk of developing CHD. For a high risk 
individual, for example an overweight middle-aged male smoker with hypertension 
and a family history of premature CHD, the question of lipid-lowering agents is much 
more pertinent than for a low risk individual with the same cholesterol level. In 
addition, the nature of the lipid abnormality must be taken into account.
1.1.3 Classification of Hyperlipidaemia.
There are several different approaches to the classification of hyperlipidaemia, for 
example - i. primary/secondary,
ii the Fredrickson classification, 
iii. family phenotyping.
Each has shortfalls and they are not mutually exclusive.
1. Primary/secondary. A secondary hyperlipidaemia is one that results from such 
underlying causes as metabolic disease, for example diabetes mellitus or 
hypothyroidism, hormonal disturbance such as pregnancy, renal disease or drugs such 
as certain anti-hypertensive agents. In primary hyperlipidaemia no underlying cause 
can be found save, in certain cases, the primary defect e.g. an enzyme or receptor 
deficiency. In all patients presenting with hyperlipidaemia it is important to screen for 
secondary causes as often their treatment will lead to the correction or improvement of 
the lipid abnormality.
2. The Fredrickson classification. In 1967 Fredrickson and colleagues devised their 
classification of hyperlipidaemia based on the electrophoretic pattern of the 
lipoproteins. This was subsequently modified by the World Health Organisation 
(Beaumont et al 1970) to subdivide type II into two groups. This classification makes 
no allowance for the primary or secondary nature of the hyperlipidaemia nor of its 
familiarity but it is widely used as a convenient shorthand in the clinical setting.
3. Family phenotyping. In the 1970s work by Goldstein and colleagues (Hazzard et 
al 1973) delineated the familial aggregation of lipoprotein phenotypes using survivors 
of myocardial infarction as probands. They identified six classes of hyperlipidaemia -
1. familial hypercholesterolaemia,
2. familial hypertriglyceridaemia,
3. familial combined hyperlipidaemia,
4. polygenic hyperlipidaemia,
5. sporadic hypertriglyceridaemia,
6. type III hyperlipidaemia.
4While this classification gives a more accurate impression of the heritability of the 
hyperlipidaemia, it necessitates screening of relatives which may not always be 
possible in a clinical situation.
In practice, a combination of all three approaches is generally used. The primary 
hyperlipidaemias are summarised below, based on the Fredrickson classification.
Table 1.2 The Classification o f Primary Hyperlipidaemia.
Phenotype Elevated
Lipoprotein
Electro­
phoretic
Pattern
Elevated
Lipid
Associated Genetic Disorders
I chylomicrons origin triglyceride LPL deficiency, 
ApoCII deficiency.
Ila LDL P cholesterol Familial hypercholesterolaemia, 
Polygenic hypercholesterolaemia, 
Familial defective apoB-100.
lib VLDL & pre-P & cholesterol & Familial combined hyperlipidaemia
LDL P triglyceride Familial hyperlipidaemia.
III p-VLDL broad P triglyceride = 
cholesterol
ApoE2 homozygosity.
IV VLDL pre-P triglyceride Familial hypertriglyceridaemia, 
Familial combined hyperlipidaemia
V chylomicrons 
& VLDL
origin & 
pre-p
triglyceride ApoCII deficiency,
Familial hypertriglyceridaemia, 
Familial combined hyperlipidaemia
1.1.4 Lipid-lowering Agents.
Intervention trials of lipid-lowering agents have shown that these drugs significantly 
decrease the incidence of major coronary events.
1. Resins. These are non-absorbable basic anion-exchange resins that bind bile acids 
in the intestine leading to their excretion in the faeces, thus interrupting the 
enterohepatic circulation. As a result of the decreased return of bile acids to the liver, 
there is an increase in their hepatic synthesis so reducing the intrahepatic cholesterol 
pool. This results in up-regulation of the low density lipoprotein (LDL) receptors and 
an increase in cholesterol uptake from the circulation. Resins can achieve a 20-30% 
reduction in LDL cholesterol but have the adverse effect of a moderate increase in 
triglycerides due to stimulation of hepatic very low density lipoprotein (VLDL) 
production. Their efficacy is dependent on functioning LDL receptors and they are 
therefore of questionable benefit in homozygous familial hypercholesterolaemia.
Because they are not absorbed, the resins do not have major systemic side effects and 
are thus of use in children and women of child-bearing age. However, compliance is 
often poor due to the gastro-intestinal side effects of bloating, flatulence and 
constipation. In addition, they can interfere with the absorption of other drugs such as 
digoxin, warfarin and thyroxine (this can be minimised by taking the drug one hour 
before or four hours after the resin).
5The Lipid Research Clinics Coronary Primary Prevention Trial (1984) studied the 
effect of the resin cholestyramine on CHD incidence in approximately 4,000 men (35- 
59 years of age) with moderate primary hypercholesterolaemia who were free of CHD 
at entry into the study, and compared them to similar controls on placebo. Treatment 
with cholestyramine was associated with a decrease in the incidence of CHD in line 
with a reduction in the levels of total cholesterol and LDL cholesterol.
2. Fibrates. This class of fibric acid derivatives increases the clearance of 
triglyceride-rich lipoproteins by activating lipoprotein lipase (one of the lipolytic 
enzymes). Their primary effect is the 50% reduction in triglycerides and thus their 
target recipients are those with elevations in this lipid. They have an additional 
beneficial effect of elevating the HDL cholesterol by 15-20% and some of the newer 
fibrates can also lower LDL cholesterol by 10-25%. The side effect profile is good, 
but with two important, but rare and reversible, adverse effects of myositis and 
elevated liver transaminases.
The first major intervention study of this class of drug was that performed by the 
World Health Organisation, Committee of Principal Investigators, (1980) of the parent 
compound, clofibrate. Unfortunately, due to the increased lithogenic index of the bile 
in subjects taking the drug there was an increase in mortality in the treatment group of 
25% due to gall bladder disease. However, this increased lithogenicity does not appear 
to be a problem with the newer compounds. The Helsinki Heart Study (Frick et al 
1987), a primary prevention trial, observed significant reductions in the incidence of 
CHD in those subjects treated with gemfibrozil. The effect was first noted after two 
years of treatment.
3. HMG-CoA reductase inhibitors (statins). These relatively new drugs were 
developed from fungal metabolites and act by the competitive inhibition of the rate- 
limiting enzyme in cholesterol synthesis, 3-hydroxy-3-methylglutaryl Coenzyme A 
reductase. The intracellular cholesterol production and pool size are reduced resulting 
in an up-regulation of the LDL receptors and hence an increased clearance of 
circulating cholesterol. There is also a reduction in LDL production and an increase in 
VLDL clearance. They can achieve 30-40% reductions in LDL cholesterol, with a 10- 
20% reduction in triglycerides and a small elevation in HDL cholesterol. The effects 
are dose-dependent, reaching a maximum within four weeks. As with the resins, they 
reportedly have little efficacy in homozygous familial hypercholesterolaemia. Side 
effects are uncommon but again myositis and elevated liver transaminases are rare 
possibilities.
Within the past two years two major intervention trials of these drugs have been 
published. The first of these, the Scandinavian Simvastatin Survival Study (4S), a 
secondary prevention trial, studied the effect of cholesterol lowering with simvastatin 
on mortality and morbidity in patients with pre-existing CHD. 4444 subjects were 
randomised to treatment or placebo groups and followed for an average of 5.4 years. 
The cholesterol range was 5.5-8.0mmol/l. Simvastatin produced highly significant 
reductions in CHD mortality and morbidity, with this effect being first observed at 
about one year. This finding extended to women and individuals over the age of 60 
years, two groups previously unstudied. There was also noted a beneficial effect on
6cerebrovascular disease. More importantly, there was no increase in non-CHD 
mortality.
The second large intervention trial was the West of Scotland Coronary Prevention 
Study (WOSCOPS). This primary prevention trial studied the effect of pravastatin on 
the subsequent development of CHD in men with primary moderate 
hypercholesterolaemia (mean 7.0mmol/l) but no past history of myocardial infarction. 
6595 men were randomised to treatment or control and followed for an average of 4.9 
years. The impact of pravastatin was seen within six months, with significant 
reductions in the incidence of CHD. Again there was no increased incidence of non- 
CHD death.
Therefore, this class of drug has two recent large intervention trials, one primary and 
one secondary, in its favour. One of the many important outcomes is the finding that 
there is no increase in non-CHD death with treatment, hopefully finally laying to rest 
the concerns over possible serious adverse effects of lipid-lowering.
4. Other lipid-lowering agents. Less commonly used drugs include nicotinic acid 
and its derivatives, probucol and omega-3 fatty acids.
Nicotinic acid is a water-soluble B vitamin that inhibits the breakdown of triglyceride 
in the adipose tissue, lowering the fatty acid supply to the liver and hence reducing 
VLDL and LDL with an increase in HDL. It is, however, poorly tolerated due to the 
side effects of severe flushing, gastro-intestinal disturbance and pigmentation. These 
can be ameliorated to a certain extent by the concomitant use of aspirin (prostaglandin 
inhibition). It also exacerbates gout and glucose intolerance. Synthetic analogues, 
such as acipimox, have been developed but although these are better tolerated they are 
less efficacious.
Probucol, a lipophilic bis-phenol, has a limited effect on lowering cholesterol and also 
adversely lowers HDL. Its benefit lies in its ability to increase LDL clearance by 
receptor-independent mechanisms and to block the oxidation of LDL. It mobilises 
cholesterol from the skin and xanthomata. Due to its lipophilicity, it is stored in the 
adipose tissue and is present for up to six months after cessation of treatment.
Omega-3 fatty acids (fish oils) reduce VLDL synthesis by the liver and thus primarily 
lower triglyceride. There is some concern that they may increase the level of LDL but 
they may also have a beneficial effect on certain coagulation factors.
71.2 Properties of Lipids and Lipoproteins.
1.2.1 Lipids.
Lipids are a heterogeneous class of naturally occurring substances, grouped together 
by common solubility properties. They are all insoluble in water but highly soluble in 
certain organic solvents such as ether, chloroform, benzene and acetone, the Tipid- 
solvents’ (Brown 1981). In the human body, the three principal lipids are cholesterol, 
triglycerides and phospholipids.
Cholesterol is a white, water-insoluble sterol found in practically all living organisms 
except bacteria. Its primary functions are i). as a component of all cell membranes, 
where it is present in the unesterified form, and ii). as a precursor for the synthesis of 
steroid hormones in the adrenal glands and gonads, and vitamin D and bile acids in 
the liver. Despite most tissues being capable of de-novo cholesterol synthesis it is 
carried out for the most part by the liver with some contribution from the distal small 
intestine. 3-Hydroxy-3-methylglutaryl Coenzyme A reductase forms mevalonic acid 
from acetate. This rate limiting enzyme is subject to feedback inhibition from 
cholesterol which is formed from acetate via a series of some 20 precursors. Hepatic 
cholesterol synthesis is regulated by absorption of dietary cholesterol and re­
absorption of biliary cholesterol, in the form of bile acids, via the enterohepatic 
circulation. Excretion is by way of bile acids into the faeces.
Triglycerides are the most abundant naturally occurring lipids and are familiar to us 
in the form of fats and oils. Exogenous triglycerides enter the circulation following 
absorption by the small intestine, whilst endogenous triglycerides are produced 
mainly by the liver. They are hydrolysed in the plasma to one glycerol molecule and 
three fatty acid molecules per triglyceride molecule, and taken up into the tissues 
where they are available for energy production, or reconstituted into triglyceride for 
storage. The majority of the triglyceride in the body is found in adipose tissue. 
Hydrolysis of this stored triglyceride by hormone sensitive lipase, the rate limiting 
enzyme found within the adipocytes, releases fatty acids into the plasma where they 
circulate as free fatty acids bound to albumin (Coppack et al 1994). The relatively 
small amount of triglyceride stored in muscle and liver turns over more rapidly than 
that in adipose tissue, providing a ready supply of fatty acids until those from adipose 
tissue are available. Fatty acids provide oxidative fuel for the liver, kidneys, skeletal 
muscle and myocardium. They differ in chain length and saturation, thus determining 
differences in physical properties such as melting point. Triglycerides differ from one 
another by variation in their fatty acid component. In addition, the majority of 
cholesterol in plasma is present as esters of long-chain fatty acids, mainly linoleic acid 
and oleic acid.
Phospholipids, the second most abundant lipid, are amphipathic molecules 
containing glycerol, fatty acids, phosphoric acid and a low-molecular weight alcohol 
such as choline or ethanolamine. They are an essential component of biological 
membranes, which typically consist of 40-50% phospholipid and 50-60% protein. As 
with cholesterol, all tissues are able to synthesise phospholipid but the majority is 
produced by the liver.
8In the routine management of hyperlipidaemic patients, phospholipid and fatty acid 
levels are not usually measured. Instead, treatment strategies are based on plasma 
levels of cholesterol, triglycerides and the lipoproteins.
1.2.2 Lipoproteins.
Plasma is largely water. Therefore, in order that lipids may circulate in the plasma, 
they associate with protein to form spherical macromolecules called lipoproteins. 
These lipoproteins consist of a hydrophobic core of cholesterol esters and triglceride 
surrounded by a hydrophilic monolayer of phospholipid, free cholesterol and protein, 
known as apolipoprotein (apo). The phospholipids are aligned such that their polar 
heads interact with the aqueous environment of plasma whilst their fatty acyl chains 
abut onto the non-polar neutral lipid core.
The lipoproteins can be classified into five major groups, namely chylomicrons, very 
low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL). They can be differentiated 
according to size, density and composition (Alaupovic 1971). These differences, 
summarised in the tables below, enable their separation by methods such as 
electrophoresis and centrifugation. They each have specific but complimentary roles 
in the transport of lipids in the circulation. With the exception of chylomicrons, the 
particles within each lipoprotein class have been shown to be heterogeneous and so 
can be further sub-classified (Krauss 1987).
Table 1.3 Physical Properties o f Plasma Lipoproteins (Thompson 1994)
Density
(g/ml)
Flotation Rate*
Sf 1.063 Sf 1.20
Mean 
Diameter (nm)
Electrophoretic
Mobility
Chylomicrons <0.95 >400 100-1000 origin
VLDL <1.006 20-400 43 prep
IDL 1.006-1.019 12-20 27 P
LDL 1.019-1.063 0-12 22 P
h d l 2 1.063-1.125 3.5-9.0 9.5 a
h d l 3 1.125-1.21 0-3.5 6.5 a
*Flotation rate (Sj), in Svedberg units, is the rate at which lipoproteins float in the analytical ultra­
centrifuge.
Table 1.4 Mean Percentage Composition o f  Plasma Lipoproteins (Warwick
1991).
Free
Cholesterol
Cholesterol
Ester
Triglyceride Phospholipid Protein
Chylomicrons 5 2 84 7 2
VLDL 12 7 55 18 8
IDL 23 8 32 21 16
LDL 38 10 9 22 21
h d l 2 16 6 4 30 44
h d l 3 12 3 4 26 55
9Chylomicrons are triglyceride-rich lipoproteins synthesised in the small intestinal 
epithelium following the absorption of dietary fat. They are not normally found in the 
plasma in the fasted state. Following a meal, dietary cholesterol, triglycerides and 
phospholipid are hydrolysed in the small intestine by intestinal lipases and absorbed 
as bile salt micelles. Within the enterocytes they are reconstituted and packaged with 
apolipoproteins B-48, Al and AIV to form chylomicrons. They are then released into 
the plasma via the lymphatics whereupon they gain more protein, in the form of 
apolipoproteins Cl, CII, CIII and E, transferred from HDL. The chylomicron 
concentrations in the plasma start to rise at approximately one hour following a meal, 
peak at two to four and normally return to fasting levels within eight.
Once in the circulation chylomicron triglycerides undergo hydrolysis by lipoprotein 
lipase, a lipolytic enzyme present on the vessel endothelium. HDL transfers 
cholesterol esters to chylomicrons while in return it accepts the surface components, 
including the apoC’s. With loss of the core lipid, chylomicrons become smaller, 
remnant particles which are removed from the circulation by apoE-facilitated hepatic 
uptake. The outcome of this process is delivery of dietary triglceride, in the form of 
fatty acids, to the adipose tissue and skeletal muscle for use in storage and energy 
production, and of dietary cholesterol esters to the liver as chylomicron remnants for 
storage or synthesis of bile acids and VLDL.
VLDL are similar to chylomicrons in that they are triglyceride-rich lipoproteins but 
they have two important differences. Firstly, the triglycerides transported are of 
endogenous origin, and secondly, the major apolipoprotein is apoB-100 rather than 
apoB-48. VLDL are secreted primarily by the liver with a minor contribution from the 
small intestine (mainly for the reabsorption of endogenous cholesterol and fatty acids 
of biliary origin). Hepatic lipids are added to the apoB-100 to form VLDL.
Following hepatic synthesis, the VLDL are released into the space of Disse and here, 
in a manner similar to that of chylomicrons, they acquire apolipoproteins C from HDL 
before undergoing stepwise delipidation by lipoprotein lipase (LPL) in the systemic 
circulation. Again HDL provides cholesterol esters and apoE. As the core triglyceride 
is hydrolysed, the particle becomes smaller so forming a remnant particle or IDL. At 
any point during delipidation the particle may be removed from the plasma by hepatic 
uptake mechanisms.
VLDL can be further classified into two major subfractions, distinct in their metabolic 
properties and separable by their hydrated density - VLDLj (Sf 60-400), larger, 
triglyceride-rich particles and VLDL2 (Sf 20-60), a smaller, relatively cholesterol- 
enriched species. Both can be synthesised directly by the liver and, in addition, 
VLDL2 are formed by the delipidation of VLDLj. VLDLj are the preferred substrate 
of cholesterol ester transfer protein (CETP) and readily undergo neutral lipid 
exchange whilst VLDL2 are overproduced in common hypercholesterolaemias 
(Shepherd and Packard 1987, Gaw et al 1995).
IDL provide an intermediate step between VLDL and LDL. Their concentration in 
plasma is only one tenth of that of LDL and they are not routinely measured in the 
assessment of hyperlipidaemia. However, they can accumulate in the plasma in certain
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pathological states. IDL are smaller, denser and more cholesterol-enriched than 
VLDL, with the main protein component being apoB, the remainder having been lost 
with the surface components. They are rapidly delipidated by hepatic lipase to form 
LDL, or alternatively cleared from the circulation by hepatic receptor-mediated 
uptake, binding to the receptor by virtue of their apoB and apoE moieties. As with 
VLDL, IDL can be further divided into several subfractions (Musliner et al 1986).
LDL transport the bulk of cholesterol in the plasma. They are the most cholesterol- 
rich of all the lipoproteins and are formed by the delipidation of IDL. Their only 
protein is apoB-100, present as one protein molecule per lipoprotein particle.
LDL are cleared from the plasma by receptor-mediated uptake. This receptor, the LDL 
or B/E receptor, recognising apoB-100 on the lipoproteins, binds and internalises 
them. Some LDL are cleared by receptor-independent mechanisms, such as 
scavenging by macrophages, which become more relevant in cases of cholesterol 
excess or receptor deficiency (Goldstein and Brown 1978, Slater et al 1982).
LDL comprise several subpopulations of heterogeneous particles (the exact number 
depending on the method of separation used). In the early 1980s, Krauss and Burke 
separated LDL into four subclasses using density gradient ultracentrifugation (DGUC) 
and gradient gel electrophoresis. The DGUC technique was later refined by Griffin et 
al (1990) to separate LDL into three subfractions - LDLI (d=l.025-1.034), LDLII 
(d=l.034-1.044), LDLIII (d= 1.044-1.060). LDLI is a large lipid-rich species whereas 
LDLIII is small, dense and rich in protein and phospholipid. The LDL subfraction 
profile can be visualised by passing the LDL that has been separated within the 
density gradient through an optical unit so giving a curve with peaks corresponding to 
the relative amounts of each subtraction present in the total LDL. From this, the 
concentration of each subfraction can be determined. These profiles provide a visual 
impression of the LDL pattern in any one individual. This study and others (Krauss 
1991, Griffin et al 1994) have shown associations between LDL subfraction profiles 
and criteria such as sex and CHD. The majority of healthy individuals have a profile 
comprising mainly LDLII. Premenopausal females have a predominance of LDLI 
whereas sufferers of CHD often have a predominance of LDLIII.
Metabolic studies have shown that LDL is kinetically as well as structurally 
heterogeneous. When plasma and urine data are considered together in the same 
model it is possible to define two metabolically distinct pools (Caslake et al 1992). 
Pool A is a rapidly catabolised pool whilst pool B is only slowly cleared from the 
plasma. This heterogeneity in LDL metabolism and structure is clinically important as 
different lipoprotein subfractions are believed to have different atherogenic potential. 
Small, dense LDL is particularly atherogenic. Its small size enables it to filter through 
the arterial wall into the sub-endothelial space where the cholesterol then accumulates. 
It is reported to bind more readily to arterial wall proteoglycans (Tribble et al 1992) so 
prolonging its residence time in the wall. It is susceptible to oxidation, enhancing 
macrophage uptake and hence foam cell formation (Packard 1994). The accumulation 
of cholesterol within the arterial wall plus a local connective tissue reaction 
characterise atherogenesis.
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HDL are the most abundant lipoproteins in plasma but also have a significant 
extravascular presence. They are synthesised by both the liver and the small intestine, 
as discoid apoA containing particles and are present in the plasma in two major forms, 
HDL2 and HDL3 (Schaeffer 1990). These can be further subclassified (Skinner 1994), 
for example by immunoaffinity methods depending on their apoA content (Cheung 
and Albers 1984). Some particles contain both apoAI and apoAII, Lp(AI-AII), and 
these are thought to be of hepatic origin. Other particles contain apoAI only, Lp(AI) 
and appear to originate in the intestine (Schaeffer 1990).
HDL function as mediators of reverse cholesterol transport, the process responsible 
for the return of cholesterol from the peripheral tissues to the liver (Barter 1993). Free 
cholesterol from cells and the surface layer of triglyceride-rich lipoproteins transfers 
to the nascent HDL. This is esterified by lecithin:cholesterol acyl transferase (LCAT) 
and these cholesterol esters then move from the surface to the core of the HDL 
particle, changing its shape from that of a flattened disc into that of a more spherical 
particle. In so doing, a gradient is established allowing more free cholesterol to 
transfer to HDL. The cholesterol ester is then transferred to triglyceride-rich 
lipoproteins, preferentially VLDL! (Eisenberg 1985), in exchange for triglyceride, 
catalysed by cholesterol ester transfer protein (CETP). The apoB containing 
lipoproteins are cleared by the liver, thus completing the reverse cholesterol transport. 
The larger, triglyceride-rich HDL (HDL2) are then hydrolysed by hepatic lipase (HL), 
forming smaller HDL3 which are then available for free cholesterol acquisition.
An additonal role for HDL is that of a repository for the small, exchangeable 
apolipoproteins (apoC and apoE) donating them to chylomicrons and VLDL prior to 
lipoplysis. The apolipoproteins are later shed back into the HDL density range. HDL 
catabolism is performed by the liver via apoE-facilitated receptor uptake.
Lp(a), lipoprotein (a), is a more recently discovered lipoprotein whose physiological 
function is as yet unclear. It is positively associated with CHD being both 
thrombogenic and atherogenic. Plasma levels vary from nil to 200mg/dl and have 
strong heritabilty. It can simplistically be described as LDL with an additional protein, 
apo(a), attached by a disulphide bond to the apoB. Apo(a) is synthesised by the liver 
and has a high degree of sequence homology with plasminogen. It is a highly 
glycosylated, hydrophilic protein with low affinity for lipid. Despite the similarity 
with LDL, Lp(a) binds less avidly to the LDL receptor (Marcovina and Morrisett 
1995).
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1.3 Apolipoproteins.
Alaupovic, in his 1971 editorial, described apolipoproteins as “the most probable 
determinants of the compositional and structural stability of lipoproteins”. He was 
also instrumental in their classification, introducing the alphabetical nomenclature that 
is now widely used. Apolipoproteins are responsible for the regulation of lipoprotein 
inter-relationships and the maintenance of lipoprotein homeostasis. They act as 
ligands for receptor binding and as cofactors for lipolytic enzymes (Mahley et al 
1984). Characteristics of the principal apolipoproteins are summarised in Table 1.5.
Table 1.5 Composition, Locations and Function o f  Human Apolipoproteins 
(Jordan-Starck et al 1992).
Apolipoprotein Molecular Lipoprotein Other Chromosomal Plasma
Weight Association Function Location Concentration
(kD) (mg/dl)
A l 28 HDL & 
chylomicrons
LCAT
activator.
11 100-150
A ll 17 HDL Hepatic lipase 
regulation.
1 30-40
AIV 46 HDL & 
chylomicrons
? LCAT 
activator.
11 -15
B-100 512 VLDL, IDL & 
LDL
LDL receptor 
ligand.
2 80-100
B-48 241 Chylomicrons Triglyceride
secretion.
C l 6.6 HDL, VLDL 
&
chylomicrons
LCAT
activator.
19 ~6
CII 8.8 HDL, VLDL 
&
chylomicrons
Lipoprotein 
lipase activator
19 -4
CIII 8.7 HDL, VLDL 
&
chylomicrons
Modulation of 
chylomicron 
and VLDL 
clearance.
11 -12
E 34 VLDL & HDL Ligand for 
chylomicron 
and VLDL 
clearance.
19 3-7
The A apolipoproteins consist of three main apoA’s - apoAI, apoAII and apoAIV. 
ApoAI is the main protein component of HDL accounting for 70% of its protein. It is 
also present to a lesser extent on chylomicrons but is transferred to HDL on hydrolysis 
of the former. It is synthesised by both the liver and small intestine and has been 
shown to have several isoforms. Its main role is as the structural apolipoprotein for 
HDL and as a cofactor for LCAT. ApoAII, synthesised by the liver, is the second 
most abundant protein in HDL. It activates LCAT and appears to enhance the lipid 
binding properties of apoAI. ApoAIV is present on newly secreted chylomicrons but 
it is readily displaced and the majority of it is found free in the plasma. Its role is as 
yet uncertain but it possibly acts as an LCAT activator.
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Apolipoprotein B in the delipidated state is insoluble in aqueous solutions and must 
therefore be denatured with, for example, sodium dodecyl sulphate or urea in order to 
be characterised. Two types of apoB are found in normal plasma - apoB-100 and 
apoB-48.
ApoB-100 is the main protein moiety of VLDL, IDL and LDL. It is synthesised 
primarily by the liver and is an obligatory component of these lipoproteins, being 
present as one mole per particle. It does not exchange between lipoproteins but 
remains with the particle from secretion to catabolism. It acts as a ligand for receptor 
recognition and uptake of the particle. However, conformational changes of the apoB 
during lipolysis of VLDL regulate the lipoprotein uptake so that it is only IDL and 
LDL that are cleared by this mechanism (Chatterton et al 1995). VLDL appear to be 
cleared by an apoE-mediated mechanism.
ApoB-48 is synthesised by the small intestine and secreted on chylomicrons. It is 
identical to the amino terminal 48% of apoB-100 (hence the nomenclature), being 
formed by post-translational modification of the apoB-100 mRNA (Scott et al 1988). 
ApoB-48 does not bind to the B/E (LDL) receptor but, as with apoB-100 and VLDL, 
it is a prerequisite for chylomicron secretion.
The C apolipoproteins are three - apoCI, apoCII and apoCIII. They are present on 
HDL, chylomicrons and VLDL, the first supplying the last two with this protein on 
their entry into the circulation. ApoCI is the smallest of the three and acts as an 
activator of LCAT. ApoCII is an essential cofactor of lipoprotein lipase. ApoCIII 
appears to have an inhibitory effect on the hydrolysis and clearance of chylomicrons 
and VLDL (Thompson 1994). It exists in three forms depending on sialylation - CIII0, 
CIII j and CIII2, the subscript reflecting the number of sialic acid residues present.
Apolipoprotein E, present on chylomicron remnants, VLDL and large HDL particles, 
is synthesised by the liver and functions as a ligand for the hepatic uptake of 
chylomicron remnants and VLDL. Iso-electric focusing reveals three common apoE 
isoforms - E3, E2 and E4. These have arisen from point mutations of the wild type, 
E3. The differing isoforms do have physiological effect, in particular on the 
metabolism of LDL precursors.
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1.4 Enzymes and Receptors Involved in Lipoprotein Metabolism.
In addition to the apolipoproteins, there are various enzymes and receptors intimately 
involved in the regulation of lipoprotein metabolism.
1.4.1 Enzymes of Cholesterol Metabolism.
3-Hydroxy-3-methylglutaryl Coenzyme A reductase (HMG-CoA reductase) 
catalyses mevalonic acid formation from acetate. This is the rate limiting step in 
cholesterol synthesis. Cholesterol is then formed from mevalonate via a series of some 
20 steps and exerts feedback inhibition on HMG-CoA reductase thus regulating its 
own production. Lecithin:cholesterol acyltransferase (LCAT) and cholesterol ester 
transfer protein (CETP) are involved in reverse cholesterol transport. LCAT 
esterifies cholesterol with fatty acids, preferably linoleic acid, taken from lecithin. 
CETP catalyses the neutral lipid exchange of cholesterol esters from HDL and LDL to 
the triglyceride-rich lipoproteins in exchange for triglyceride.
1.4.2 Enzymes of Triglyceride Metabolism.
Lipoprotein lipase (LPL) hydrolyses triglyceride in chylomicrons and VLDL and 
requires apoCII as a cofactor. It is found mainly in adipose tissue and skeletal muscle 
where it is bound to the capillary endothelium. In women LPL activity is greater in 
the gluteal adipose tissue than in the abdominal tissue, whereas in men the converse is 
true (Amer et al 1991). Overall, the amounts of LPL in adipose tissue are higher in 
women than in men. Regular alcohol consumption increases the amount of LPL in the 
adipose tissue, whereas exercise increases that in the skeletal muscle.
Hepatic lipase (HL) hydrolyses triglyceride in HDL2 and by so doing mediates the 
conversion of HDL2 to HDL3. Additionally it delipidates IDL to form LDL and is 
thought to be responsible for the interconversion between LDL subclasses. It is found 
on hepatic endothelial cells and concentrations in women are lower than those in men.
The triglyceride lipases are structurally related to pancreatic lipase. In addition to their 
role as enzymes, both have been shown to act as ligands for the binding of 
triglyceride-rich lipoproteins to cell membranes. Although each lipase is capable of 
hydrolysing each lipoprotein, they are selective - LPL preferentially acts on 
triglyceride-rich lipoproteins, and HL on HDL and LDL (Decklebaum 1987).
Hormone sensitive lipase (HSL) is the rate limiting enzyme in the intracellular 
hydrolysis of triglyceride in adipose tissue, releasing fatty acids into the circulation. It 
is regulated reciprocally to LPL (Coppack et al 1994).
1.4.3 Receptors.
The LDL (or B/E) receptor was first identified by Goldstein and Brown (1977) 
winning them a Nobel prize for their discovery. The receptors are found 
predominantly on hepatocytes but a significant proportion are present in the adrenals 
and gonads. They are responsible for the clearance of IDL and LDL from the plasma,
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with the apoB-100 on these lipoproteins acting as the ligand for receptor binding. 
Their expression on cell surfaces is regulated by the intracellular cholesterol 
concentration such that when cholesterol is plentiful within the cell the LDL receptors 
are down-regulated and vice versa, thus maintaining a balanced intracellular 
cholesterol content.
The LDL receptor-related protein (LRP) has been described as a receptor for 
chylomicron and VLDL remnants (Beisiegel 1995). In this case the ligand is said to 
be apoE. It is present on numerous cell types, including macrophages and smooth 
muscle cells, suggesting a possible involvement in atherogenesis.
Other receptors that have more recently been described include extrahepatic VLDL 
receptors, scavenger receptors on macrophages and HDL receptors (Beisegel 1995, 
Thompson 1994).
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1.5 An Overview of Lipoprotein Metabolism.
In health the apolipoproteins, receptors and enzymes interact intimately with the 
lipoproteins to maintain lipid homeostasis. This system can be described as having 
three main components. Firstly, the backbone of the system is the delipidation cascade 
for the sequential delipidation of apoB-100 containing lipoproteins and the dispersion 
of lipids to tissues in the fasted state. Secondly, the intermittent presence of 
chylomicrons serves to provide the system with exogenous lipids, with minimal 
disruption to endogenous turnover. Thirdly, the HDL removes excess cholesterol from 
the periphery and remodels apoB containing lipoproteins. Thus the homeostasis is 
maintained despite dramatic swings in plasma lipid levels (particularly triglyceride) 
between the fasted and fed states.
In the post-prandial state the plasma is flooded with chylomicrons. They are 
delipidated by the action of lipoprotein lipase and their remnants are cleared by the 
liver. These chylomicrons compete with VLDL for lipoprotein lipase and appear to be 
preferentially delipidated. Thus post-prandially there is an increase in plasma VLDL, 
mainly VLDLb although the majority of the triglyceride increase is due to 
chylomicrons (Karpe et al 1993). HDL mediates neutral lipid exchange, depleting the 
chylomicrons of triglyceride. The longer chylomicrons reside in the plasma the more 
cholesterol-enriched they become (and the more triglyceride-rich the HDL become). 
These cholesterol-rich chylomicrons are believed to be highly atherogenic (Packard 
and Shepherd 1990).
VLDL are secreted into the plasma by the liver in response to hormonal control of 
hepatic triglyceride synthesis, entering at the top of the delipidation cascade. They are 
sequentially delipidated firstly to IDL by lipoprotein lipase, mediated by apoCII, and 
then to LDL by hepatic lipase. The LDL are then cleared from the plasma by the LDL 
receptor, following binding mediated by apoB.
The liver can directly secrete any class of lipoprotein and so apoB can enter into any 
point of the delipidation cascade. In addition, any lipoprotein can be directly cleared 
from the plasma, thus removing the apoB from the cascade. The concept of direct 
LDL synthesis is controversial, with some workers suggesting that LDL are not 
secreted directly, but in fact as a small pool of VLDL which are very rapidly 
metabolised to LDL. The topic is reviewed by Shames and Havel (1991) who 
summarise the results from many radio-isotope metabolic studies. The authors 
conclude that the issue is far from solved, but they argue that the apparent direct LDL 
synthesis can be explained by VLDL heterogeneity. A recent study (Gaw et al 1995) 
noted that the degree of direct LDL synthesis appeared to be inversely related to 
plasma triglyceride level. This fits with the concept that it is the availability of lipid 
within the hepatic pool that determines the class of lipoprotein secreted - in states of 
low triglyceride the triglyceride-poor lipoproteins are secreted.
1.5.1 Metabolic Channelling of ApoB-100 Containing Lipoproteins.
The idea of metabolic channelling was first introduced by Fisher in the 1980s (Fisher
1982). He described the concept whereby “a chemical substance may be metabolised
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along alternate metabolic pathways which do not necessarily intersect”. Dual tracer 
radio-isotope studies have shown that this concept can be applied to the delipidation 
cascade (Packard 1995, Griffin and Packard 1994). VLDL entering the cascade at 
VLDLj appears to be delipidated slowly through VLDL2 and IDL to LDL, 
predominantly forming LDLIII following neutral lipid exchange by CETP and 
subsequent hydrolysis by hepatic lipase. On the other hand, VLDL entering directly as 
VLDL2 is channelled rapidly down the cascade to LDLI. The LDL are then cleared 
from the plasma at different rates, with LDLI being rapidly cleared by receptor 
uptake, while LDLIII is less attractive to the receptor and is cleared slowly, mostly by 
receptor-independent mechanisms (Caslake et al 1992). The synthesis of the two 
VLDL subfractions also appears to respond to different stimuli. VLDL! synthesis is 
under hormonal control e.g. increasing in the presence of insulin resistance and 
oestrogen, whereas VLDL2 synthesis is increased in states of hypercholesterolaemia.
1.5.2 Regulation of ApoB Metabolism.
The metabolism of lipoproteins is regulated by local factors such as lipid 
concentrations, but also responds to more distant hormonal influences such as the sex 
steroids and, more importantly, insulin.
Insulin is the major anti-lipolytic hormone (Coppack et al 1994), functioning, 
primarily in the post-prandial state, by the following three mechanisms (Frayn 1993) -
i). inhibition of hormone sensitive lipase thereby suppressing fatty acid release from 
adipocytes, ii). decreasing hepatic VLDL production, and iii). increasing LPL activity 
in adipose tissue and so clearing triglyceride from the circulation.
In states of insulin resistance, such as obesity, non-insulin dependent diabetes mellitus 
(NIDDM) and hypertriglyceridaemia, this anti-lipoplytic effect is lost. Excess 
lipolysis leads to worsening of glucose tolerance and hypertriglyceridaemia, and is 
seen at its most unrestrained in diabetic ketoacidosis (Coppack et al 1994). Excess 
fatty acid is present in the plasma and hepatic VLDL synthesis is increased. Reduced 
LPL activity prolongs the residence time of the triglyceride-rich VLDL in the plasma 
so exposing them to prolonged CETP and HL action with the resultant formation of 
small, dense LDL and a lowered HDL cholesterol level. This pattern of 
hypertriglyceridaemia, low HDL cholesterol and small, dense LDL has been 
characterised by Austin (1990) as the Atherogenic Lipoprotein Phenotype. The 
dyslipidaemia may predate the development of NIDDM and persists despite 
glycaemic control, resulting in an increased incidence of CHD. In obesity (which 
often co-exists with NIDDM) LPL loses its sensitivity to insulin (Frayn 1993).
The Insulin Resistance Syndrome was first described by Reaven in the Banting lecture 
in 1988. This polymetabolic syndrome describes the clustering of insulin resistance 
and the characteristic dyslipidaemia with central obesity and hypertension. There 
appears to be a genetic component to its development and it is associated with an 
increased risk of CHD.
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1.6 The Triglyceride Issue - a deeper look at the ‘at risk* lipoprotein profile.
Whilst for some time the relationship between plasma cholesterol and CHD has been 
accepted as ‘continuous and graded’ (Stamler et al 1986) the role of triglyceride is less 
clear cut. Triglyceride is not found to any appreciable degree in atheromatous plaques 
and for many years was ignored as a risk factor.
Austin, in her 1991 review, summarised the problems in assessing the relationship 
between triglyceride and CHD. Epidemiological studies have shown a univariate 
relationship but in many studies this relationship is lost with multivariate analysis, 
especially those that introduce LDL and HDL as variables. Additional complications 
include the large intra-individual variation in triglyceride and its relatively imprecise 
measurement as compared, for example, to that of HDL. Intervention studies thus far 
have only addressed the triglyceride issue to a limited degree. Furthermore, genetics 
appear to play a role in determining triglyceride levels. However, what has emerged 
from these studies is the positive correlation between triglyceride and small, dense 
LDL, and the negative correlation with HDL cholesterol.
In moderate hypertriglyceridaemia (2.3-6.0mmol/l) the primary metabolic defect is 
increased VLDL production. However, in more severe elevations (>6.0mmol/l) the 
problem appears to be one of defective catabolism (Stalenhoef et al 1986). Overall, 
triglyceride levels greater than 1.5mmol/l show an increasing association with CHD 
up to a level of 5.0mmol/l. It then appears to tail off with the main risk of severe 
hypertriglyceridaemia being pancreatitis, a condition with a mortality rate of 5-60%. 
Therefore, although the relationship between excess triglyceride and CHD is less clear 
than that of cholesterol, it has specific and detrimental effects on lipoprotein 
metabolism that can result in the atherogenic lipoprotein phenotype. This in turn, has 
been shown to be associated with increased risk of CHD.
We thus have three main categories of lipoprotein profile which are associated with an 
increased risk of CHD, i). a simple elevation of LDL, as epitomised by familial 
hypercholesterolaemia, ii). a low level of HDL, the hypoalphalipoproteinaemias, and
iii). the atherogenic lipoprotein phenotype, encompassing elevated triglycerides, 
small, dense LDL and low HDL cholesterol. The aetiology of each is different and 
each requires a different approach in its management, but the clinical manifestation of 
each if left untreated is the same.
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1.7 Studying and Modelling Lipoprotein Kinetics.
The detailed study of lipoprotein kinetics requires both an appropriate tracer and an 
applicable model.
1.7.1 The Choice of Tracer.
Over the years several tracers have been tried and tested. A tracer is merely a label for 
the system, or tracee, under study, in this case lipoproteins or apolipoproteins. In their 
recent review, Barrett and Foster (1996) described the ideal tracer as having the 
following characteristics - “i). it is detectable, in experimental samples, by an 
observer, ii). its introduction into the system does not perturb the system, i.e. steady 
state is maintained, and iii). it is indistinguishable with respect to the properties of the 
system being studied, that is the kinetics of the tracer are identical to those of the 
tracee.” These last two points are largely assumed although in some instances may not 
be strictly correct.
Much of the earlier kinetic work utilised radio-isotope tracers but more recently stable 
isotopes have come to the fore. The use of stables isotopes in metabolic studies 
actually predates that of radio-isotopes, being first used in the 1930’s.
The use of each has advantages and disadvantages. Radio-isotopes are generally less 
expensive and more easily processed. Their use is limited by the safety aspects of 
handling radioactivity, their preclusion for use in children and pregnant or lactating 
women, and their restricted repeatability in any one individual. Stable isotopes, at 
doses used in metabolic studies, have a good safety profile (Jones and Leatherdale 
1991) and can be widely and repeatedly used. However, they are costly and require 
labour-intensive methods of analysis. The latter is being overcome to a certain extent 
by the development of sophisticated mass spectrometry techniques.
With few exceptions, radio-isotopes are attached to a lipoprotein or apolipoprotein ex 
vivo whilst stable isotopes are administered as small molecular weight precursors to 
lipid (e.g. 13C-acetate) or protein (e.g. d3-leucine). Each method has advantages and 
disadvantages. Exogenous tracers allow specific labelling of the lipoprotein or 
lipoproteins under study. (This potential for separate labelling of individual 
lipoproteins has been utilised in several kinetic studies, see below). Of concern, 
however, is that the isolation, labelling and re-introduction of the lipoprotein may 
alter its kinetics such that it is no longer a true representation of the system (see the 
third point of Barrett and Foster).
With endogenous labelling a naturally occurring substance is administered and 
becomes incorporated into the protein or lipoprotein as it is synthesised. However, 
this incorporation is non-specific, for example, when using an amino acid tracer all 
body protein becomes labelled rather than solely the apolipoprotein of interest. In 
addition, as these proteins are catabolised the tracer is recycled, necessitating complex 
modelling methods to accomodate this ‘tail’ that is seen in the enrichment curves. In 
general, endogenous tracers give a better representation of synthetic rates but are less 
accurate for interconversions and catabolic events (Packard 1995).
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‘The notion o f  kinetics o f a lipoprotein particle as a whole becomes vague 
when all o f  its components can undergo transitions independently, unless 
it contains at least one marker with which it can be totally identified’. 
(Mones Berman 1982).
When studying the kinetics of VLDL, IDL and LDL, apoB-100 is that marker. It can 
be identified with amino acids labelled with stable isotopes. Various amino acids have 
been compared - leucine, valine and lysine (Lichtenstein et al 1990), leucine and 
glycine (Parhofer et al 1991) - with the conclusion that all produce similar results. For 
this thesis apoB-100 was labelled with tri-deuterated (d3) leucine. Leucine is one of the 
better amino acids for this purpose as it is an essential amino acid, is ubiquitous in 
body protein, plentiful within apoB and is minimally recycled due to its catabolism to 
ketoisocaproate.
2 13The natural abundance of deuterium ( H) is 0.015%, substantially lower than C at 
1.11% and 15N at 0.37%. Additionally, the relative mass difference from the natural 
element is greater for deuterium than the others. The use of multiple labelling increases 
the sensitivity of measurement by minimising the background of natural isotope 
(Schaefer et al 1992).
Parhofer et al (1991) compared two methods of administration of stable isotopes - 
primed constant infusion and bolus dose - and found that the method used had no 
significant effect on the metabolic parameters provided that both were analysed using 
multicompartmental modelling. Both methods have been used in this thesis.
1.7.2 Multicompartmental Modelling and Model Design.
As research progresses the lipoprotein system as we understand it becomes 
increasingly complex and thus requires detailed modelling for its interpretation. The 
three commonly used methods of analysis are linear regression, monoexponential 
functions and multicompartmental modelling. Parhofer et al (1991) compared the three 
and found that, while in a group of subjects the fractional catabolic rates did not differ 
significantly between methods, in any one individual there was no correlation between 
values obtained by each method. Of the three, multicompartmental modelling is the 
gold standard. Linear regression analysis is lacking in physiological basis and 
monoexponential functions are not applicable to a heterogeneous population of 
particles such as lipoproteins.
A model is simply a mathematical representation of a physiological system, from 
which we can calculate the rates of production, interconversion and catabolism of the 
particles under study. Model design has increased in complexity over the past two 
decades. In 1975 Phair et al proposed a ‘delipidation chain’ to account for the shoulder 
in the VLDL data. This delipidation chain or cascade is still prominent in more recent 
models and represents the decreasing size of the lipoprotein as lipid is removed. 
Berman et al (1978) expanded on Phair’s VLDL model by adding a pathway for the 
slow catabolism of VLDL. The consensus model of 1980 included the above two 
features plus a delay component to reflect the intrahepatic assembly of lipoproteins.
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LDL was modelled by a single compartment within the plasma but allowed 
extravascular exchange. This single compartment is appropriate if the LDL is 
monodisperse but an additional compartment is required if it is polydisperse, as in the 
case of hypertriglyceridaemia (Fisher et al 1980).
Beltz et al (1985) modelled with all of the preceeding but included a compartment of 
IDL sequestered outwith the plasma. Allowance was made for irreversible loss of 
apoB from the system at the level of VLDL and IDL. In addition, a ‘direct’ input into 
LDL was allowed, representing a very rapidly metabolized VLDL compartment.
Parhofer’s model of 1991 is illustrated in Figure 1.1. Compartment 1 represents the 
precursor amino acid in the plasma and is modelled with a forcing function. 
Compartment 2 is the delay component. All apoB enters the plasma as VLDL 
(compartment 11) and from here can proceed to a slowly metabolised VLDL pool 
(compartment 12) or directly to IDL (21) or LDL (31). Compartments 11 and 12 
represent a minimum delipidation chain and allow for VLDL heterogeneity. ApoB is 
irreversibly lost from the plasma at the level of VLDL or IDL. This model was 
designed as the simplest structure based on previous publications and the authors own 
experimental data. Its expansion is necessary in hyperlipidaemic subjects.
Dual tracer metabolic studies enable the concept of metabolic channelling to be taken 
into account. Using 131I-labelled VLDLt and 12 I-labelled VLDL2 Packard et al (1995) 
developed a model with parallel delipidation pathways to explain the different kinetics 
of VLDLt and VLDL2 (Figure 1.2). This would not be possible using endogenous 
stable isotope labelling techniques.
As models become increasingly complex so the number of parameters increases. Thus 
the concept of identifiability must be introduced. This is reviewed by Cobelli and 
DiStefano (1980) as the possibility of obtaining ‘unique solutions for unknown 
parameters of interest in a mathematical model, from data collected in well defined 
stimulus-response experiments performed on a dynamic system represented by the 
model’. A model can be made uniquely identifiable by the introduction of parameter 
constraints or dependencies to reduce the number of unknowns. Ideally, these 
constraints should have a physiological basis.
One of the most recent models to be published is that of Demant et al (1996). It has 
many similarities to that of Packard et al (1995). Six normolipaemic individuals 
underwent turnover studies using tri-deuterated leucine with extension of the length of 
the turnover to 14 days to include the more slowly turning over LDL. (Details of the 
turnover procedures are given in the following chapter). Isotopic enrichments in the 
lipoprotein fractions VLDLb VLDL2, IDL and LDL were measured by sensitive gas 
chromatography-mass spectrometry techniques and a multicompartmental model 
developed from the enrichment curves. The model was made uniquely identifiable by 
the application of certain physiologically plausible constraints and is described fully in 
the following chapter.
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1.8 Aims and Objectives.
The primary aim of this thesis was to characterise the kinetics of apoB containing 
lipoproteins in certain dyslipidaemic states. In order to achieve this, stable isotope 
methodology was used that has already been established for use in normolipidaemic 
states (Demant et al 1996). Thus a secondary aim was to determine whether this 
methodology is appropriate for use in these abnormal states. In particular, the 
multicompartmental model, designed for modelling normal apoB kinetics, was applied 
to the pathological situations and its ability to explain abnormal apoB kinetics tested. 
Studies of apoB kinetics have been performed in the past but the majority used radio­
isotope techniques and different methods of data analysis. Stable isotope studies 
combined with multicompartmental modelling are perhaps more ideal for this sort of 
work.
To meet the above aims three main objectives were set. First, a non-kinetic study was 
performed on a group of eighty normolipidaemic individuals to characterise the inter­
relationships between lipoprotein subfractions and indices of obesity, insulin resistance 
and lipase activity. The same parameters were determined in a smaller group of 
normolipidaemic CHD sufferers and the two groups compared. In particular, the 
differences between males and females and between non-CHD and CHD sufferers 
were noted despite all the individuals having lipid levels within the same range. This 
provided an insight into the normal regulation of lipids and lipoproteins on which to 
interpret the findings from the kinetic studies.
Secondly, stable isotope studies of apoB metabolism were performed on individuals 
with selected pathological conditions. Familial hypercholesterolaemia and familial 
defective apoB-100, two conditions with a similar clinical presentation and both due to 
defective LDL receptor-mediated catabolism but each with a different underlying 
aetiology, were studied and compared both to each other and to the results obtained in 
a study of normolipidaemic individuals performed using identical methodology 
(Packard, unpublished). Two unusual individuals, one with hypobetalipoproteinaemia 
and one with analbuminaemia, with plasma apoB levels at opposite ends of the range 
were studied and their apoB metabolism characterised. Although these conditions are 
rare and their apoB metabolism extreme, they can add understanding to apoB 
metabolism in more common states. Lastly, a group of subjects with a more common 
form of dyslipidaemia, mixed hyperlipidaemia, was studied. This type of individual is 
probably the most common to attend Lipoprotein Clinics and so it is important to 
determine the abnormalities in the apoB metabolism.
Finally, using the mixed hyperlipidaemic group the mechanisms of action of two 
HMG-CoA reductase inhibitors, simvastatin and atorvastatin (a new HMG-CoA 
reductase inhibitor), were determined by observing the effect of treatment on apoB 
metabolism. The HMG-CoA reductase inhibitors have come to the fore in recent years 
as drugs of choice for the treatment of various forms of dyslipidaemia and so an 
understanding of the effect that they have on apoB metabolism is important.
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Figure 1.1 Parhofer’s 1991 Model.
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Figure 1.2 Packard’s 1995 Model.
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Chapter 2 General Methods.
2.1 Materials.
Names and addresses of manufacturers and suppliers of reagents, hardware and 
software used for this thesis are given in Appendix 1.
2.2 Subject Selection and Clinical Measurements.
2.2.1 Hyperlipidaemic Subjects.
For each study a computer printout (courtesy of Ms Jennie Johnson, Department of 
Biochemistry) was obtained for all those patients attending Glasgow Royal Infirmary 
within a specified time period whose lipid levels fell within the required range. The 
patients’ case notes were screened to exclude those who fell out with selection 
criteria. Suitable subjects were contacted by letter with a pre-paid reply slip enclosed 
to indicate their interest or otherwise in participating. Interested subjects were then 
contacted by telephone and asked to attend for a screening visit. The majority of 
subjects were patients attending the Lipoprotein and Cardiology Clinics. Where more 
than a single blood sample was required all gave signed informed consent.
2.2.2 Normolipidaemic Controls.
Normolipidaemic subjects were recruited from laboratory staff, friends and colleagues 
from elsewhere in the hospital. In the case of any previously unrecorded abnormality 
being found on physical examination or blood sampling the subject’s general 
practioner (GP) was informed. In all cases where drugs were administered the GP was 
informed.
For all studies, a medical history, including family and social histories, was taken and 
examinations performed as specified by the relevant protocol. Blood pressure was 
taken with the subjects seated for at least five minutes using an Accoson mercury 
sphygmomanometer. Diastolic pressure was recorded as Korotkov phase five. Height 
and weight were measured with shoes and outdoor clothing removed. Anthropometric 
indices were measured in the standing position as follows - waist = the smallest 
circumference between the rib cage and iliac crest, hip = the largest circumference 
between waist and thigh. Where specified by protocol, a standard full physical 
examination was performed.
Venous blood samples were taken via a 22G needle from the ante-cubital fossa with 
subjects seated and the tourniquet applied for the minimum time necessary. All lipid 
and lipoprotein measurements, glucose and insulin levels were taken following an 
overnight fast. Appropriate haematological and endocrine samples were taken to 
exclude a secondary cause for the hyperlipidaemia. These were analysed by the 
haematology and biochemistry laboratories in this hospital. Plasma was either 
separated immediately or samples stored temporarily at 4°C.
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2.2.3 Protocol for Post-heparin Lipase Sampling.
Prior to the administration of heparin the subjects completed a questionnaire to 
exclude any containdications to its use, such as bleeding disorders, hypersensitivity to 
heparin, recent ingestion of aspirin or non-steroidal ant-inflammatory drugs, and 
history of cerebrovascular accident, peptic ulcer disease or rheumatic fever. In 
addition, a recent normal haematology report was required.
Following an overnight fast subjects received an intravenous bolus of heparin at a 
dose of 70iU/kg body weight. Twelve minutes later a 10ml venous sample was taken 
into lithium heparin and placed immediately on ice. Plasma was separated as soon as 
possible.
2.2.4 Protocol for Stable Isotope Administration and Sampling.
Subjects were admitted at 8am after an overnight fast and a 22G cannula placed in one 
forearm. Samples were taken through this during the day, the cannula being kept 
patent by flushing with normal (0.9%) saline. Sterile tri-deuterated leucine (Isotec 
Inc), made up in normal saline, courtesy of the hospital pharmacy, was administered 
into the contralateral arm either as a bolus dose (7mg/kg body weight) or as a primed 
constant infusion using an Imed volumetric infusion pump (0.7mg/kg prime,
0.7mg/kg/hour infusion for 10 hours). The subjects remained fasted during the day but 
were allowed unlimited low calorie fluids. At 6pm they were given a standardised low 
fat meal before the final samples were taken and they were allowed home. Over the 
following two weeks a community nurse came daily to their home or work to take a 
further fasting sample. In total, less than one pint of blood was taken per turnover and 
haemoglobin levels were monitored throughout. The bleeding schedule (with division 
of plasma for analysis) is given in Appendix 2.
2.3 Ethical Approval.
All studies were approved by the Ethical Committee of Glasgow Royal Infirmary.
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2.4 Laboratory Methods.
2.4.1 Beta Quantification of Lipids and Lipoproteins.
The method used is a modification of the standard Lipid Research Clinics Protocol 
(1982) involving the selective precipitation of lipoproteins by the addition of 
sulphated polysaccharides and divalent cations to plasma. This routine analysis was 
kindly performed by the Lipid Section of the Biochemistry Department.
One aliquot (lOOpl) of plasma is set aside for measurement of total cholesterol and 
triglyceride (see below). 5ml plasma in an ultracentrifuge tube is overlayered with 
normal saline, density 1.006, and centrifuged overnight at 35,000rpm, 4°C. The tubes 
are then ‘sliced’ at a constant height to separate the top fraction containing VLDL 
from the bottom fraction containing HDL and LDL. HDL is then separated from LDL 
by precipitation of the latter with heparin and manganous chloride leaving the HDL in 
solution. Cholesterol is measured in the bottom fraction, top (VLDL) fraction and 
HDL. Calculations are performed as follows:-
bottom fraction chol. - HDL chol. = calculated LDL chol. 
total chol. - bottom fraction chol. = calculated VLDL chol.
The measured top (VLDL) cholesterol should equal the calculated VLDL cholesterol 
to within 0.35mmol/l.
The analysis of lipoprotein composition, apoAI and B, apoE phenotyping, Lp(a), 
postheparin lipases and HDL subfractions, and the preparation of tubes for 
ultacentrifugation were kindly performed on a semi-routine basis by the following 
members of the Lipid Research team - Mr Michael McConnell, Mrs Liz Murray, Ms 
Julie MacKenzie and Mrs May Stewart.
2.4.2 Compositional Analysis.
1. Cholesterol -
This was measured by automated analysis on a Hitachi 717 analyser of an enzymatic 
calorimetric test (Boehringer Mannheim). The test principle is as follows :-
chol. esters + H20  - - - ■§ter-ase > chol. + RCOOH 
chol. + 0 2 chol oxidase > 4cholestenone + H20 2 
2H20 2 + 4-aminophenazone + phenol PQD >
4-(p-benzoquinone-monoimino)-phenazone + H20
Sample volume - 3pl, 2 point calibration, read at wavelength 505nm.
2. Triglycerides -
These were measured by automated analysis on a Hitachi 717 analyser of an 
enzymatic calorimetric test (Boehringer Mannheim). The test principle is as follows:-
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triglycerides + 3H20  hpase > glycerol + 3RCOOH 
glycerol + ATP GK ) glycerol-3-phosphate + ADP 
glycerol-3-phosphate + 0 2 GPG "> dihydroxyacetone phosphate + H20 2 
H20 2 + 4-aminophenazone + 4-chlorophenol ^
4(p-benzoquinone-monoimino)-phenazone + 2H20  + Hcl
Sample volume - 3 pi, 2 point calibration, read at wavelength 505nm.
3. Phospholipids -
These were measured by an enzymatic colorimetric test kit (Boehringer Mannheim 
Cat. No. 691844), measured at 500nm, using a Centrifichem Encore analyser (Baker 
Instruments).
Quality controls Precinorm (Boehringer Mannheim Cat. No. 781827)
Precipath (Boehringer Mannheim Cat. No. 1285874).
4. Free Cholesterol -
This was measured using an enzymatic calorimetric test kit (Boehringer Mannheim 
Cat. No. 310328) by the CHOP-PAP method of total cholesterol but omitting the 
enzyme cholesterol esterase. It was analysed using a Centrifichem Encore analyser 
(Baker Instruments) and read at wavelength 500nm
Quality controls as for phospholipids.
5. Esterified Cholesterol -
This was calculated from the total and free cholesterol as follows:-
1.68 x (total chol. - free chol.)
The correction factor of 1.68 is to account for the molecular weight of the different 
cholesterol esters.
Conversion Factors -
The factors used to convert from mmol/1 to mg/dl are as follows:-
cholesterol in mg/dl = 38.7 x value in mmol/1 
triglycerides in mg/dl = 88.7 x value in mmol/1
2.4.3 Measurement of ApoAI and ApoB.
These were measured using liquid-phase immunoprecipitation test kits (Orion 
Diagnostica Cat. Nos. 67249 & 67265), read at 340nm, in a Centrifichem Encore 
analyser (Baker Instruments).
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2.4.4 ApoE Phenotyping.
ApoE phenotyping was carried out using the method of Havekes et al (1987) which is 
based on isoelectric focusing of delipidated plasma followed by electroblotting with 
an anti-apoE antibody. Plasma is incubated with neuraminidase in sodium acetate 
buffer. Samples are delipidated and dried using ethanol:ether, 3:1, and ether and 
dissolved in solubilising buffer with 2-mercaptoethanol. Iso-electric focusing is 
performed overnight on acrylamide gels followed by Western (electro) blotting for 3 
hours. Blots are incubated overnight with the first antibody, an anti-apoE monoclonal 
antibody produced within the laboratory. Following washing, the second antibody is 
incubated with the blots for a minimum of 2 hours. This is a horseradish peroxidase 
anti-mouse IgG antibody (SAPU Prod. No. S 081-201). Plasma from a subject known 
to have the apoE 2/2 phenotype is used as quality control. Blots are developed and 
read.
2.4.5 Measurement of Lp(a).
Lp(a) was quantitatively determined using an enzyme linked immunoassay (ELISA) 
in the form of an Innotest Lp(a) kit (Innogenetics NV), (Dagen et al 1991). All 
solutions, standards, controls and antibodies (mouse monoclonal Lp(a), polyclonal 
sheep anti-apoB labelled with horseradish peroxidase) are supplied. Polystyrene 
microplate strips are pre-coated with the 1 st antibody. Lp(a) binds to this and unbound 
substances are removed by washing. The 2nd antibody binds to the 1st antibody/Lp(a) 
complex due to the apoB moiety of Lp(a). A blue colour forms on incubation which 
turns to yellow when the reaction is stopped with sulphuric acid. The colour, 
proportional to the Lp(a) concentration, is read on a spectrophotometric plate reader at 
450nm.
2.4.6 Post-heparin Lipase Assay.
Post-heparin plasma (PHP) is incubated with 14C-labelled triglyceride/gum arabic 
emulsion. Free fatty acids, released by the action of lipase, are captured by albumin 
and extracted into a solvent. The radioactivity present in this solvent allows 
calculation of the lipase activity. LPL activity is measured by inactivating HL with 
sodium dodecyl sulphate and adding apoCII (Baginsky and Brown 1979). HL activity 
is measured at 0.1M NaCl to inactivate LPL. Activity is measured in a Packard 
scintillation counter and results calculated as follows:-
Lipase activity in pmoles free fatty acid (FFA) released/ml/hour
fCPM samples - CPM blanks x 755.1 
CPM total - background
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2.4.7 Isolation of High Density Lipoprotein Subfractions from Plasma.
Two methods have been used for this isolation - analytical ultracentrifugation and 
precipitation with dextran sulphate.
1. Analytical Ultracentrifugation of HDL -
HDL subfraction masses were estimated in a Beckman Model L8 ultracentrifuge 
equipped with an ultraviolet scanning attachment, (Beckman Instruments) using an 
AnF rotor with double sector centrepiece cells. Plasma density is adjusted by the 
addition of d = 1.31g/ml solution and centrifuged at 40,000rpm, 18°C for 30 hours. 
The top 1ml is gently aspirated and diluted 1:8 with d = 1.20g/ml solution to adjust 
the optical density at 280nm to between 0.8 and 0.9. The double-sectored cell is filled 
with solvent and sample and centrifuged at 42K, 26°C for 2 hours, 11 minutes. The 
cell is then scanned and the HDL2 and HDL3 masses calculated (Shepherd et al 1984).
2. HDL2 and HDL3 Measurement by Dextran Sulphate Precipitation -
ApoB containing lipoproteins were precipitated with 1 Og/1 dextran sulphate (Genzyme 
Dextralip 50), 0.5M MgCl2. The concentration of the supernatant was raised to 1.5M 
which precipitates specifically HDL2. The cholesterol contents of the supernatants 
were measured and HDL3 cholesterol calculated by subtraction (Wamick et al 1982).
2.4.8 Surface Modification of Beckman Ultraclear Centrifuge Tubes.
This modification of the tubes with polyvinyl alcohol allows solutions to gravity-feed 
down their sides (Holmquist 1982).
2.4.9 Protein Assay.
The measurement of protein was performed using a modification of the Lowry et al 
(1951) method involving measurement of proteins with the Folin phenol reagent after 
alkaline copper treatment.
Reagents - 
1) Stock Reagents
2) Working Reagents
Standards -
1) Stock Standard
2) Working Standard
solution A - 2% Na2C 03 in 0. IN NaOH
solution B - 2% Na K Tartrate in deionized water
solution C - 1% Cu S 04 in deionized water
Folin Ciocalteu reagent (BDH, Prod 19058 3Q)
Biuret reagent = 100ml solution A + lml B + 1ml C
- if the sample to be analysed is turbid, e.g. VLDL, add 
sodium dodecyl sulphate (1 mg/ml) to the Biuret reagent 
Folin Ciocalteu diluted 1:1 with deionized water
human serum albumin (Sigma A-8763),
- 1 mg/ml, stored at -70°C
a standard curve in the range 0-5Opg is made by taking 
0, 15, 25, 35, 50pl of stock standard and adjusting 
to a final volume of 400pl with deionized water
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Quality Control -
Stock Solutions bovine serum albumin (Sigma A-4503)
- 0.15mg/ml and 0.30mg/ml, stored at -70°C, IOOjj.1 
adjusted to 400pl with deionized water
Sample Preparation -
Samples were made up to 400pl with deionized water as necessary. Volumes used are
as follows - Total subfractions VLDL! 200pl
VLDL2 lOOpl
IDL 50pl
LDL 25 pi
Isopropanol subfractions 400pl
Method -
i) to 400pl of standard, control and sample add 2ml Biuret reagent
ii) vortex and stand for 10 minutes
iii) add 200pl of working Folin Ciocalteu reagent
iv) vortex and stand for 30 minutes
v) read optical density (OD) at 750nm
vi) plot OD750 against concentrations of standards and read the unknowns from the 
standard curve.
2.4.10 Isolation of Low Density Lipoprotein Subfractions from Plasma.
This was performed as part of collaborative work with Dr Muriel Caslake. The 
method used is that of Griffin et al (1990) involving a density gradient centrifugation 
procedure for the rapid separation of discrete LDL fractions directly from plasma.
Density solutions - 
d = 1.006g/ml
d = 1.182g/ml
Remainder
11.4g NaCl + 0.1 g Na2EDTA + 1 ml NNaOH 
in 1 litre + 3ml H20 , NaCl cone" = 0.195M 
24.98g NaBr + 100ml of d = 1.006g/ml solution
NaCl conen = 0.195M, NaBr cone" = 2.44M
g/ml ml 1.006g/ml ml 1.182g/ml
1.019 100 + 8.5
1.024 100 + 13.6
1.034 100 + 18.6
1.045 100 + 27.8
1.056 100 + 42.9
1.060 100 + 49.3
All densities are checked with a digital densitometer.
Method -
The density of 3ml fresh (not frozen) plasma is adjusted to 1.09g/ml by the addition of 
0.25g solid KBr. The sample and a discontinous six step salt gradient of the above 
densities are introduced into a coated Beckman Ultraclear tube by peristaltic pump, as 
follows:-
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g/ml ml
top 1.019 1
1.024 2
1.034 2
1.045 1
1.056 1
1.060 1
sample 3
bottom 1.182 0.5
This is then centrifuged at 40K, 23°C, 24 hours and stopped without braking. The 
tubes are placed in a purpose-built tube piercing apparatus (Beckman) and the 
separated LDL fractions are upwardly displaced by the introduction of a dense, inert, 
hydrophobic material, Maxidens 1.9g/ml (Nycomed Pharma AS). The eluate is passed 
through a UV detector, with computer link (Beckman Data Graphics), and 
continuously monitored at 280nm to provide an LDL subfraction density profile. In 
most cases it is possible to detect three distinct subfractions, LDLI (1.025-1.034g/ml), 
LDLII (1.034-1.044g/ml) and LDLIII (1.044-1.060g/ml). The LDL concentration at 
280nm is corrected to lipoprotein mass equivalence by applying specific extinction 
coefficients - LDLI 1 optical density unit (1 OD) = 2.63mg lipoprotein/ml, LDLII 1 
OD = 2.94mg lipoprotein/ml, LDLIII 1 OD = 1.92mg lipoprotein/ml.
2.4.11 Sequential Isolation of VLDLj, VLDL2, IDL and LDL.
The four subfractions were prepared from plasma by a modification of the method of 
Lindgren et al (1972).
Density solutions -
d = 1.006g/ml and d = 1.182g/ml were prepared as for LDL subfraction isolation. The 
remainder were prepared as follows:-
g/ml ml 1.006g/ml ml 1.182g/ml
1.0988 50 + 57.78
1.0860 50 + 41.66
1.0790 75 + 53.16
1.0722 75 + 46.50
1.0641 75 + 36.93
1.0588 100 + 42.92
All densities were checked with a digital densitometer.
Method -
The density of 2ml plasma is adjusted to 1.118g/ml by the addition of 0.34lg NaCl. A 
six step salt gradient is set up in a coated Beckman Ultraclear tube as follows:-
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top
bottom
g/ml
sample
1.182
1.0588
1.0641
1.0722
1.0790
1.0860
1.0988
ml
2
2
2
2
1
1
2
0.5
The tube is centrifuged at 39,000rpm, 23°C for 1 hour 38 minutes, lml, containing 
VLDLb is carefully removed from the top by aspiration and replaced with lml d = 
1.0588 solution. VLDL2 is removed in 0.5ml following centrifugation at 18,500rpm 
for 15 hours 41 minutes. Further volumes are not replaced. IDL is removed in 0.5ml 
following centrifugation at 39,000rpm for 2h 35min and LDL is removd in lml 
following 30,000rpm for 21h lOmin. The subfractions are stored at 4°C until analysis.
2.4.12 Preparation of Lipoproteins for Gas Chromatography-Mass 
Spectrometry.
ApoB is precipitated by the addition of an equal volume of isopropanol (Egusa et al
1983) and allowed to stand overnight at 4°C. The samples are centrifuged at 
3,000rpm, 4°C for 30 minutes and the supernatant removed by aspiration. The 
supernatant is saved for protein measurement by the method of Lowry. 3ml 
ethanol:ether, 3:1, is added to each sample (6ml to IDL and LDL) and allowed to 
stand overnight at 4°C. Following centrifugation at 3,000rpm, 4°C for 30 minutes the 
supernatant is removed. This step is repeated for IDL and LDL to ensure complete 
delipidation (the apoB pellet should now be white in colour). The samples are dried 
by the addition of 3ml ether which is allowed to stand for a minimum of 1 hour. This 
is then removed following centrifugation as above and the apoB pellets dried at 37°C 
overnight. The pellets are hydrolysed by addition of 2ml 6N ‘ Aristar’ HC1 (BDH) and 
heated at 110°C for 24 hours. The amino acid hydrolysate is concentrated in a vacuum 
concentrator centrifuge (Howe) and transferred to Chromacol vials before being dried 
completely.
2.4.13 Calculation of Lipoprotein ApoB Plasma Pools.
The apoB content of VLDL!, VLDL2, IDL and LDL was calculated as the difference 
between the total protein and the isopropanol soluble protein for each lipoprotein 
fraction, both measured by the Lowry method. Plasma volume (dl) was estimated as 
40% body weight (kg). ApoB plasma pool sizes (mg) were calculated as the apoB 
mass (mg/dl) multiplied by the plasma volume. The leucine content of the apoB pools 
was then calculated from the apoB amino acid composition.
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2.4.14 Correction for Centrifugal Losses.
Compositional analysis of VLDL b VLDL2, IDL and LDL was performed as described 
above. The recovery of VLDL! + VLDL2 + IDL + LDL cholesterol was compared to 
the ‘non-HDL’ cholesterol in plasma. In addition, the cholesterol content of Lp(a) was 
taken into account (taken as 25%) and the final pool sizes corrected accordingly :-
VLDL^ + VLDLt + IDL + LDL + Lpfai chol. x 100 = % recovery
‘non-HDL’ chol.
Analysis of samples by gas chromatography-mass spectrometry was kindly performed 
by Mrs Dorothy Bedford and Mr Philip Stewart. Preparation of the plasma free amino 
acids was carried out by Mrs Dorothy Bedford and Mrs Grace Stewart.
2.4.15 Preparation of Plasma Free Amino Acids for Gas Chromatography-Mass 
Spectrometry.
lml 10% trichloroacetic acid (TCA) is added to lml plasma to precipitate protein. 
Following centrifugation at 3,000rpm, 4°C for 30 minutes the supernatant is poured 
down a cation exchange column pre-treated with IN HC1 and filled with Dowex AG- 
50W-X8 resin (H+ form, 50-100 mesh, Bio-Rad). The columns are washed with 
deionized water to remove remaining TCA and the amino acids desorbed by twice 
washing with 3ml fresh 4M NH4OH. Samples are then partially dried by centrifugal 
evaporation (Howe) using high temperature before transferring the reduced volume to 
Chromacol vials and taking to dryness.
2.4.16 Sample Analysis by Gas Chromatography-Mass Spectrometry (GC-MS).
Amino acids prepared from plasma and apoB are first derivitised to tert-butyl- 
dimethyl-silyl- (TBDMS-) derivatives before GC-MS analysis. The specific 
enrichment of tracer amino acid in the plasma and apoB derivatives, (the atom percent 
excess or APE), is then measured. The Fisons Trio 1000 quadrupole system (Fisons 
Instuments) was used. The gas chromatograph performs the volatilisation and 
separation of the particles of interest with helium as the carrier gas. The particles are 
then ionised in the mass spectrometer and deflected in an electric field. The resultant 
spectrum shows the relative abundance of each ionised particle. Selected ion 
recording increases the accuracy of measurement by focusing on only a few specific 
masses. Sensitivity is increased by multiple labelling of the tracer amino acid and by 
measuring the m/z 277:m/z 276 (m+3:m+2) ion ratio (Demant et al 1994). The ability 
to measure these higher mass fragments against a low background allowed a more 
precise estimate of enrichment to be made than is possible with direct assay of the m/z 
277:m/z 274 ratio. The m/z 277:m/z 276 ratio is transformed into values for specific 
isotopic enrichment (E) by multiplication by the m/z 276:m/z 274 value which is 
constant. E is calculated as follows:-
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E = (R-Ro)/[(l+R)+(l+Ro)]
where R and Rq are the m/z 277:m/z 274 ratios of the sample and naturally occurring 
leucine respectively. The tracer:tracee ratio (Z) is then calculated as follows:-
Z = E/(Et-E)
2where Et is the isotopic abundance of the infused [ H3]leucine over that which is 
naturally occurring. This method can reliably distinguish 0.1% APE from 0% APE.
2.5 Data Analysis.
2.5.1 Statistical Analysis.
This was performed using Minitab Release 10 for windows (Minitab Inc).Variables 
were analysed either as normal distributions or transformed where necessary. 
Specifications of the statistics used are given where results are reported.
2.5.2 Multicompartmental Modelling.
This was performed using the Simulation Analysis and Modelling programme II 
(SAAM II) version 1.0.2 for Windows (SAAM Institute, 1994). This is an interactive 
programme for the creation of models, design and simulation of experiments, and 
analysis of data. Using the Compartmental Module a model is designed to provide a 
visual representation of the system under study. SAAM II automatically creates 
systems of ordinary differential equations from the model structure. The experiment is 
then specified and added to the differential equations. Samples are associated with 
data. SAAM II then solves and fits the model to the data using complex mathematical 
and statistical techniques.
The model used throughout this thesis is that of Demant et al (1996) and is illustrated 
in Figure 2.1. The plasma leucine is modelled by four compartments. Compartment 3 
is the plasma itself with the input representing the intravenous administration of the 
tracer and the output representing the irreversible loss of leucine from the plasma. 
Compartment 2 is a rapidly turning over pool of body protein, such as 
immunoglobulins, whilst compartment 1 is a more slowly turning over pool, for 
example skeletal muscle. Compartment 4 is the intracellular leucine pool. Exchange 
of leucine is allowed between these compartments. A delay component (15) represents 
the intrahepatic synthesis of apoB. The backbone of the model is the delipidation 
chain representing the stepwise delipidation of VLDL through to LDL. There are 
pathways for the slow removal of remnants from VLDLj (k75 & k0 7), VLDL2 (k10 8 & 
k010) and IDL (k129 & k012). Allowance is made for direct input into each of the four 
fractions and there is irreversible loss of apoB from the system at every level. Finally, 
LDL is allowed to exchange with an extravascular compartment (14). The model was 
made uniquely identifiable by the application of certain physiologically plausible 
constraints. This model is in keeping with current knowledge of the lipoprotein 
system. However, it is perhaps limited by the lack of parallel delipidation pathways
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for VLDL (difficult to accommodate with stable isotope tracers) and by the single 
compartment for LDL (not applicable for polydisperse LDL).
The constraints applied to the model are as follows
k(3,4) “  k(4,3) plasma leucine
II o oo remnant formation
k(o,7)= k(o,io) remnant removal
k(6,5) = k(9;8) VLDLj & VLDL2 peak widths vary together
k(o,9)= k(o,ii) VLDL2 & IDL catabolism
k(0,12) = k(12,9) IDL remnant formation and removal
k(i3,i4) = 2.5 x k(14)13) established from a previous model of LDL kinetics
(Packard 1995)
A systematic approach to the modelling of each experiment was followed. The data 
sets were created and the data weighted accordingly. A model of the plasma only was 
drawn and fitted. This usually took 5-8 iterations. The plasma parameters were then 
fixed. VLDL! then VLDL2 were added and fitted, first unconstrained and then with all 
constraints included. In some instances a constraint was omitted if it worsened the fit. 
The model remained uniquely identifiable provided no more than 21 parameters were 
undefined. Only when these fits were acceptable were IDL and LDL similarly added 
to the model and fitted. A fit was deemed acceptable when the calculated curves 
closely approximated the observed curves, the fractional standard deviations were less 
than 20% and the calculated pool sizes came to within 10% of those observed. In all 
instances good fits were obtained.
Figure 2.2 shows a typical fit for the plasma data with an illustration of the plasma 
model below. Table 2.1 gives the associated parameter and fractional standard 
deviation (FSD) values. Figure 2.3 shows the fits for VLDLj, VLDL2, IDL and LDL 
from the same individual.
Plasma
VLDL1
VLDL2
IDL
LDL
Figure 2.1 The Complete Model (Demant 1996).
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Figure 2.2a The Plasma Curve
Figure 2.2b The Plasma Model
Parameter Value Standard Deviation F.S.D.
k(0,4) 0.070 ** Fixed ** ** Fixed **
k(4,3) 2.500 ** Fixed ** ** Fixed **
k(3,2) 0.067 1.923-003 2.850 - 002
k(2,3) 1.271 2.207 - 002 1.736-002
k(2,l) 0.021 1.059-003 5.124-002
k(l,2) 0.098 3.077 - 003 3.138-002
plasma leucine 318.58 4.357-001 1.368-003
k(0,3) 1.271 2.162-002 1.701 -002
Table 2.1. Typical Plasma Parameter and F.S.D. Values.
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Figure 2.3 The Fits for VLDL/, VLDL 2, IDL and LDL.
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Chapter 3 Normolipidaemia - The Relationships Between
VLDL. LDL and HPL Subfractions and Indices of 
Obesity. Insulin Resistance and Lipase Activity.
3.1 Introduction.
The ‘diagnosis’ of normolipidaemia, in the sense that a lipid pattern is free of 
associated CHD risk, can sometimes be as difficult as diagnosing hyperlipidaemia, 
both in the instance of the population and in that of the individual. What is normal, or 
average, for one population may be elevated for another. This is illustrated in the case 
of the West of Scotland where the average total cholesterol is 6.4mmol/l, which is 
1.2mmol/l higher than the ‘ideal’ level of 5.2mmol/l. In the case of an individual, if he 
suffers from CHD it could be argued that whatever his cholesterol level is, it is too 
high for him. It is not uncommon for sufferers of CHD to have cholesterol levels 
below 6.0mmol/l. The aim of this study was to characterise the inter-relationships 
between various lipid and lipoprotein parameters in a group of normolipidaemic, 
healthy individuals, with attention being paid to differences between the sexes. In 
particular, the differences between lipid levels and VLDL, LDL and HDL subfractions 
were investigated. In addition, the relationships between indices of obesity (body 
mass index, waist:hip ratio), insulin resistance (insulin, glucose) and lipase activity 
(lipoprotein and hepatic lipase) were explored. Much of this work was combined with 
that done by Dr CE Tan (Tan et al 1995) on families of CHD sufferers and 
subsequently published. However, in the current study the definition of 
‘normolipidaemia’ was perhaps more stringent than that used in the paper, being set at 
plasma cholesterol <6.0mmol/l and triglyceride <2.0mmol/l.
Additionally, a small comparative study was performed on a group of CHD sufferers 
with apparently normal lipid levels, looking in particular for evidence of the 
atherogenic lipoprotein phenotype, the insulin resistance syndrome or
hyperapobetalipoproteinaemia. These three disorders have all been linked to 
premature CHD and to a certain extent the characteristics of each overlap. The 
atherogenic lipoprotein phenotype (Austin et al 1990) describes the clustering in an 
affected individual of small, dense LDL, elevated plasma triglycerides and low HDL 
cholesterol. It is thought to be inherited as a single gene trait with a dominant mode of 
inheritance, although the phenotype is often not expressed until the fifth decade in 
males and after the menopause in females. The insulin resistance syndrome (Reaven 
1988), also known as syndrome X, is a plurimetabolic syndrome that includes 
elevated plasma triglycerides, low HDL cholesterol, hypertension, central obesity and 
impaired glucose tolerance. More recently a preponderance of small, dense LDL has 
been added to the syndrome. Hyperapobetalipoproteinaemia (Sniderman et al 1980) 
was first described in sufferers of CHD who were found to have elevated levels of 
LDL apoB despite normal levels of LDL cholesterol and total cholesterol. There is an 
increase in the number of LDL particles and the particles are relatively depleted in 
cholesterol ester such that there is an increased level of small, dense LDL. There may 
be associated elevations in plasma triglyceride and low HDL cholesterol levels but the 
plasma cholesterol is often, although not always, normal. The underlying metabolic
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defect is thought to be an overproduction of VLDL apoB plus a decreased clearance 
of post-prandial triglycerides and free fatty acids. It appears to be inherited in a 
Mendelian codominant fashion and has been linked to familial combined 
hyperlipidaemia. The disorder is often expressed following puberty and prior to the 
development of CHD (Kwiterovich 1988).
3.2 Subject Selection.
3.2.1 Normolipidaemic, Healthy Subjects.
Eighty healthy subjects (41 males, 39 females) with total cholesterol <6.0mmol/l and 
total triglyceride <2.0mmol/l were recruited from laboratory staff, friends, family 
friends and colleagues from this and other hospitals. Individuals were excluded if they 
were taking any medication known to affect lipid metabolism, and if their lipid levels 
were greater than the selection criteria. None of the females were post-menopausal (as 
judged by cessation of menstruation) but 4 may have been peri-menopausal. However, 
none were taking hormone replacement therapy.
3.2.2 Normolipidaemic, CHD Sufferers.
Fifteen individuals (12 males, 3 females) were recruited from a database of patients 
recently admitted to the cardiology wards in this hospital. They were selected due to 
their normal lipid levels (cholesterol <6.0mmol/l, triglyceride <2.0mmol/l). All 
suffered from CHD, with a past history of myocardial infarction, coronary angioplasty 
or coronary artery by-pass grafting. None were on drugs known to affect lipid 
metabolism, in particular beta blockers or thiazide diuretics. The three females in the 
group were all post-menopausal and therefore not separated from the males for 
analysis. None was taking hormone replacement therapy.
3.3 Methods.
Venous blood samples were taken following an overnight fast. The usual endocrine 
and haematological samples were taken to exclude any undetected abnormality that 
may affect lipid levels. Blood pressure and anthropometric indices (height, weight, 
waist and hip) were measured as previously described. Body mass index (BMI) was 
calculated as weight in kg/(height in metres)2 and waist:hip ratio was calculated as 
waist in cm/hip in cm. Forty subjects from the normal group (26 males, 14 females) 
then returned for a second visit for the measurement of post-heparin lipase levels. 
Post-heparin lipases were not measured in the CHD sufferers and in this group only 
seven subjects had LDL subfractions measured.
The following analyses were performed :- beta-quantification, glucose, insulin, non- 
esterified fatty acids (NEFA), apoAI, apoB, post-heparin lipases (lipoprotein lipase, 
LPL, hepatic lipase, HL), HDL subfractions, LDL subtractions and sequential 
isolation of VLDL1? VLDL2, IDL and LDL. In addition, the chemical compositions of 
VLDLj,VLDL2, IDL and LDL were determined. The total concentration of each 
lipoprotein in mg/dl was calculated as the sum of protein + free cholesterol + 
esterified cholesterol + triglyceride + phospholipid (all in mg/dl).
37
Data analysis was then performed firstly on the healthy group as a whole and then 
with the sexes separated. Tables 3.1 and 3.2 give the descriptive statistics for these 
three groups and the comparisons between the sexes using the two sample t-test. 
Significance is set at the higher level of p<0.01 to accommodate the fact that multiple 
comparisons were made and there was, therefore, a possibility of spuriously 
significant findings if the p value was set at 0.05. When indicated by the Anderson- 
Darling test for normality (p<0.05) data were transformed - total triglyceride, waist, 
insulin, apoAI, lipases, LDLI concentration, LDLIII concentration, %LDLI and 
%LDLIII were transformed to their logarithms, whilst the square root of NEFA was 
taken. To further explore the significant results correlation analyses were performed 
on certain parameters. Relationships with Pearson correlation coefficients of r>0.3 or 
r<-0.3 were tested for significance using regression analysis.
The group of CHD sufferers was then compared to the total healthy group. Again 
significance was set at p<0.01 for the reasons given above.
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Table 3. la  Normolipidaemic, Healthy Subject Characteristics.
Group—  
Range
— Males
Mean
(SEM)
--Females
Mean
(SEM)
p value
(males v 
females)
— — -  x  U l d l
Mean
(SEM)
Range Range
Age 32.6 18-50 29.9 18-48 35.3 20-50 0.0056
(years) (0.98) (1.19) (1.46)
SBP 119 92-160 121.4 100-150 117.0 92-160 NS
(mmHg) (1.37) (1.66) (2.16)
DBP 79.0 50-100 80.3 60-100 77.6 50-100 NS
(mmHg) (0.98) (1.21) (1.52)
Height 1.70 1.44-1.93 1.77 1.64-1.93 1.64 1.44-1.88 <0.0001
(m) (0.01) (0.01) (0.01)
Weight 68.5 45.8-93.2 75.1 52.2-93.2 61.6 45.8-81.0 <0.0001
(kg) (1.22) (1.48) (1.23)
Body 23.4 18.2-29.8 23.9 18.3-29.4 23.0 18.2-29.8 NS
Mass (0.30) (0.43) (0.41)
Index
Waist 77.3 60-99 82.3 70-99 72.0 60-89 <0.0001
(cm) (1.02) (1.24) (1.14)
Hip 97.9 84-119 99.5 84-111 96.3 85-119 NS
(cm) (0.77) (0.99) (1.14)
W:H 0.79 0.65-0.96 0.83 0.72-0.92 0.75 0.65-0.96 <0.0001
Ratio (0.01) (0.01) (0.01)
Choi. 4.54 2.70-5.95 4.49 2.70-5.90 4.62 3.05-5.95 NS
(mmol/1) (0.09) (0.12) (0.12)
Trig. 0.86 0.45-1.90 0.94 0.50-1.90 0.79 0.45-1.35 NS
(mmol/1) (0.03) (0.05) (0.03)
VLDL 0.37 0.05-0.90 0.42 0.10-0.90 0.32 0.05-0.65 0.0072
(mmol/1) (0.02) (0.03) (0.02)
LDL 2.82 1.20-4.60 2.84 1.60-4.60 2.79 1.20-4.45 NS
(mmol/1) (0.08) (0.77) (0.10)
HDL 1.35 0.70-2.15 1.20 0.70-2.00 1.50 1.05-2.15 <0.0001
(mmol/1) (0.03) (0.04) (0.04)
SBP = systolic blood pressure, DBP = diastolic blood pressure, W:H Ratio = waist.hip ratio, Choi. = 
plasma cholesterol, Trig. = plasma triglyceride, SEM  = standard error o f  the mean, NS = non­
significant.
On account o f  the multiple comparisons being made the significance level is set at p<0.01.
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Table 3.1b Normolipidaemic, Healthy Subject Characteristics (continued).
Group—  
Range
— Males
Mean
(SEM)
—Females
Mean
(SEM)
p value
(males v 
females)
1 Uldl
Mean
(SEM)
Range Range
Glucose 4.84 3.90-5.90 4.97 4.20-5.90 4.69 3.90-5.50 0.0037
(mmol/1) (0.05) (0.07) (0.07)
Insulin 7.44 1.26-26.6 8.16 2.32-26.6 6.73 1.26-16.3 NS
(mU/1) (0.46) (0.78) (0.49)
NEFA 0.34 0.005- 0.27 0.05-0.79 0.41 0.005- NS
(mmol/1) (0.03) 1.58 (0.03) (0.05) 1.58
ApoAI 119 68-168 116 68-167 122 93-168 NS
(mg/dl) (2.09) (3.01) (2.85)
ApoB 77 41-120 79 41-112 76 42-120 NS
(mg/dl) (1.96) (2.69) (2.87)
LPL 5.12 1.86-12.6 4.82 1.86-9.86 5.67 2.58-12.6 NS
(p.molFA/ (0.35) (0.38) (0.70)
ml/h)
HL 14.5 4.41-34.1 17.7 10.2-34.1 8.58 4.41-14.5 <0.0001
(pmolFA/ (1.15) (1.34) (0.87)
ml/h)
h d l 2 70.8 7-180 54.2 7-153 90.7 17-180 0.0001
(mg/dl) (4.65) (5.0) (6.8)
h d l 3 246.3 116-392 245 116-392 247 182-371 NS
(mg/dl) (6.61) (10) (8.1)
Total 246 196-287 254 150-415 238 150-363 NS
LDL (7.15) (10.7) (9.43)
(mg/dl)
LDLI 59.6 6.25-195 48.9 6.25-117 70.1 22.2-195 0.0019
(mg/dl) (3.86) (4.37) (5.88)
LDLII 148.2 63.7-331 160.5 63.7-331 136.3 67.8-258 NS
(mg/dl) (6.29) (9.54) (7.87)
LDLIII 38.9 4.51-128 46.4 12.6-128 31.6 4.51-67.8 NS
(mg/dl) (2.72) (4.69) (2.32)
%LDLI 27.1 3.07-225 19.2 3.07-41.8 34.8 11.2-225 0.0001
(3.09) (1.53) (5.68)
%LDLII 59.3 32.6-84.6 61.8 33.9-84.6 56.8 32.6-76.4 NS
(1.34) (1.82) (1.89)
%LDLIII 16.3 3.01-63.0 19.0 5.58-63.0 13.6 3.01-25.0 NS
(1.17) (2.05) (1.00)
NEFA = non-esterifiedfatty acid, LPL = lipoprotein lipase, HL = hepatic lipase.
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Table3.2a VLDLj and VLDL2 Compositions (healthy subjects).
Group—  
Range
— Males
Mean
(SEM)
-Females
Mean
(SEM)
p value
(males v 
females)
— — -  i  U l d l
Mean
(SEM)
Range Range
%VLDL, 11.2 4.0-19.9 10.1 4.0-19.9 12.4 6.7-19.2 0.0009
protein (0.36) (0.49) (0.45)
%VLDL, 1.6 0.0-7.5 1.67 0.0-5.9 1.45 0.0-7.5 NS
free chol. (0.21) (0.26) (0.32)
%VLDL, 10.1 0.0-22.3 10.6 2.1-19.1 9.65 0.0-22.3 NS
ester, chol. (0.49) (0.64) (0.75)
%VLDL, 62.2 12.3-78.1 58.8 12.3-76.2 65.8 44.4-78.1 NS
trig. (1.42) (2.50) (0.99)
%VLDL, 14.9 0.0-72.7 18.8 0.0-72.7 10.7 0.0-38.5 NS
phos. (1.73) (3.07) (1.22)
VLDL, 40.3 5.4-136.3 52.4 8.7-136.3 27.6 5.4-34.8 0.0002
Cone" (3.30) (5.19) (2.89)
(mg/dl)
%v l d l 2 15.4 5.8-32.0 14.4 5.8-32.0 16.5 11.1-21.5 0.0071
protein (0.38) (0.63) (0.37)
%v l d l 2 3.2 0.0-9.5 3.3 0.0-9.5 3.1 0.0-7.2 NS
free chol. (0.25) (0.36) (0.36)
%v l d l 2 24.1 9.0-37.6 24.0 9.0-37.6 24.3 12-36.8 NS
ester, chol. (0.72) (1.12) (0.92)
%v l d l 2 37.9 12.8-52.6 35.4 12.8-47.7 40.5 27.5-52.6 0.0022
trig. (0.85) (1.36) (0.83)
%v l d l 2 19.4 0.7-69.2 22.9 12.4-69.2 15.7 0.7-29.6 0.006
phos. (1.34) (2.41) (0.70)
v l d l 2 30.8 6.0-77.7 37.8 6.0-77.7 23.3 7.6-50.5 0.0002
Cone" (1.87) (2.90) (1.65)
(mg/dl)
Free chol. = free cholesterol, ester, chol. = esterified cholesterol, trig. = triglyceride, phos. = 
phospholipid.
On account o f  the multiple comparisons being made the significance level is set at p<0.01.
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Table 3.2b IDL and LDL Compositions (healthy subjects).
__'I ’n fn  1 Group—  
Range
— Males
Mean
(SEM)
-Females
Mean
(SEM)
p value
(males v 
females)
1 U ldl
Mean
(SEM)
Range Range
%IDL 20.1 14.7-25.7 19.8 14.7-25.7 20.3 16.1-25.6 NS
protein (0.26) (0.39) (0.36)
%IDL 5.83 0.0-10.9 5.58 0.0-10.9 6.09 3.1-9.3 NS
free chol. (0.22) (0.37) (0.24)
%IDL 42.8 30.1-55.0 43.6 33.8-55.0 41.9 30.1-49.9 NS
ester, chol. (0.52) (0.70) (0.75)
%IDL 13.2 7.3-33.4 13.4 7.3-33.4 13.0 7.5-26.5 NS
trig. (0.52) (0.77) (0.69)
%IDL 18.2 3.4-24.9 17.6 3.4-24.8 18.7 13.8-24.9 NS
phos. (0.41) (0.73) (0.36)
IDL 40.1 14.4-86.7 40.1 14.4-86.7 40.1 17.8-74.6 NS
Cone" (1.77) (2.67) (2.34)
(mg/dl)
%LDL 24.4 19.8-30.7 24.6 20.6-30.7 24.1 19.8-28.0 NS
protein (0.22) (0.33) (0.30)
%LDL 8.8 4.8-14.3 8.7 4.8-13.8 8.9 4.8-14.3 NS
free chol. (0.26) (0.38) (0.35)
%LDL 43.4 35.6-55.5 43.4 35.6-55.5 43.3 37.0-52.5 NS
ester, chol. (0.42) (0.65) (0.54)
%LDL 4.6 2.1-9.9 4.4 2.1-6.2 4.7 32-9.9 NS
trig. (0.13) (0.16) (0.22)
%LDL 18.9 2.0-26.1 18.8 2.0-26.1 18.9 13.1-23.7 NS
phos. (0.36) (0.65) (0.28)
LDL 196.3 57.9-301 199.7 110-301 192.8 57.9-288 NS
Cone" (5.22) (7.58) (7.22)
(mg/dl)
Free chol. = free cholesterol, ester, chol. = esterified cholesterol, trig. = triglyceride, phos. = 
phospholipid.
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3.4 Results.
3.4.1 Normolipidaemic, Healthy Subjects.
The females were on average five years older than the males (35.3y v 29.9y). There 
was no significant difference in the total lipid levels of the two groups, although the 
males had a tendency to higher triglycerides (p=0.021) as is reflected in their higher 
VLDL cholesterol levels (Table 3.1a). The total concentrations of VLDL! and VLDL2 
were higher in the males (Table 3.2a). Compositional analysis revealed a lower 
protein content in male VLDLj and lower protein and triglyceride in VLDL2 in the 
males but there were no significant differences in the VLDLj and VLDL2 
triglyceride:protein ratios between the sexes. IDL and LDL compositions also showed 
no significant difference (Table 3.2b). The HDL level of the females was higher, 
specifically HDL2 (Table 3.1b). In addition, the LDLI concentration and LDLI 
percentage of the females were greater.
As would be expected, the males were taller and heavier than the females but the 
BMI’s of each group were not significantly different. The waist measurements and 
waist:hip ratios of the males were greater than those of the females, but there was no 
significant difference in the hip measurements. This suggests that the males have 
more central obesity than the females (Table 3.1a). Fasting glucose was significantly 
higher in the males, whilst insulin and NEFA measurements were also higher but not 
significantly so (p=0.13 and p=0.019 respectively). There was no significant 
difference in lipoprotein lipase between the sexes but males had significantly higher 
levels of hepatic lipase (Table 3.1b).
When correlation analysis was performed, first on the total group and then on each sex 
separately, some interesting differences were revealed. Some of the correlations for 
the total group were lost when the sexes were separated probably due to the reduction 
in numbers. As would be expected, the following parameters were correlated with 
each other - total cholesterol, LDL cholesterol, total LDL concentration and total 
apoB. In addition, LDLII concentration correlated with all of the above suggesting 
that it is the major determinant of total LDL in these individuals. These correlations 
persisted when the sexes were separated. Total triglyceride correlated with VLDL 
cholesterol in the whole group. VLDLj concentration correlated with VLDL 
cholesterol in the total group and the females, but not in the males. HDL cholesterol in 
all groups correlated with HDL2 but not with HDL3. LDLI concentration correlated 
positively with HDL cholesterol in the total group but this correlation was lost when 
the sexes were separated. Analysis of the LDL subfraction percentages showed some 
differing correlations between the groups (Table 3.3). %LDLI correlated significantly 
with HDL cholesterol and HDL2 in all groups. %LDLI correlated negatively with 
LDLII concentration in the total group and the females but this was not significant in 
the males (p=0.550). %LDLI correlated negatively with LDLIII concentration in all 
the groups. %LDLII correlated negatively with LDLI concentration in the total group 
and the females, whilst in the males %LDLII correlated negatively with LDLIII 
concentration. %LDLIII correlated negatively with LDLI concentration in all the 
groups. In the males, %LDLIII correlated negatively with LDLII concentration, but 
this was not significant in the total group (p=0.07) or the females (p=0.846).
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Indices of Obesity (Table 3.4).
In the total group, BMI correlated positively with waist, triglyceride, glucose, insulin, 
apoB and VLDL! concentration, and negatively with HDL cholesterol and HDL2. In 
the males, BMI correlated with waist, waisthip ratio, triglyceride, insulin and apoB 
but the correlations with glucose, VLDLj concentration, HDL cholesterol and HDL2 
lost significance. In the females, BMI showed no significant correlations. Waisthip 
ratio in the total group correlated negatively with HDL cholesterol and positively with 
glucose, hepatic lipase and VLDLj and VLDL2 concentrations. None of these 
correlations remained significant when the sexes were separated. In males, waisthip 
ratio correlated with BMI.
Indices of Insulin Resistance (Table 3.5).
In the total group, insulin correlated positively with waist, BMI, triglyceride, glucose 
and VLDLj concentration. In males, only the correlation with BMI remained 
significant, whilst in females all correlations were lost. Glucose correlated positively 
with waist, waisthip ratio, BMI, and insulin in the total group, but all these lost 
significance when the sexes were separated. In females, glucose correlated negatively 
with %LDLIII. As a possible alternative measure of insulin resistance, the 
insulin:glucose ratio was calculated but this showed no significant correlations and so 
was not used further.
Indices of Lipase Activity (Table 3.6).
Lipoprotein lipase correlated only with HDL2 and this lost significance when the 
sexes were split. Hepatic lipase showed more correlations, correlating positively with 
waist:hip ratio and VLDLj concentration, and negatively with HDL cholesterol and 
HDL2. However, again these lost significance when the sexes were analysed 
separately. Because lipoprotein lipase and hepatic lipase are known to have opposing 
actions on HDL, the LPL:HL ratio was calculated, normalised by transformation to its 
logarithm, and used for analysis (Brinton et al 1994). However, it added nothing to the 
analysis, reflecting only the positive correlation of lipoprotein lipase and the negative 
correlation of HL with HDL2 (r = 0.654, pO.OOl).
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Table 3.3 LDL Subfraction Percentages - Pearson correlation coefficients (r).
LDLI
%
Male
LDLII
%
Male
LDLIII
%
MaleTotal Female Total Female Total Female
W aist -0.331 -0.310 0.150 0.063 0.008 -0.163 0.131 0.145 -0.191
m
W:H
Ratio
-0.262 -0.239 0.152 -0.005 -0.123 -0.171 0.112 0.264 -0.254
BMI -0.245 -0.245 -0.186 0.132 0.014 0.198 0.165 0.133 0.151
Chol.
mmol/l
0.090 0.033 0.106 0.033 0.186 -0.083 -0.175 -0.192 -0.128
Trig.
mmol/l
-0.308 -0.249 -0.241 0.157 - 0.110 0.353 0.075 0.155 -0.135
HDL-C
mmol/l
0.589§ 0.508* 0.439* -0.396* -0.226 -0.456* -0.276 -0.176 -0.200
h d l 2
mg/dl
0.656§ 0.546* 0.669§ -0.413* -0.085 -0.643§ -0.35* -0.328 -0.283
h d l 3
mg/dl
-0.007 -0.162 0.282 -0.142 -0.131 -0.160 0.095 0.372 -0.368
Glucose
mmol/l
-0.165 -0.268 0.317 0.065 0.109 -0.158 -0.098 0.031 -0.445*
Insulin
mU/l
-0.157 -0.301 0.106 0.220 0.435 -0.023 -0.140 -0.244 -0.105
LPL
pmolFA
/ml/h
0.138 -0.125 0.377 -0.291 -0.137 -0.467 -0.023 0.132 -0.055
HL
pmolFA
/ml/h
-0.259 0.242 -0.279 0.133 -0.168 0.208 0.345 0.032 0.396
LPL:
HL
0.322 -0.167 0.510 -0.319 -0.034 -0.513 -0.290 0.070 -0.399
ApoB
mg/dl
-0.306 -0.286 -0.316 0.344 0.298 0.361 -0.080 -0.128 -0.084
VLDLt
Cone"
mg/dl
0.253 -0.123 -0.154 0.116 -0.120 0.221 0.167 0.192 -0.057
v l d l 2
Cone"
mg/dl
0.317 -0.278 -0.279 0.224 -0.049 0.360 0.191 0.263 -0.102
Total
LDL
mg/dl
-0.132 -0.074 -0.093 0.297 0.370 0.182 -0.169 -0.262 -0.147
LDLI
mg/dl
(0.897) (0.897) (0.859) -0.355* 0.049 -0.717§ -0.59§ -0.595§ -0.495*
LDLII
mg/dl
-0.366* -0.103 -0.597§ (0.722) (0.702) (0.722) -0.213 -0.479* -0.033
LDLIII
mg/dl
-0.584§ -0.566§ -0.496* -0.077 -0.474* 0.173 (0.91) (0.902) (0.907)
IV: H ratio waist:hip ratio, BMI body mass index , chol. total plasma cholesterol, trig. total
plasma triglyceride, HDL-C total HDL cholesterol, LPL lipoprotein lipase, HL hepatic lipase,
apoB = total plasma apoB, *  p<O.Ol, §  = p<0.00l.
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Table 3.4 Indices o f  Obesity - Pearson correlation coefficients (r).
ofvt i __ W 'H__
Total Males Females Total Males Females
Waist
(m)
Waist: Hip 
Ratio
Body Mass 
Index
0.616§
0.261
0.875§
0.646§
0.361
-0.150
(0.808)
0.261
(0.744)
0.646§
(0.716)
-0.150
Chol.
(mmol/l)
0.180 0.247 0.140 -0.005 0.085 0.040
Trig.
(mmol/l)
0.452§ 0.537§ 0.285 0.276 0.221 0.133
HDL-chol.
(mmol/l)
-0.340* -0.346 -0.254 -0.378* -0.282 0.012
h d l 2
(mg/dl)
-0.289 -0.249 -0.304 -0.273 -0.268 0.116
h d l 3
(mg/dl)
0.088 0.262 -0.184 0.096 -0.022 0.307
Glucose
(mmol/l)
0.343* 0.273 0.331 0.350* 0.266 0.172
Insulin
(mU/l)
0.396§ 0.551 § 0.183 0.118 0.133 -0.025
LPL
(pmolFA/
ml/h)
0.061 0.075 0.180 -0.131 0.007 -0.053
HL
(pmolFA/
ml/h)
0.187 0.075 0.047 0.511* -0.005 0.304
LPL:HL
Ratio
-0.057 0.048 0.088 -0.380 0.019 -0.167
ApoB
(mg/dl)
0.308* 0.435* 0.158 0.129 0.236 -0.004
VLDL,
Cone"
(mg/dl)
0.354* 0.322 0.322 0.311* 0.113 0.115
v l d l 2
Cone"
(mg/dl)
0.271 0.290 0.142 0.341* 0.102 0.214
Total LDL 
(mg/dl)
0.217 0.327 0.071 0.051 0.098 -0.123
LDLI
(mg/dl)
-0.126 -0.048 -0.142 -0.218 -0.158 0.076
LDLII
(mg/dl)
0.242 0.256 0.186 0.048 0.036 -0.200
LDLIII
(mg/dl)
0.268 0.323 0.167 0.133 0.329 -0.295
BALI body mass index, W:H = waist: hip ratio, chol. total plasma cholesterol, trig. total plasma
triglyceride, HDL-chol. total HDL cholesterol, LPL lipoprotein lipase, HL hepatic lipase,
apoB total plasma apoB, *  p<0.01, §  p<O.OOI.
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Table 3.5 Indices o f  Insulin Resistance - Pearson correlation coefficients (r).
— Insulin—
Males
-G lucose--
MalesTotal Females Total Females
Waist
(m)
0.310* 0.403 0.101 0.433§ 0.291 0.320
Waist: Hip 
Ratio
0.118 0.133 -0.025 0.350* 0.266 0.172
Body Mass 
Index
0.396§ 0.551 § 0.183 0.343* 0.273 0.331
Chol.
(mmol/l)
-0.022 0.178 -0.207 0.161 0.119 0.345
Trig.
(mmol/l)
0.324* 0.362 0.214 0.210 0.085 0.212
HDL-chol.
(mmol/l)
-0.275 -0.317 -0.139 -0.175 0.014 0.050
HDL2
(mg/dl)
-0.188 -0.370 0.082 -0.298 -0.072 -0.188
h d l 3
(mg/dl)
Glucose
(mmol/l)
Insulin
(mU/1)
0.146
0.398*
0.109 
0.315
0.212
0.399
0.110
0.398*
0.126
0.315
0.164
0.399
LPL
(pmol FA/ 
ml/h)
-0.123 -0.239 0.156 0.188 0.124 0.418
HL
(pmoIFA/
ml/h)
0.281 0.278 0.034 0.270 0.094 0.362
LPL:HL
Ratio
-0.199 -0.288 0.099 0.015 0.081 0.223
ApoB
(mg/dl)
0.078 0.244 -0.119 0.150 0.104 0.169
VLDL,
Cone"
(mg/dl)
0.336* 0.303 0.311 0.273 -0.005 0.369
v l d l 2
Cone"
(mg/dl)
0.190 0.173 0.103 0.210 0.025 0.153
Total LDL 
(mg/dl)
0.020 0.244 -0.248 0.284 0.220 0.308
LDLI
(mg/dl)
-0.142 -0.166 -0.037 -0.041 -0.158 0.418
LDLII
(mg/dl)
0.147 0.381 -0.169 0.267 0.251 0.144
LDLIII
(mg/dl)
-0.113 -0.099 -0.211 0.020 0.116 -0.322
BMI = body mass index, W:II = waist.hip ratio, chol. =  total plasma cholesterol, trig. =  total plasma
triglyceride, IIDL-chol. = total IIDL cholesterol, LPL = lipoprotein lipase, IIL = hepatic lipase,
apoB = total plasma apoB, *  = p<0.01, §  =p< 0.001.
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Table 3.6 Lipase Activity  -  Pearson correlation coefficients (r).
V P I ___h l
Total
------L i  L --------
Male Female Total Male Female
Waist
(m)
-0.002 0.117 0.229 0.386 -0.128 0.087
W:H
Ratio
-0.131 0.007 -0.053 0.511* -0.005 0.304
BMI 0.061 0.075 0.180 0.187 0.075 0.047
Chol.
(mmol/l)
0.090 0.125 0.030 -0.056 -0.209 0.163
Trig.
(mmol/l)
-0.074 -0.017 0.011 0.294 0.203 -0.222
HDL-chol.
(mmol/l)
0.286 0.307 0.025 -0.441* -0.187 -0.196
HDL2
(mg/dl)
0.535* 0.446 0.770 -0.545* -0.404 -0.469
h d l 3
(mg/dl)
0.262 0.245 0.366 -0.153 -0.083 -0.815
Glucose
(mmol/l)
0.188 0.124 0.418 0.270 0.094 0.362
Insulin
(mU/l)
LPL
(jamolFA/
ml/h)
HL
(jimolFA/
ml/h)
-0.123
-0.337
-0.239
-0.484
0.156
0.033
0.281
-0.337
0.278
-0.484
0.034
0.033
LPL:HL
Ratio
(0.815) (0.942) (0.780) (-0.76) (-0.73) (-0.58)
ApoB
(mg/dl)
-0.236 -0.108 -0.426 0.023 -0.152 -0.038
VLDL,
Cone"
(mg/dl)
-0.206 -0.342 0.316 0.557§ 0.427 0.100
v l d l 2
Cone"
(mg/dl)
-0.189 -0.159 -0.012 0.296 -0.074 -0.230
Total LDL 
(mg/dl)
0.134 0.199 0.065 -0.001 -0.183 0.165
LDLI
(mg/dl)
0.175 -0.027 0.354 -0.219 0.142 -0.132
LDLII
(mg/dl)
-0.046 0.084 -0.196 0.110 -0.190 0.333
LDLIII
(mg/dl)
0.030 0.226 -0.032 0.356 -0.008 0.445
IV:II ratio = waist. hip ratio, BMI =  body mass index, chol. = total plasma cholesterol, trig. =  total
olasma triglyceride, HDL-chol. =  total HDL cholesterol, LPL =  lipoprotein lipase, HL = hepatic
!ipase, apoB  =  total plasma apoB, *  =  p<0.01, §  =  p< 0.001.
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3.4.2 Normolipidaemic, CHD Sufferers.
When compared to the healthy subjects, the CHD sufferers were significantly older 
(54.3y v 32.6y) and had higher blood pressures (145/89mmHg v 119/79mmHg). Total 
cholesterol, triglyceride, LDL cholesterol and apoB levels were significantly elevated 
despite the lipid level inclusion criteria being the same in each group. In addition, 
HDL cholesterol was lower. Total LDL and LDLIII concentration were elevated 
whilst percentage LDLI was reduced. Compositional analysis revealed no significant 
differences with the exception of elevated phospholipids in IDL and LDL and reduced 
esterified cholesterol in LDL. Weight, body mass index, waist measurement and 
waist:hip ratio were elevated. Glucose and insulin measurements were also 
significantly higher in this group. Thus, despite having lipid levels within the ‘normal 
range’, this group of CHD sufferers appears to be a different population of individuals 
differing significantly from the healthy group. These findings are shown in Table 3.7, 
(a & b).
Correlation analysis was then performed on the CHD group and the relationships 
observed compared to those seen in the healthy group. In general, most of the 
correlations seen in the healthy group were also seen in the CHD group. However, 
many of these correlations were not significant, probably as a consequence of the 
smaller numbers analysed. As in the healthy group, total cholesterol, LDL cholesterol 
and total LDL correlated with each other. However, in the CHD group, LDLII 
concentration and apoB did not correlate with the above. Instead apoB showed a 
significant negative correlation with HDL cholesterol and HDL2. Total triglyceride in 
this group correlated with VLDL cholesterol, VLDLj concentration and LDLIII 
concentration. As in the healthy group, HDL cholesterol correlated with HDL2 but not 
HDL3. A s in the healthy males, %LDLIII showed a significant negative correlation 
with LDLII concentration. Correlations between the indices of obesity and insulin 
resistance and other parameters did not reach significance in this group, again this is 
likely to be due to the small sample size.
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Table 3 .7a Normolipidaemic, CHD Sufferers - subject characteristics.
------------CHD
Mean
(SEM)
Sufferers------
Range
p values
CHD sufferers v 
healthy group
Age 54.3 37-66 <0.0001
(years) (2.32)
SBP 145 110-210 0.0040
(mmHg) (7.34)
DBP 89 78-110 0.0020
(mmHg) (2.51)
Height 1.71 1.47-1.84 NS
(m) (0.03)
Weight 82.5 43-104 0.0095
(kg) (4.49)
Body Mass 27.8 19.9-34.4 0.0009
Index (1.02)
Waist 93.9 71-113 <0.0001
(cm) (2.73)
Hip 103.1 88-113 NS
(cm) (1.89)
Waist:hip 0.91 0.8-1.1 <0.0001
Ratio (0.02)
Cholesterol 5.58 4.80-6.00 <0.0001
(mmol/l) (0.24)
Triglyceride 1.37 0.80-2.00 <0.0001
(mmol/l) (0.11)
VLDL-chol. 0.47 0.15-0.95 NS
(mmol/l) (0.07)
LDL-chol. 4.05 2.85-4.90 <0.0001
(mmol/l) (0.13)
HDL-chol. 1.07 0.80-1.65 0.0022
(mmol/l) (0.07)
SBP = systolic blood pressure, DBP = diastolic blood pressure, W:H Ratio = waist.hip ratio. 
On account o f  the multiple comparisons being made the significance level is set at p<0.01.
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Table 3.7b Normolipidaemic, CHD Sufferers - subject characteristics 
(continued).
------------CHD
Mean
(SEM)
Sufferers------
Range
p values
CHD sufferers v 
healthy group
Glucose 5.59 4.40-7.70 0.0085
(mmol/I) (0.24)
Insulin 10.72 5.30-13.3 0.0006
(mU/1) (0.81)
ApoAI 113 79-154 NS
(mg/dl) (5.45)
ApoB 114 88-147 <0.0001
(mg/dl) (4.05)
h d l 2 78.3 9-263 NS
(mg/dl) (18.0)
h d l 3 261.1 146-331 NS
(mg/dl) (14.4)
Total LDL 374 292-414 <0.0001
(mg/dl) (16.1)
LDLI 40.1 12.8-89.4 NS
(mg/dl) (9.65)
LDLII 213.7 148.7-300.5 NS
(mg/dl) (25.7)
LDLIII 120.1 30.2-199.1 0.0077
(mg/dl) (26.3)
%LDLI 10.4 3.5-21.8 0.0085
(2.21)
% LDLII 56.9 39.7-75.9 NS
(5.87)
% LDLIII 32.7 7.4-55.2 NS
(7.18)
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3.5 Discussion.
The most striking finding to emerge from this study is that even within a population 
defined by common criteria as normolipidaemic (plasma cholesterol <6.0mmol/l, 
triglyceride <2.0mmol/l) several subpopulations can be found, distinguishable by a 
clustering or otherwise of factors known to have an adverse effect on the risk of CHD 
development. In the group of healthy individuals the separation is based on sex, with 
males showing lower HDL cholesterol and HDL2 levels, lower %LDLI, higher 
hepatic lipase, higher glucose and a tendency to central obesity. The CHD sufferers 
showed more extreme differences from the healthy group. Their lipid levels were at 
the upper end of the normal range, HDL levels were lowered, the LDL subfraction 
profiles showed decreased LDLI and elevated LDLIII, apoB was raised and indices of 
obesity and insulin resistance were elevated.
The sex differences in lipid and lipoprotein parameters in healthy individuals have 
been investigated before (Watson et al 1994, Tan et al 1995). Most of the findings 
here are in keeping with those from the other studies although in some instances the 
relationships are less strong. This may be due to the stricter selection criteria in the 
current study that effectively excludes those individuals whose slightly higher lipid 
levels may have more influence on parameter relationships. Correlation analysis of the 
healthy group reveals certain patterns. LDLII concentration appears to be the major 
determinant of total LDL, and HDL2 the major determinant of total HDL. Analysis of 
the LDL subfractions in the total group showed that %LDLI, whilst correlated 
positively with HDL2, was negatively correlated with the concentrations of LDLII and 
LDLIII. For %LDLII, there was a split in the relationship when the sexes were 
separated - in males %LDLII correlated negatively with LDLIII concentration, whilst 
in the females %LDLII correlated negatively with LDLI concentration.
The indices of obesity used in this study are body mass index (BMI) and waist:hip 
ratio. BMI gives an indication of total obesity whilst waisthip ratio reflects the 
regional distribution of body fat. The distinction is relevant as studies have suggested 
that regional body fat distribution is a more significant risk factor for CHD 
development than total obesity, in particular that those individuals with more visceral 
or intra-abdominal obesity are at a greater risk (Despres et al 1990). Males have a 
tendency when gaining weight to increase their abdominal girth (becoming ‘apple- 
shaped’) whilst in females weight gain is mostly in the gluteal region (‘pear-shaped’). 
In the current study, despite having similar BMI measurements the males had 
significantly greater waist measurements and waisthip ratios. In the males, BMI and 
waisthip measurement showed a positive relationship that was not seen in the 
females. In addition, the relationships seen between various study parameters and 
BMI and waist:hip ratio in the total group mostly persisted when the males were 
analysed alone but were not significant in the females alone. In this study, BMI 
showed more significant correlations with other parameters than did waisthip ratio, 
perhaps because the subjects were mostly of normal weight and without the metabolic 
complications of abdominal obesity. As BMI increased there was an associated 
increase in triglyceride and decrease in HDL cholesterol. There was also a significant 
correlation between increasing BMI and increases in glucose and insulin, reflecting 
the metabolic link between obesity and insulin resistance. The males in this study had
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higher glucose levels than the females and non-significant elevations in insulin. They 
therefore appear to be relatively more insulin resistant than the females. A 
predominance of small, dense LDL, as seen in these males, has also been linked with 
the insulin resistance syndrome. Lipase activity also showed links with obesity, as 
hepatic lipase correlated positively with waist:hip ratio.
When compared to the healthy group, the CHD sufferers show a clustering of adverse 
lipid and lipoprotein factors - elevations in total cholesterol, triglyceride, LDL 
cholesterol and apoB levels, low levels of HDL cholesterol and a predominance of 
small, dense LDL. In addition, these individuals are hypertensive and centrally obese 
with elevations in fasting glucose and insulin. They, therefore, show characteristics in 
keeping with each of the three ‘disorders’ of atherogenic lipoprotein phenotype 
(ALP), the insulin resistance syndrome (IRS) and hyperapobetalipoproteinaemia 
(hyperapoB). Their small, dense LDL, elevated triglyceride and apoB, and low HDL 
cholesterol would fit with the ALP. These factors, plus their central obesity, 
hypertension and elevated glucose and insulin levels are in keeping with the IRS. 
HyperapoB is suggested by their elevated apoB levels and the relative depletion of 
esterified cholesterol in LDL. As each of these disorders has been associated with an 
increased risk of CHD it is not difficult to see why these individuals should suffer 
from CHD despite normal plasma cholesterol and triglyceride levels. Of particular 
interest in this group were the relationships between plasma triglyceride levels and 
LDLIII concentration and VLDL! concentration (see below), as this influence of 
triglyceride was not seen in the healthy group.
The correlations seen between the subfractions of VLDL, LDL and HDL and indices 
of obesity, insulin resistance and lipase activity can be explained by the metabolic 
model shown in Figure 3.1. As noted in our subjects, elevations in BMI are associated 
with relative insulin resistance (seen as increases in fasting glucose and insulin 
levels). In the insulin resistant state, the increased intrahepatic availabilty of 
triglyceride is believed to result in the secretion of apoB predominantly as 
triglyceride-rich VLDL!. VLDL} is only slowly metabolised to LDL. The persistance 
in plasma of triglyceride-rich VLDL allows CETP mediated neutral lipid exchange of 
triglyceride from VLDL to LDL and HDL2 in exchange for cholesterol ester. This 
then provides suitable substrates for hepatic lipase resulting in the production of 
small, dense species of LDL (LDLII and LDLIII) and HDL (HDL3). The higher levels 
of hepatic lipase seen in males and in those with increased waisthip ratios increases 
the conversion of LDLI to LDLIII. In this study, the healthy males had a higher 
hepatic lipase activity than the healthy females, associated with lower LDLI and HDL 
cholesterol. This sex difference in hepatic lipase activity can also explain the 
reciprocal relationship seen between %LDLII and the concentrations of LDLI and 
LDLIII. In males LDLII concentration decreases as more is lipolysed to LDLIII by the 
action of hepatic lipase. In females the lower activity of hepatic lipase means that the 
majority of LDL remains as the less dense species of LDLI rather than being lipolysed 
to LDLII and LDLIII. Also seen in this study was the positive correlation between 
LDLI and HDL, in particular HDL2, and the negative association between hepatic 
lipase and HDL cholesterol levels.
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The study of Watson et al found hepatic lipase to be responsible for the sex 
differences in LDL subfraction profiles, whilst the study of Tan et al found plasma 
triglyceride to be the most important determinant of the LDL subfraction profile. In 
the healthy group, neither hepatic lipase nor plasma triglyceride showed significant 
correlations with the LDL subfraction profile. However, the males did have a higher 
hepatic lipase activity than the females and a tendency to higher triglyceride levels. 
The group of CHD sufferers had significantly higher triglyceride levels and in 
addition showed a strong relationship between plasma triglyceride and LDLIII 
concentration, as noted above. Thus, it could be that the CHD sufferers have reached a 
critical or ‘threshold’ triglyceride level above which the LDL subfraction profile 
appears to change, moving towards a predominance of LDLIII. This threshold level 
has been reported previously by other workers as triglyceride levels of 1.1 mmol/l 
(Austin et al 1990), 1.3mmol/l (Tan et al 1995) and 1.6mmol/l (Superko and Krauss
1992). The mean plasma triglyceride in the CHD sufferers was 1.37mmol/l as 
compared to 0.86mmol/l in the healthy group, whilst the mean LDLIII concentrations 
in each group were 120mg/dl and 39mg/dl respectively.
To summarise, even in normolipidaemia relationships exist between the lipoprotein 
subfractions and indices of obesity, insulin resistance and lipase activity that can 
influence an individual’s risk of CHD development. They are dependent on obesity 
and on the relative activity of hepatic lipase, both of which show differences between 
the sexes. Insulin resistance appears to mediate its adverse effect through the 
increased intrahepatic triglyceride availability and resultant production of triglyceride- 
rich lipoproteins, as is seen in the CHD group. In the complete group of 95 
normolipidaemic individuals there appears to be three distinct subgroups with a 
gradient of CHD risk. At least risk are the healthy females and at most risk are those 
already identified as suffering from CHD. The healthy males sit between the two 
groups in their degree of risk. Even within this narrow range of lipid levels, the 
gradual increase in the levels appears to be adversely related to the existance of a 
clustering of adverse lipoprotein parameters. This study serves to illustrate the fact 
that total plasma lipid levels can be falsely reassuring when used as an indication of 
CHD risk.
INSULIN RESISTANCE-
a. Glucose \
b. Insulin \
OBESITY-
a. BMI -
b. W:H
HEPATIC LIPASE-
a. Sex ^5^.
b. W:H TG-rich VLDLHDL
LPL It  CETP
LDL
LDLIII
HDL
Figure 3.1 The Relationships Between the Subfractions o f VLDL, LDL and HDL 
and Indices o f  Obesity, Insulin Resistance and Lipase Activity.
BMI = body mass index, W:H = waist. hip ratio, CETP = cholesterol ester transfer protein,
LPL = lipoprotein lipase.
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Chapter 4 Stable Isotope Turnovers in Familial
Hypercholesterolaemia and Familial Defective ApoB-100.
4.1 Introduction.
Two inherited conditions, familial hypercholesterolaemia (FH) and familial defective 
apoB-100 (FDB), arise from a disruption of the catabolism of LDL by the LDL (or 
B/E) receptor, resulting in elevations in plasma LDL cholesterol and total cholesterol. 
Their difference lies in the manner in which LDL catabolism is disrupted. In FH there 
is a deficiency of functioning LDL receptors leading to reduced receptor-mediated 
LDL clearance, whilst in FDB it is the receptor ligand, apoB-100, that is defective 
thus reducing the binding of LDL to the receptor and so its clearance. Both are 
inherited in an autosomal dominant fashion with a frequency in the population in the 
heterozygous form of approximately 1:500, making them two of the most common 
autosomal dominant conditions reported. Each can present with the same features - 
elevated plasma cholesterol (specifically LDL cholesterol), tendon xanthomata and 
premature CHD. These features, plus a family history of affected members, have 
traditionally been used to define FH. However, the more recently recognised 
condition of FDB fits with the same definition and so the two cannot be distinguished 
by these criteria. Perhaps a more correct definition should include the aetiological 
feature in each case i.e. i). a receptor defect, or ii). a ligand defect. In the clinical 
context, however, this discrimination may be neither possible, requiring more 
complex laboratory techniques, nor relevant to patient management, as in the 
heterozygous form both conditions are managed similarly.
4.2 Familial Hypercholesterolaemia - a brief overview.
The medical literature of last century saw an increasing interest in xanthomata leading 
to the suggestion in the 1870’s that they might arise from hyperlipidaemia. However, 
it was Muller in 1938 who first recognised the condition of Familial 
Hypercholesterolaemia to include the three features “xanthomata, 
hypercholesterolaemia and angina pectoris”. Its autosomal dominant mode of 
inheritance was definitively described in 1964 by Khachadurian in his studies of FH 
families in Lebanon. The prevalence of FH is estimated at 1:500 in the heterozygous 
form and 1:1,000,000 in the homozygous form (Goldstein and Brown 1989). In 
certain populations, however, the prevalence is much greater. For example, due to the 
founder effect in South African Afrikaaners the prevalence is 1:100 for heterozygotes 
and 1:30,000 for homozygotes (Seftel et al 1980).
The most consistent manifestation of FH is an elevated plasma cholesterol level, 
specifically LDL cholesterol. Xanthomata and premature CHD (defined as occurring 
before the age of 55 years in men and 65 years in women) are highly prevalent 
amongst FH sufferers but not inevitable. This intra-individual variation in the clinical 
manifestation of FH arises for several reasons. Firstly, to date over 150 mutations of 
the LDL receptor gene have been reported leading to different severities of receptor 
deficiency. Secondly, the unaffected LDL gene and other more minor genes, e.g. 
apoE, HDL etc, can influence the lipid metabolism in any one individual. Thirdly,
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lifestyle factors such as diet, obesity and smoking are as important in FH as in 
polygenic hypercholesterolaemia. It is interesting to note that in rare instances it is 
possible to have FH but have a normal cholesterol level. This can arise if there is an 
additional genetic defect of lipid metabolism that counterbalances the cholesterol 
elevation due to FH. This is illustrated in the case reported by Zambon et al in 1993 of 
an individual with heterozygous FH plus homozygous LPL deficiency. Despite having 
FH, his total cholesterol was 6.5mmol/l with an LDL cholesterol of only 0.6mmol/l 
due to the absence of LPL-mediated VLDL to LDL delipidation. This is an extreme 
illustration of how individuals with FH may present with a variety of phenotypes.
The treatment of heterozygous FH includes the modification of lifestyle factors, with 
particular attention to dietary control. However, most patients will require drug 
therapy. Those most commonly used are the bile acid sequestrants (resins) and the 
HMG-CoA reductase inhibitors (statins), either alone or in combination. These 
presumably act by up-regulating the functioning LDL receptors and so increasing 
LDL catabolism. In the homozygous form of FH treatment with resins or statins is, in 
theory, ineffectual as there are no functioning receptors available for up-regulation. 
However, this is not strictly the case as certain LDL receptor mutations retain some 
receptor activity, albeit markedly reduced. Furthermore, studies of individuals with 
complete absence of receptor function have shown some response to statins (Feher et 
al 1993) suggesting that these drugs can act by a mechanism additional to receptor up- 
regulation. The majority of homozygous FH individuals (and some with severe 
heterozygous FH) require more aggressive treatment with plasmapharesis or LDL- 
apharesis to significantly lower their cholesterol levels.
The prognosis in heterozygous FH is variable reflecting the variability in clinical 
presentation. However, most affected individuals will ultimately develop CHD, many 
prematurely. Studies have suggested that the development of CHD is happening at an 
increasingly early age from one generation to the next (Williams et al 1993). This 
anticipation phenomenon is illustrated by the case of one Africaaner family with FH - 
in the first generation the age of death of the one affected individual was 76 years, in 
the second the average age of death was 55 +/- 10 years (n=4), and in the third the 
average age of death was 37 +/- 8 years (n=5), (Marais 1994, unpublished 
observation). Much of this apparent increase in disease severity can be explained by 
detrimental lifestyle changes and thus, in theory, is amenable to correction.
The LDL receptor (Goldstein and Brown 1973) is a trans-membrane protein of 160kD 
present predominantly on hepatocytes. There are currently more than 150 mutations of 
the receptor known at DNA level. The majority of FH is caused by mutations in the 
ligand binding domain which is the functional part of the receptor. Conformational 
changes or promoter mutations can result in a complete absence of the protein. 
Alternatively, internalisation of the receptor following normal ligand binding may not 
occur and LDL dissociates back into the plasma, or binding and internalisation may be 
normal but the ligand may then fail to be released and so is degraded with the receptor 
protein. Depending on the mutation there may be a complete lack of LDL binding - 
less than 2% of normal is classified as ‘receptor negative’ - or a reduction in binding 
as compared to normal - usually less than 25% of normal, classified as ‘receptor 
deficient’. This is an important distinction both regarding disease severity and
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treatment as receptor negative individuals tend to have more severe disease and 
respond less well to treatment.
4.3 Familial Defective ApoB-100 - a brief overview.
The more recently discovered condition, Familial Defective ApoB-100 (FDB) was 
first described in 1987 by Innerarity et al when he reported on the defective binding of 
LDL to normal human fibroblasts. In this condition the LDL receptors are normal but 
the apoB moiety of the lipoproteins is abnormal resulting in defective binding of LDL 
to the receptors. The LDL itself is otherwise normal in composition, shape and size. 
As a consequence of this disrupted LDL receptor-mediated catabolism LDL 
accumulates in the plasma giving rise to an elevated plasma cholesterol level and its 
ultimate clinical sequelae.
FDB is inherited in an autosomal dominant fashion and is estimated to have a 
prevalence of 1:500 in the population (Innerarity et al 1990). It has been reported in 
various populations, mostly Caucasian and in one Chinese individual (Bersot et al
1993), but to date there are no reports of its occurrence in Finnish (Hamalainen et al
1990), Russian (Schuster et al 1992), Israeli and Japanese (Friedlander et al 1993) 
populations in keeping with their different ethnic origins. FDB can present with the 
same clinical picture as FH, with the prevalence of hypercholesterolaemia, 
xanthomata and premature CHD being much the same (Rauh et al 1992). However, 
there have more recently been suggestions in the literature that the phenotype may be 
generally less severe (Miserez et al 1995). For the same reasons as in FH, there is 
great inter-individual variation in the presentation of FDB, although the number of 
responsible mutations so far reported is only three as opposed to the over 150 in FH. 
As in FH, FDB can be treated with resins and statins that lead to the up-regulation of 
LDL receptors and so enhanced clearance of LDL, primarily the normal LDL. 
However, it is also likely that the efficacy of these drugs in FDB reflects increased 
clearance of LDL precursors by the LDL receptors due to the apoE moiety (Maher et 
al 1993).
A case of homozygous FDB has been reported (Marz et al 1993). It is interesting to 
note that the receptor-mediated clearance of LDL in this individual, although 
diminished, was not completely abolished. The larger, less dense LDL particles were 
being catabolised to a certain degree, possibly due to their apoE moiety, but the small, 
dense LDL particles remained in the plasma. This individual also had a less severe 
phenotype than is seen in homozygous FH individuals. These findings have been 
confirmed more recently (Gallagher and Myant 1995) by a study of two sibling 
homozygotes for FDB. In addition to the residual binding of LDL to the receptors, the 
level of VLDL remnants (i.e. LDL precursors) was found to be normal presumably 
due to normal catabolism. This in turn was stimulated by treatment with a statin and 
lead to a significant response to therapy.
The underlying mutation in classical FDB has been identified as a single point 
mutation in the receptor binding domain of apoB - a G to A mutation at nucleotide 
10708 in exon 26 results in a glutamine for arginine substitution at amino acid 3500 in 
the mature protein (Soria et al 1989). Haplotype analysis has shown that the majority
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of the FDB mutations so far identified have a common European origin (Rauh et al
1991) with the exception of an individual from Munich (Rauh et al 1993) and one 
from China (Bersot et al 1993) whose mutations appear to have arisen independently. 
A haplotype identical to that of the Chinese individual has recently been reported in a 
Caucasian individual in Scotland (Gaffney et al 1995). Recently Pullinger et al (1995) 
described a mutation at amino acid 3531 which resulted in defective apoB binding. A 
C to T transition at nucleotide 10800 results in a cysteine for arginine substitution at 
position 3531 of the mature apoB. Most recently a further mutation affecting the 
amino acid at position 3500 has been identified (Gaffney et al 1995). In this mutation, 
coined FDB3500W, arginine is replaced by tryptophan resulting in reduced binding of 
the LDL, as shown by U937 cell growth. The binding of FDB-LDL to LDL receptors 
has been reported as 5-20% of normal (Myant 1993) for FDB3500 and 27% of normal 
for FDB3531 (Pullinger et al 1995). The relative plasma concentrations of FDB-LDL to 
normal LDL are 70%:30% and 60%:40% respectively due to the more efficient 
clearance of the normal LDL. It is possible to separate normal and FDB-LDL by 
immunoaffinity methods.
Thus, FH and FDB are both conditions of disrupted receptor-mediated LDL 
catabolism that can present with identical clinical phenotypes. Despite their different 
aetiology, the prognosis is similar and they both respond to treatment with agents that 
up-regulate the LDL receptors. In the homozygous form the conditions differ to a 
greater degree with homozgous FH being more severe than homozygous FDB. Cases 
of double heterozygotes for FH and FDB have been reported and studies of these 
individuals should prove interesting (Rubinsztein et al 1993). The aim of this study 
was to compare the metabolism of apoB-100 in heterozygotes for FH and FDB.
4.4 Subject Selection.
4.4.1 Heterozygous Familial Hypercholesterolaemic Subjects.
Five unrelated male subjects were recruited from the Lipoprotein Clinic at Glasgow 
Royal Infirmary based on criteria adopted by the Simon Broome Register (Table 4.1). 
Subjects all screened negative for FDB.
4.4.2 Heterozygous Familial Defective ApoB-100 Subjects.
Two unrelated male subjects were identified as heterozygotes for the mutation 
FDB3500w following screening of all attenders at the Lipoprotein Clinic, courtesy of 
the DNA Laboratory, Pathological Biochemistry. One subject (JR) is Caucasian and 
the other (NS) is of Asian origin. To our knowledge this is the first report of FDB in 
an Asian individual. Haplotype analysis suggested two separate mutations.
The characteristics of the seven subjects are given in Table 4.2 and their lipid and 
lipoprotein levels in Table 4.3. Biochemical and haematological screening excluded 
hepatic, renal and endocrine dysfunction and in each case lipid-lowering medication 
was stopped four weeks prior to the study. No subject was taking drugs known to
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affect lipid metabolism. Each subject gave signed informed consent and the study was 
approved by the Ethical Committee of Glasgow Royal Infirmary.
Table 4.1 The Simon Broome Register Definition o f Familial 
Hypercholesterolaemia.
Definite Familial Hvpercholesterolaemia
(a) Cholesterol level above 7.5mmol/l or LDL level above 4.9mmol/l, plus
(b) Tendon xanthomata in patient or first or second-degree relative.
Possible Familial Hypercholesterolaemia
(a) As (a) above, plus one o f (b) or (c) below
(b) Family history o f myocardial infarction below the age o f 50 years in second-degree relative or 
below the age o f 60 years in first-degree relative
(c) Family history o f raised cholesterol levels above 7.5mmol/l in first or second-degree relative.
Table 4.2 FH and FDB Subject Characteristics.
Subject Type Age
(years)
Weight
(kg)
ApoE Physical
Signs
Family
History
AC FH 34 77 3/2 father: died 
35y MI
WT FH 32 80 3/3 CABG 30y. father: MI 
50y
RM FH 52 82 3/3 TX, corneal 
arcus.
father: died 
52y MI
MM FH 42 78 3/3 TX, corneal 
arcus.
son : 13y 
chol. 7.6
RH FH 28 100 3/3 Corneal
arcus.
mother &
sister:
hyperchol.
JR FDB 58 83 3/3 - 1 sibling &
2 children 
with FDB
NS FDB 42 52 4/3 TX 2 siblings & 
1 child with 
FDB
MI = myocardial infarction, TX = tendon xanthomata, CABG = coronary artery by-pass graft.
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Table 4.3 FH and FDB Subject Lipid Profiles.
Subject Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
VLDL-chol.
(mmol/1)
LDL-chol.
(mmol/1)
HDL-chol.
(mmol/1)
AC 7.75 1.90 1.10 5.70 0.95
WT 8.45 2.10 1.15 6.20 1.10
RM 8.40 1.30 0.80 6.15 1.45
MM 9.40 1.50 1.15 7.75 0.90
RH 14.20 3.10 1.35 11.90 0.95
JR 8.35 1.60 0.90 6.35 1.10
NS 7.05 0.75 0.10 5.55 1.40
4.5 Methods.
Following a ten hour overnight fast each individual underwent a turnover study of 
apoB kinetics using a primed constant infusion of tri-deuterated leucine at a dose of
0.7mg/kg body weight bolus followed by an infusion of 0.7mg/kg/h for 10 hours. 
Subjects remained fasting throughout the day and venous blood samples were taken 
according to the protocol described in Chapter 2. The methodology for sample 
preparation, GC-MS measurement of isotopic enrichment and kinetic analysis by 
multicompartmental modelling is as given previously. The results obtained were 
compared to those of a similar study of 15 normal individuals (cholesterol 
<6.0mmol/l, triglyceride <2.0mmol/l) carried out previously in this laboratory using 
the same methodology (Packard, unpublished data). Comparisons between the FH and 
normal subjects were performed using the two sample t-test. Due to the small sample 
size of FDB subjects, no statistical analysis was performed.
4.6 Results.
4.6.1 Familial Hypercholesterolaemia.
1. Lipids and Lipoproteins (Table 4.4).
The five heterozygous FH individuals had significantly higher total cholesterol and 
LDL cholesterol levels than the normals as would be expected in this condition. In 
addition, their triglyceride and VLDL levels were higher. In keeping with other work, 
HDL had a tendency to be lower but this did not reach significance.
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Table 4.4 Lipids and Lipoproteins - normal v FH subjects.
Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
VLDL-chol.
(mmol/1)
LDL-chol.
(mmol/I)
HDL-chol.
(mmol/1)
Normal
mean
(SEM)
FH
mean
(SEM)
p value
4.90 (0.20) 
9.60(1.20)
p=0.02
1.00 (0.07)
2.00 (0.30) 
p=0.03
0.50 (0.04)
1.05 (0.10) 
p=0.003
3.05 (0.15) 
7.45 (1.10)
p=0.02
1.35 (0.06)
1.05 (0.10) 
NS
SEM = standard error o f  mean, NS = not significant.
Compositional analysis (Table 4.5, a & b) of the lipoproteins revealed significant 
(p<0.05) increases in VLDLj and VLDL2 free and esterified cholesterol, with 
significant decreases in the protein content. In IDL there were decreases in both 
protein and triglyceride. The composition of LDL in our subjects was essentially 
normal. Here the compositions were compared to results of a study of eighty 
normolipaemic subjects (cholesterol <6.0mmol/l and triglyceride <2.0mmol/l) as 
compositional analysis of the 15 normal subjects used for the kinetic comparisons was 
not available.
Table 4.5a Percentage Compositions ofVLDLj and VLDL2 - normal v FH
subjects.
Prot FC
VLDLj
EC PL Prot FC
v l d l 2
EC PLTG TG
Normal
mean 11.2 1.6 10.1 62.2 14.9 15.4 3.2 24.1 37.9 19.4
(SEM) (0.4) (0.2) (0.5) (1.4) (1.7) (0.4) (0.2) (0.7) (0.8) (1.3)
AC 6.5 3.3 20.4 57.9 11.9 11.4 8.0 41.2 32.4 16.6
WT 7.0 4.3 12.2 62.3 14.2 13.0 3.9 25.5 39.2 18.3
RM 7.4 4.2 12.8 64.0 11.6 14.0 7.1 31.2 29.5 18.1
MM 6.4 2.7 16.0 61.6 13.3 13.4 4.8 38.3 25.3 18.3
RH 3.9 5.4 15.8 59.9 15.1 13.3 11.9 32.5 21.7 20.6
FH
mean 6.2 4.0 15.4 61.1 13.2 13.0 7.1 33.7 27.7 18.4
(SEM) (0.6) (0.5) (1.5) (1.0) (0.7) (0.4) (1.4) (2.8) (3.2) (0.6)
p value 0.000 0.005 0.03 NS NS 0.001 0.05 0.03 NS NS
Prot = protein, FC = free cholesterol, EC = esterified cholesterol, TG = triglyceride, PL = 
phospholipid.
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Table 4.5b Percentage Compositions o f IDL and LDL - normal v FH
subjects.
Prot FC
IDL ~
EC TG PL Prot FC
LDL —  
EC TG PL
Normal
mean 20.1 5.9 42.3 13.7 18.2 24.4 8.8 43.4 4.6 18.9
(SEM) (0.3) (0.2) (0.5) (0.5) (0.4) (0.2) (0.3) (0.4) (0.1) (0.4)
AC 19.5 7.8 48.4 8.4 15.9 22.5 10.4 42.1 5.5 16.5
WT 18.4 5.8 43.6 11.9 20.4 22.9 9.8 41.6 4.8 20.9
RM 18.4 10.6 44.0 7.9 19.2 24.1 14.5 39.0 3.6 18.8
MM 18.6 8.4 49.1 6.7 17.3 24.4 15.9 34.2 4.0 21.5
RH 17.6 12.8 39.0 7.9 22.7 26.9 20.1 25.5 5.8 21.8
FH
mean 18.5 9.1 44.8 8.6 19.1 24.2 14.1 36.5 4.7 19.9
(SEM) (0.3) (1.2) (1.8) (0.9) (1.2) (0.8) (1.9) (3.1) (0.4) (1.0)
p value 0.003 NS NS 0.003 NS NS 0.05 NS NS NS
2. ApoB Pool Sizes (Table 4.6).
The total apoB in the FH subjects was significantly greater than normal. In the 
subfraction apoB pool sizes only IDL apoB mass was significantly increased, 
although in the case of LDL all the FH pool sizes were at or above the upper limit of 
the normal range. For the VLDL2 apoB two of the five FH subjects had pool sizes 
within the normal range whilst the rest were above the upper limit. The FH VLDLj 
pool sizes all fell into the normal range with the exception of one which was 
increased.
3. Kinetic Analysis.
Table 4.7 (a & b) gives the kinetic results for all seven subjects and the mean values 
for the 15 normal subjects. The full set of rate constants and calculated leucine pool 
sizes is given in Appendix 3. Figure 4.1 summarises the kinetic findings. Figures 4.2 
and 4.3 show VLDL, IDL and LDL tracer mass curves from the two subject groups.
The kinetics of VLDLj in the FH subjects are largely as normal. The production rates 
and fractional rates of direct catabolism (FDC) all fall within the normal range. 
However, the fractional rate of transfer (FTR) of apoB to VLDL2 is significantly 
decreased. VLDL2 shows both a decreased FDC and a decreased FTR. The production 
rate is again within the normal range, with one exception (RH) which is increased. 
The production rate of IDL in FH is as normal. The FDC values all tend towards the 
lower limit of the normal range but this does not reach statistical significance 
(p=0.07). As with VLDLj and VLDL2, the IDL FTR is decreased. LDL shows normal 
production rates with a significantly decreased fractional catabolic rate (FCR).
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4. LDL Subfractions.
The LDL subfraction profiles of these subjects were largely determined by the 
individual triglyceride level - those with moderately elevated triglycerides tended to 
have an increased percentage of small, dense LDL III, whilst those with lower 
triglycerides had profiles normal for males i.e. a predominance of LDL II. These 
observations are in keeping with previously reported work in both normal and FH 
individuals (Tan et al 1995, Caslake 1996).
4.6.2 Familial Defective ApoB-100.
These results were compared to those of the normal and FH subjects but not analysed 
statistically due to the small sample size. Both subjects had an elevated plasma 
cholesterol level, with associated increases in LDL cholesterol. Compositional 
analysis of the lipoproteins gave no differences from normal. The total apoB levels 
were both above the normal range, with specific increases in the LDL apoB pool sizes 
(Table 4.6). In the kinetic analysis (Table 4.7) the most marked abnormality was a 
reduced LDL FCR as would be expected. There was a suggestion of reduced FTR’s 
for VLDLj, VLDL2 and IDL with both values in each case being at or below the 
lower limit of the normal range. In both subjects the production rates and FDC’s of 
each lipoprotein were normal. The LDL subfraction profiles of the two subjects 
showed a predominance of LDL II (75% and 59%), with some LDL I (16% and 32%) 
and little LDL III (9% and 9%). Such profiles are normal for males.
Table 4.6 ApoB Pool Sizes - normal, FH and FDB subjects.
Total ApoB 
(mg/dl)
VLDL, Pool 
(mg)
VLDL2 Pool 
(mg)
IDL Pool 
(mg)
LDL Pool 
(mg)
Normal
mean (SEM) 60 (3.5) 42 (6.3) 93 (13) 269 (40) 1420 (99)
range 42-84 18-100 41-220 71-724 860-2248
AC 98 94 237 441 2232
WT 115 159 254 365 2899
RM 104 41 183 610 2583
MM 127 97 198 470 3193
RH 210 39 713 974 6691
FH
mean (SEM) 131 (21) 86 (22) 317 (100) 572 (108) 3519 (809)
p value p=0.03 p=0.13 p=0.09 p=0.05 p=0.06
JR 120 75 197 486 3217
NS 95 14 51 302 1605
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Table 4.7a Kinetic Results - VLDL} and VLDL2, normal, FH and FDB
subjects.
VLDLj
PROD
(mg/d)
VLDLj
FDC
(pool/d)
VLDL,
FTR
(pool/d)
v l d l 2
PROD
(mg/d)
v l d l 2
FDC
(pool/d)
v l d l 2
FTR
(pool/d)
Normal
mean 686 (84) 6.17 (1.84) 13.5 (2.00) 176 (26) 1.26 (0.33) 6.60 (0.69)
(SEM)
range 264-1508 0.05-27.2 5.81-37.7 21-358 0.06-3.90 3.6-12.7
AC 912 7.1 2.4 127 0.16 1.3
WT 1254 1.0 7.0 86 0.80 3.6
RM 862 16.1 4.7 308 0.50 2.2
MM 727 5.3 1.6 220 0.11 2.1
RH 327 1.2 6.5 771 0.24 1.2
FH
mean 816 (150) 6.14 (2.75) 4.44 (1.07) 302 (123) 0.36 (0.13) 2.08 (0.43)
(SEM) 
p value NS NS p=0.001 NS p=0.02 p=0.0000
JR 395 2.1 3.1 156 0.3 1.6
NS 418 16.8 0.6 293 5.6 3.8
PROD = production rate, FDC = fractional rate o f direct catabolism, FTR = fractional transfer rate.
Table 4.7b Kinetic Results - IDL and LDL.
IDL
PROD
(mg/d)
IDL
FDC
(pool/d)
IDL
FTR
(pool/d)
LDL
PROD
(mg/d)
LDL
FCR
(pool/d)
Normal
mean 152 (31) 1.00 (0.24) 2.47 (0.36) 117(28) 0.49 (0.04)
(SEM)
range 3-381 0.02-3.30 1.01-6.50 1-326 0.26-0.94
AC 92 0.22 0.66 35 0.15
WT 0 1.10 1.20 101 0.21
RM 308 0.40 0.80 62 0.20
MM 154 0.25 0.95 0 0.14
RH 52 0.10 0.90 144 0.15
FH
mean 121 (53) 0.41 (0.18) 0.90 (0.09) 68 (25) 0.17 (0.01)
(SEM) 
p value NS (p=0.07) p=0.0007 NS p=0.0000
JR 140 0.5 0.5 184 0.13
NS 107 0.1 1.2 71 0.21
FCR = fractional catabolic rate.
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4.7 Discussion.
Using the combination of stable isotope techniques and multicompartmental 
modelling, the kinetics of apoB-100 was studied in subjects heterozygous for familial 
hypercholesterolaemia (n=5) and familial defective apoB-100 (n=2). For the FH 
individuals, the results were largely in agreement with those obtained using radio­
isotope techniques and other methods of data analysis despite the limitations of a 
small sample size and some inter-individual heterogeneity. However, the labour- 
intensive nature of stable isotope studies precludes studies of larger numbers. In the 
case of FDB, there is a minimal amount of literature on apoB kinetics for comparison 
and certainly none on individuals with the specific mutation FDB350ow Furthermore, 
subject NS is the first case of FDB to be reported in an Asian individual.
4.7.1 Familial Hypercholesterolaemia.
The lipid and lipoprotein values in these five FH subjects are largely in keeping with 
those in the current literature although two subjects had minimally raised 
triglycerides. However, their clinical and biochemical characteristics were more 
suggestive of FH than familial combined hyperlipidaemia. Moderate elevations in 
triglyceride levels have been reported elsewhere in FH subjects. The compositional 
findings of an increased cholesterol content in VLDL, especially VLDL2, and 
triglyceride depletion in IDL was also seen by James et al (1989) in his study of FH 
homozygotes and perhaps reflects a prolonged residence time of these lipoproteins in 
the plasma and so increased exposure to neutral lipid exchange.
The kinetic abnormalities found in this study are i). reduced fractional transfer rates of 
apoB down the delipidation chain from VLDLb through VLDL2, and IDL to LDL, ii). 
reduced fractional rates of direct clearance of VLDL2 and IDL, and iii). a reduced 
LDL fractional catabolic rate.
The reduced VLDL2 and IDL FTR’s are in keeping with other studies, but the 
metabolism of VLDL! has previously been reported as normal (Shepherd and Packard 
1989). This could perhaps be a reflection of the moderately increased triglyceride 
levels of two out of the five FH subjects in this study - large, triglyceride-rich VLDL 
(VLDLj) tend to pass slowly down the delipidation cascade as compared to the less 
triglyceride-rich VLDL2. Classically the delipidation of VLDL2 and IDL to LDL is 
mediated by hepatic lipase and, therefore, should not be influenced by defects in LDL 
receptor function. It is possible that the enlarged IDL and LDL pool sizes seen in FH 
have a negative feedback effect on hepatic lipase action. However, a more interesting 
possibility is that the LDL receptor acts in a way complimentary to hepatic lipase by 
approximating the lipoproteins to the enzyme and thus making them more accessible 
for delipidation (James et al 1989). Both the LDL receptors and hepatic lipase are 
found predominantly on sinusoidal hepatocytes. In the event of reduced LDL receptor 
function this cooperation would be diminished. Recently, an analogous situation has 
been seen with lipoprotein lipase (LPL) and the LDL receptor-related protein (LRP). 
LPL, in addition to its enzyme action, appears to have a role as a ligand and promotes 
the binding of triglyceride-rich lipoproteins to the LRP (Applebaum-Bowden 1995).
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The observed reduction in direct catabolism of VLDL2 and IDL reflects inefficient 
clearance of these LDL precursors by the LDL receptor which, in health, would 
ordinarily recognise the apoE moiety on these lipoproteins. This is illustrated by the 
findings in the FDB subjects who had normal clearance rates for VLDL and IDL (see 
below).
In any study of apoB kinetics in FH the most consistent finding is a reduced LDL 
FCR. In heterozygotes this is usually reduced to about one half of normal, whilst in 
homozygotes it is about one third. This is a direct consequence of the deficient LDL 
receptor function, resulting in reduced LDL clearance from the plasma and thus its 
accumulation. This is reflected in the elevated LDL apoB pool sizes seen in this study 
with all individuals having LDL pool sizes at or above the upper limit of the normal 
range.
Most other studies of FH kinetics, including those using endogenous tracers, have 
found increases in the production rates of various apoB containing lipoproteins. The 
fact that this was not seen in the present study may be due to the small sample size, 
the subjects selected or to different methods of kinetic analysis and modelling. In 
1977, in their radio-isotope study of homozygous FH, Soutar et al reported an increase 
in LDL apoB production (with normal VLDL apoB production). She found that the 
total amount of apoB could not be accounted for by that produced as VLDL alone and 
so introduced the concept of direct LDL synthesis. This was further elaborated on by 
Janus et al (1980) when he found that direct LDL synthesis could account for up to 
70% of LDL apoB production in FH. However, in some FH subjects with additional 
triglyceride elevations he reported an increase in VLDL apoB production and a lesser 
amount of direct LDL synthesis. This inverse relationship between direct LDL 
synthesis and triglyceride level was also reported by Gaw et al (1995). When hepatic 
triglyceride is plentiful apoB is mainly secreted as triglyceride-rich lipoproteins 
(VLDL). However, when hepatic triglyceride is low an increased amount of apoB is 
secreted directly as LDL. In our subjects, direct LDL synthesis only accounted for 
0-11% of total apoB secretion with the majority of apoB being secreted as VLDL, 
reflecting the moderately raised triglyceride levels in these subjects. Cummings et al 
(1995) reported an increase in total VLDL apoB production in heterozygous FH, but 
did not differentiate between VLDL! and VLDL2. Although this study was performed 
using an endogenous tracer, the results were analysed using a monoexponential 
function rather than multicompartmental modelling and this may explain the differing 
findings. These increases in apoB production appear initially to be unrelated to the 
LDL receptor deficiency. However, in FH, despite the suppressed activity of HMG- 
CoA reductase, there is an elevation in hepatic cholesterol (Fisher et al 1994). Since 
receptor-mediated uptake is deficient, this is likely to be due to receptor-independent, 
and thus unrestrained, uptake. This increase in the intrahepatic availability of 
cholesterol stimulates an increased production of apoB and apoB containing 
lipoproteins and thus further exacerbates the elevated LDL levels due to reduced 
clearance.
Thus, the effects of the LDL receptor deficiency of FH appear to have consequences 
more far reaching than LDL clearance alone, giving us several reasons for the 
atherogenicity of this condition. First, LDL accumulates in the plasma due to reduced
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clearance. Secondly, the delayed transfer of apoB down the delipidation chain and 
reduced clearance leads to the accumulation in the plasma of LDL precursors which 
are in themselves atherogenic. Finally, unrestrained receptor-independent lipoprotein 
uptake results in an elevated hepatic cholesterol which in turn stimulates increased 
lipoprotein production. In addition to these three problems, the effect of prolonged 
residence of the lipoproteins in the plasma is increased exposure to neutral lipid 
exchange and thus formation of particles of a more atherogenic nature, as can be seen 
by the increased cholesterol to triglyceride content of VLDL and IDL.
4.7.2 Familial Defective ApoB-100.
The lipid and lipoprotein findings in the two FDB subjects are in keeping with those 
reported in the literature i.e. elevations in total cholesterol and LDL cholesterol, with 
normal lipoprotein compositions. The reduced LDL FCR is also as expected and 
reflected in the increased LDL apoB pool size. In contrast to FH, there was no 
reduction of VLDL and IDL direct catabolism, suggesting that their clearance in FDB 
is mediated by apoE interacting with normal LDL receptors (an event that is impaired 
in FH by the receptor deficiency). However, there was a tendency for the transfer of 
apoB down the delipidation chain to be retarded in FDB, a finding similar to that in 
FH and possibly explained by the same disruption of receptor-lipase interaction that is 
in this case being upset by the apoB moiety. The normal production rate of VLDL 
seen in this study is in keeping with that found in another study (Zulewski et al 1996). 
However, we did not see the reduced IDL production reported by these investigators.
Thus, despite the different aetiology, much of the pathology of FDB can be explained 
by the same mechanisms as in FH, stemming from reduced LDL clearance and 
delayed progress of apoB down the delipidation chain. However, perhaps the normal 
apoB production rates can account for the less severe phenotype seen in some FDB 
subjects. In addition, the presence of functioning receptors that can clear LDL 
precursors by virtue of their apoE moiety possibly lessens the severity of the situation. 
This is reflected in the normal LDL subfraction profiles seen in our two subjects.
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Chapter 5 Stable Isotope Turnovers in a Case of
Hvpobetalipoproteinaemia 
and a Case of Analbiiminaemia.
5.1 Introduction.
Hypobetalipoproteinaemia is associated with very low levels of apoB and cholesterol, 
whilst in analbuminaemia subjects have very high levels of apoB and total cholesterol. 
The metabolism of apoB in the two conditions is, therefore, likely to be starkly 
contrasting. To illustrate these extremes of apoB metabolism, stable isotope turnover 
studies were performed in two individuals, one with hypobetalipoproteinaemia and 
one with analbuminaemia.
5.2 Hypobetalipoproteinaemia.
Familial hypobetalipoproteinaemia is a rare genetic condition, first described by Salt 
et al in 1960. It is inherited in an autosomal codominant fashion. Homozygotes are 
often from consanguinous matings. The condition is characterised by 
hypocholesterolaemia. Heterozygotes can be diagnosed by the following criteria: “(1) 
LDL abnormally low but present and identifiable immunochemically, while 
concentrations of VLDL and HDL are normal, (2) absence of diseases to which 
hypobetalipoproteinaemia may be secondary, and to be certain (3) detection of a 
similar pattern in a first-degree relative” (Fredrickson et al 1972). The heterozygous 
condition is often asymptomatic, and, therefore, frequently not detected, whilst 
homozygotes may have a more striking presentation with many of the features of 
classical abetalipoproteinaemia although somewhat moderated. However, 
abetalipoproteinaemia is a distinct and more severe condition that arises from a 
different genetic mutation and is inherited in an autosomal recessive fashion. The 
genetic cause of abetalipoptoteinaemia is thought not to be linked to the apoB gene 
(Talmud et al 1988) but to a defect in microsomal triglyceride transfer protein 
(Wetterau et al 1992). A subset of hypobetalipoproteinaemic individuals has been 
shown to have various truncations of apolipoprotein B (Aguilar-Salinas et al 1995). 
To date about 25 such truncations of varying length have been described.
Hypobetalipoproteinaemia primarily affects four body systems - gastro-intestinal, 
neuromuscular, ocular and haematological - in addition to the abnormalities in lipids 
and lipoproteins (Herbert et al 1978). Due to a limited ability to synthesise 
chylomicrons there may be fatty intolerance with associated steatorrhoea. In 
homozygotes, jejunal biopsies show lipid accumulation in the enterocytes, there is 
increased faecal fat excretion and there may be mild hepatic steatosis. Absorption of 
the fat soluble vitamins A, D, E and K is reduced with corresponding reductions in 
their plasma levels, with the exception of vitamin D which is usually normal 
(Innerarity 1990). Neuromuscular abnormalities are not consistent and again are often 
absent in heterozygotes. They are presumed to be due to the reduced levels of vitamin 
E, and include diminished deep tendon reflexes and ataxia. The main ocular 
manifestation in homozygotes is retinitis pigmentosa, with heterozygotes possibly
only having minor retinal changes. The characteristic haematological finding in 
homozygotes is acanthocytosis which may be the result of an altered phospholipid 
content of the red blood cell membrane. Heterozygotes can show a mild degree of 
acanthocytosis. The extent of the hypolipidaemia in affected individuals is variable. 
Heterozygotes generally have low but detectable amounts of VLDL and LDL with 
normal or elevated levels of HDL. The lipoprotein composition is mostly normal. 
VLDL and LDL in the homozygote are markedly reduced and sometimes 
undetectable. There is also an absence of post-prandial chylomicronaemia.
5.3 Analbuminaemia.
Analbuminaemia is a rare (< 1:106) autosomal recessive condition that was first 
described in 1954 by Benhold et al. It is characterised by the absence or virtual 
absence of albumin from the plasma. A recent literature search identified less than 30 
reported cases worldwide. Affected subjects are often asymptomatic or may complain 
only of mild fatigue, postural hypotension and dependent oedema. Identification of an 
affected individual is, therefore, usually incidental which may go some way to 
explaining the apparent rarity of the condition, although the relative ease and 
frequency with which plasma albumin is measured would tend to identify more cases 
if it were more prevalent. Heterozygotes tend to have low-normal plasma albumin 
levels and are completely asymptomatic. Consanguinuity has been noted in 
approximately half of the reported cases. The underlying defect in this condition 
appears to be one of reduced albumin synthesis rather than increased catabolism. 
Indeed studies of affected individuals who have been infused with exogenous albumin 
have shown that the catabolism of the albumin is in fact reduced so resulting in a 
longer half life (Russi and Weigand 1983).
Despite normally being the most abundant plasma protein and having many major 
functions, including maintenance of colloid-oncotic pressure and transport of many 
metabolites, hormones, fatty acids and anions, it is, perhaps, amazing that the absence 
of albumin from the plasma can result in so benign a condition. This may be 
explained in part by the compensatory increase in other plasma proteins that is seen in 
affected individuals, and by the relative reduction in capillary hydrostatic pressure 
(Baldo-Enzi et al 1987). In particular, there is a marked increase in the levels of 
lipoproteins with an associated increase in plasma cholesterol but not in triglyceride. 
However, of note is the fact that despite these increased levels of cholesterol and 
lipoproteins affected individuals do not invariably suffer from CHD.
An animal model for analbuminaemia, the Nagase analbuminaemic rat, was identified 
as a mutant amongst Sprague-Dawley hypercholesterolaemic rats (Nagase et al 1979). 
Much of the research into analbuminaemia has been performed on these rats due to 
the limited number of affected humans available for study. Van Tol et al (1991) 
showed that the majority of cholesterol in these rats was carried on HDL which was 
present in the plasma at high levels. They also noted an increase in lecithinxholesterol 
acyltransferase activity which may explain the elevated HDL levels. Catanozzi et al 
(1994) found increased triglyceride and VLDL synthesis in Nagase rats, while Joles et 
al (1993) found that the hyperlipidaemia in these rats was in part due to extrahepatic 
lipogenesis.
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The precise genetic mutation responsible for analbuminaemia has not yet been 
identified and in fact it appears that several different mutations can lead to reduced 
albumin synthesis. A review of five cases that had been studied at DNA level 
(Watkins et al 1994) identified different single nucleotide insertions producing stop 
codons in four of the subjects and an exon-splicing defect in the fifth.
5.4 Subject Selection.
5.4.1 Hypobetalipoproteinaemic Subject.
The original subject, a twenty year old Caucasian girl (JR), was referred to this 
department from The Institute of Neurology, The National Hospital, London with a 
diagnosis of HARP syndrome (Amrolia 1992, unpublished report). HARP syndrome 
is a recently described condition of hypoprebetalipoproteinaemia, acanthocytosis, 
retinitis pigmentosa and pallidal degeneration (Higgins et al 1992). She presented 
with a two year history of facial dystonia, dysarthria and dysphagia associated with 
poor dietary intake. Examination revealed a slightly educationally subnormal girl of 
small, underweight stature. There was dystonic dysarthria with diminished palatal and 
tongue movements and gag reflex. Retinitis pigmentosa was seen on fundoscopy. 
Investigations showed hypolipidaemia with a total plasma cholesterol of 2.70mmol/l, 
triglycerides of 0.35mmol/l and a reduced LDL cholesterol of 1.00mmol/l. Peripheral 
blood films showed acanthocytosis. Vitamins A and E were normal on 
supplementation. An MRI scan confirmed degeneration of the pallidal nuclei. A fat 
absorption test was performed which showed interestingly that fatty acids were being 
absorbed, although not as chylomicrons but as non-esterified fatty acids. The 
subsequent VLDL apoB rise was in keeping with hepatic VLDL production, with the 
fatty acid content of the VLDL triglycerides reflecting those of the fat load. Electron 
microscopy of duodenal biopsy specimens revealed patchy lipid deposition in the 
enterocytes. Video fluoroscopy of swallowing was performed and this showed 
spasticity of the tongue and muscles of mastication.
Both the mother and the sister of the proband had similar lipid biochemistry but were 
otherwise healthy and without the neurological manifestations described above. The 
father was normolipaemic and there was no suggestion of consanguinuity in the 
family history. The original intention was to study apoB metabolism in both the 
proband and her mother (LR). However, due to technical difficulties with the proband 
(recurrent blocking of intravenous cannulae) it was felt unfair to persist and the stable 
isotope study was performed on the mother only. The characteristics of the proband 
(JR) and her mother (LR) are given in Table 5.1.
5.4.2 Analbuminaemic Subject.
This patient (AK) was a 60 year old black South African gentleman who was 
incidentally found to have analbuminaemia. His only complaint was of occasional 
ankle oedema following prolonged immobility which was first noted seven years 
previously. Importantly he gave no symptoms suggestive of CHD. He was descended 
from the Griqua and Tswana tribes with no known consanguinuity and no family 
history of note. Physical examination revealed bilateral circumferential arcus
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comealis, mild bilateral pitting oedema to the knees and unusually white and opaque 
fingernails. More interestingly, he had an unusual body fat distribution with excess 
adipose tissue over his buttocks and thighs but a slim upper body and face. To his 
knowledge he has always had this body shape and is the only member of his family of 
this build. This body shape is often seen amongst the Griqua bushmen. However, it 
also resembles partial lipodystrophy, a condition which has possibly been reported in 
two other analbuminaemic subjects (Gordon et al 1959, Montgomery et al 1962).
Investigations revealed a serum albumin level of <9g/l (normal range 35-50g/l). Liver 
biochemistry, urea, creatinine and electrolytes were normal. Total plasma cholesterol 
was 14.80mmol/l with an LDL cholesterol of 11.30mmol/l and an HDL cholesterol of 
3.20mmol/l. Plasma triglycerides were 0.70mmol/l. ApoAI was elevated at 218mg/dl 
and total plasma apoB was also elevated at 229mg/dl. An ECG showed only left axis 
deviation and a chest x-ray was normal. Ultrasound scanning of the carotid and 
femoral arteries was performed and this showed a normal intimal-medial thickness 
with a smooth regular surface. There was no evidence of atherosclerosis. The 
characteristics of this subject are summarised in Table 5.2.
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Table 5.1 Characteristics o f  Hypobetalipoproteinaemic Proband (JR) 
and Mother (LR).
JR LR JR LR
Age (years) 20 41 ApoE
phenotype
3/3 3/3
Height (cm) 158 154 Apo A l 
(mg/dl)
114 138
Weight (kg) 48.2 53 Apo B 
(mg/dl)
27 23
Body Mass 
Index
19.3 22.3 Lp(a)
(mg/dl)
1 1
Cholesterol
(mmol/1)
2.70 3.20 HDL2
(mg/dl)
92 148
Triglyceride
(mmol/1)
0.35 0.40 h d l 3
(mg/dl)
191 201
VLDL-chol.
(mmol/1)
0.20 0.20 %LDLI 31 28
LDL-choI.
(mmol/1)
1.00 1.05 %LDLII 60 58
HDL-chol.
(mmol/1)
1.50 1.95 %LDLIII 9 14
Table 5.2 Characteristics o f  Analbuminaemic Subject (AK).
AK AK
Age (years) 60 Albumin (g/1) <9
Height (cm) 171 Cholesterol (mmol/1) 14.80
Weight (kg) 86 Triglyceride (mmol/1) 0.70
Body Mass Index 29.4 VLDL-chol. (mmol/1) 0.30
Apo A l (mg/dl) 218 LDL-chol. (mmol/1) 11.30
Apo B (mg/dl) 229 HDL-chol. (mmol/1) 3.20
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5.5 Methods.
Stable isotope turnover studies were performed on the two subjects using the 
methodology described in Chapter 2. The hypobetalipoproteinaemic subject received 
a primed constant infusion of tri-deuterated leucine with the size and duration of the 
infusion being reduced to 500ml over eight hours to accommodate the small size of 
the subject. The dose of leucine remained the same at 0.7mg/kg body weight bolus, 
followed by 0.7mg/kg/hour infusion. In addition, VLDL was separated 
ultracentrifugally as total VLDL rather than as its subfractions VLDLj and VLDL2. 
This was to allow for the low levels of apoB in the VLDL which could not have been 
reliably measured on the separated subfractions. To allow for this change when doing 
the kinetic analysis, the model was altered to a 12 compartment model with three 
compartments for total VLDL. No modifications were made to the methodology for 
the analbuminaemic individual who received a bolus dose of leucine at 7mg/kg body 
weight. However, this work was carried out in the Lipid Laboratory of Groote Schuur 
Hospital, Cape Town, South Africa, made possible by the Sue McCarthy Travelling 
Scholarship of the British Hyperlipidaemia Association. Ethical approval was granted 
by the Ethical Committee of Groote Schuur Hospital. The lipid and lipoprotein results 
were compared to those of the normolipidaemic subjects described in Chapter 3, while 
the kinetic analyses were compared to those of 15 normolipidaemic subjects whose 
apoB metabolism was studied previously in this department using the same 
methodology (Packard, unpublished results).
5.6 Results.
5.6.1 Hypobetalipoproteinaemic Subject.
1. Lipids and Lipoproteins.
The total plasma cholesterol in this subject varied from 2.60mmol/l to 3.20mmol/l and 
LDL cholesterol varied from 0.90mmol/l to 1.10mmol/l. These levels are lower than 
or at the lower limit of the normal range. However, HDL cholesterol tended to be on 
the high side of normal, ranging between 1.60mmol/l and 1.95mmol/l. The LDL:HDL 
ratios were 0.5-0.6. Triglyceride and VLDL cholesterol levels were also low at 0.25-
0.40mmol/l and 0.05-0.20mmol/l respectively. These results are similar to those seen 
in the original proband (JR). Compositional analysis of the VLDL, IDL and LDL 
subfractions was essentially normal. Both the mother and daughter had LDL 
subfraction profiles of predominantly LDLII with little LDLIII, the percentage 
amounts being approximately 30% LDLI, 60% LDLII and 10% LDLIII (Table 5.1). 
Such profiles are normal for pre-menopausal women. Apo Al, HDL2 and HDL3 levels 
were at the upper end of normal in keeping with the elevated HDL cholesterol. 
Measured apoB levels were low at 23mg/dl (LR) and 27mg/dl (JR).
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2. ApoB Pool Sizes (Table 5.3).
The total apoB concentration and apoB pool sizes were all markedly reduced with 
values of about 25% of normal. Total VLDL apoB mass was 14mg, IDL apoB mass 
was 44mg and LDL apoB mass was 234mg. The total calculated apoB concentration 
was 14.2mg/dl.
3. Kinetic Analysis.
Total apoB production in this individual was low at 123mg/day. The majority of the 
apoB (>80%) was produced as VLDL, with the remainder being produced directly as 
LDL. Both VLDL and LDL production rates were low. Direct IDL synthesis was 
negligible. The direct catabolic rates of VLDL and IDL were low at 0.01 pools/day 
and 0.08 pools/day respectively, whilst the transfer rates of VLDL apoB to IDL apoB 
and IDL apoB to LDL apoB were within the normal range at 6.2 pools/day and 1.9 
pools/day respectively. The fractional catabolic rate of LDL was normal at 0.55 
pools/day. These findings are summarised in Table 5.4 and the tracer mass curves are 
shown in Figure 5.1. The complete set of rate constants and calculated leucine pool 
sizes is given in Appendix 4.
5.6.2 Analbuminaemic Subject.
1. Lipids and Lipoproteins.
The total plasma cholesterol was elevated at 14.80mmol/l, with an elevated LDL 
cholesterol of 11.30mmol/l and an elevated HDL cholesterol of 3.20mmol/l. This 
gave an LDL:HDL ratio of 3.5. Plasma triglyceride and VLDL cholesterol on the 
other hand were normal at 0.70mmol/l and 0.30mmol/l respectively. Compositional 
analysis showed a tendency towards elevated percentage free cholesterol and 
decreased percentage phospholipid in VLDLb VLDL2, IDL and LDL. LDL 
subffaction analysis revealed a predominance of the large LDL species. Apo Al was 
elevated in keeping with the elevated HDL cholesterol. Measured total apoB was also 
elevated.
2. ApoB Pool Sizes (Table 5.3).
The VLDLj apoB mass in this individual was normal at 60mg. However, the pool 
sizes of VLDL2, IDL and LDL were all grossly elevated at 626mg, 3369mg and 
4710mg respectively. The total calculated apoB concentration was also elevated at 
255mg/dl.
3. Kinetic Analysis.
Initial inspection of the tracer mass curves for the four subfractions suggested normal 
VLDLj apoB metabolism but a massively increased direct production of VLDL2 with 
little VLDL! to VLDL2 apoB transfer. This was in fact borne out by the 
multicompartmental modelling which showed 85% of total apoB production being 
produced directly as VLDL2 with the remaining 15% being produced as VLDLj.
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Direct synthesis of IDL and LDL was negligible. The production rate of VLDL2 was 
elevated at 8146mg/day whilst that of VLDLj was normal at 1437mg/day. The 
fractional transfer rate of apoB from VLDLj to VLDL2 was reduced at 1.3pools/day 
but the rate of direct catabolism was within the normal range (although towards the 
upper limit) so maintaining the normal VLDLj apoB pool size. VLDL2 direct 
catabolism was elevated at 6.6pools/day but the transfer rate of apoB to IDL was 
normal at 6.7pools/day. IDL direct catabolism was normal (0.94pools/day) but the 
transfer rate to LDL was reduced (0.27pools/day). The fractional catabolic rate of 
LDL was also reduced at 0.20pools/day. These findings are summarised in Table 5.4 
and the tracer mass curves are shown in Figure 5.2. The complete set of rate constants 
and calculated leucine pool sizes is given in Appendix 4.
Table 5.3 ApoB Pool Sizes for Hypobetalipoproteinaemic Subject (LR) 
and Analbuminaemic Subject (AK).
Subfraction Subject LR Subject AK Normal Range
Total VLDL (mg) 14
VLDLj (mg) 60 18-100
VLDL2 (mg) 626 41-220
IDL (mg) 44 3369 71-724
LDL (mg) 234 4710 860-2248
Total apoB (mg/dl) 14.2 225 42-84
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Table 5.4 Kinetic Results for Hypobetalipoproteinaemic Subject (LR) 
and Analbuminaemic Subject (AK).
Subfraction Kinetic
Parameter
Subject LR Subject AK Normal Range
Total VLDL Production (mg/d) 99.4
FDC (pools/d) 0.01
FTR (pools/d) 6.2
VLDLj Production (mg/d) 1437 264-1508
FDC (pools/d) 22.6 0.05-27.2
FTR (pools/d) 1.3 5.81-37.7
v l d l 2 Production (mg/d) 8146 21-358
FDC (pools/d) 6.6 0.06-3.90
FTR (pools/d) 6.7 3.6-12.7
IDL Production (mg/d) 0 0 3-381
FDC (pools/d) 0.08 0.94 0.02-3.30
FTR (pools/d) 1.9 0.27 1.01-6.50
LDL Production (mg/d) 23.3 0 1-326
FCR (pools/d) 0.55 0.20 0.26-0.94
Total ApoB Production (mg/d) 122.7 9583 561-2209
FDC = fractional rate o f direct catabolism, FTR = fractional transfer rate, FCR = fractional catabolic 
rate.
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5.7 Discussion.
Stable isotope turnover studies of apoB kinetics were performed in two very different 
subjects with plasma cholesterol and apoB levels at opposite extremes. 
Hypobetalipoproteinaemia is associated with low levels of plasma cholesterol and 
apoB, whilst in analbuminaemia the converse is true. Comparison of the results, both 
to normolipidaemic subjects and to each other, has highlighted some interesting 
findings.
5.7.1 Hypobetalipoproteinaemia.
It is unfortunate that a stable isotope study of the apoB kinetics in the original proband 
(JR) was not possible, but the similarity in the lipid and lipoprotein levels between her 
and her mother allows some inference of her apoB kinetics. What is not entirely 
understood is the reason why JR should be symptomatic while her mother, and sister, 
are not. As her father is unaffected it is not possible that JR is a homozygote for 
hypobetalipoproteinaemia and her mother a heterozygote so explaining the more 
severe phenotype. A possibility is that JR’s poor dietary intake in fact preceded the 
development of neurological symptoms and in some way exacerbated the 
hypobetalipoproteinaemia to such a degree that the neurological symptoms became 
manifest and in turn further worsened the dietary intake. Whatever the reason, the 
neurological symptoms seem more extreme than is usually seen in heterozygous 
hypobetalipoproteinaemia and are out of keeping with the degree of fat malabsorption 
and lipid abnormality.
The proband’s mother (LR) proved interesting to study. Her low plasma lipids, low 
LDL cholesterol and VLDL cholesterol, elevated HDL cholesterol and normal 
lipoprotein composition are in keeping with previous reports of such subjects (Herbert 
et al 1978). In an early study of LDL kinetics in three heterozygotes for this condition 
Levy et al (1970) found that LDL synthesis was reduced but LDL catabolism was 
normal. From these findings they suggested that the disorder was secondary to 
reduced LDL synthesis rather than increased catabolism. Subject LR had LDL 
production and catabolic rates that fell within the normal range, but the production 
rate was at the lower end of the normal range whilst the catabolic rate was normal. 
The production rate of VLDL was also low. In this subject the transfer of apoB down 
the delipidation chain appeared to be occurring at a normal rate. However, the direct 
catabolism of VLDL and IDL was low to low-normal. Thus the primary abnormality 
in this subject appears to be one of reduced apoB synthesis. More recently studies 
have been performed on hypobetalipoproteinaemic subjects with various truncations 
of apoB. Using endogenous tracer methodology, Aguilar-Salinas et al (1995) found 
decreased apoB production (both as VLDL and LDL apoB) in 
hypobetalipoproteinaemic subjects heterozygous for an apoB truncation. These 
subjects had normal apoB transfer down the delipidation chain and normal catabolism 
of VLDL, IDL and LDL. This was further elaborated on by Parhofer et al (1996) 
when he found a positive linear correlation between the length of the truncated apoB 
and its secretion rate, such that the shorter the apoB molecule the lower was its 
production rate. Extrapolation of the linear regression suggested apoB secretion would 
be zero at a truncation length of apoB-28 which is in keeping with the observation that
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apoB molecules shorter than apoB-28 are not seen in the plasma. This is perhaps due 
to the inability of short forms of apoB to acquire enough lipid prior to secretion and 
they are therefore degraded intracellularly. Interestingly this study also found 
increased catabolic rates for the longer apoB truncations, presumably because they 
still contain the LDL receptor recognition region, although this does not explain why 
they should bind to the receptor with a greater affinity than apoB-100. Unfortunately, 
the apoB of subject LR was not examined for a truncation. It may be that her apoB is 
of normal length and that the underlying genetic defect lies in the promoter-enhancer 
region of the apoB gene (Innerarity 1990). This would fit with the findings of reduced 
apoB production rates but normal catabolism. However, of note is the fact that the 
proband (JR) does not produce chylomicrons and therefore presumably cannot 
synthesise apoB-48, despite having low but measurable amounts of apoB-100 in her 
plasma. This finding remains to be explained.
5.7.2 Analbuminaemia.
This subject (AK) is one of less than thirty individuals identified worldwide as having 
analbuminaemia. His incidental finding and benign clinical course are in keeping with 
the others. His strikingly low serum albumin level of <9g/l and grossly elevated 
plasma cholesterol are characteristic of the condition. As with the other affected 
individuals, his LDL and HDL cholesterol levels were elevated while triglyceride and 
VLDL cholesterol were normal. Plasma apoB was also elevated in keeping with the 
elevated LDL.
To our knowledge stable isotope turnover studies of apoB kinetics have not been 
performed previously in analbuminaemic subjects and this is, therefore, the first 
reported case of such work. This subject had normal production and catabolic rates of 
VLDL! with a resultant normal VLDLj pool size. This is reflected in his normal 
plasma triglyceride level. The pool sizes of VLDL2, IDL and LDL were all elevated. 
However, the most striking finding was the greatly increased direct production rate of 
VLDL2. This was increased by approximately 20 times the upper limit of the normal 
range. Little VLDL2 came from transfer from VLDLj as is reflected in the low 
VLDL! fractional transfer rate. The VLDL2 fractional rate of direct catabolism was 
elevated, possibly reflecting increased substrate availability for clearance e.g. by 
apoE-mediated receptor clearance. However, the catabolism was not elevated to such 
an extent that the pool size was reduced to normal. The production of predominantly 
VLDL2 rather than VLDL! is in keeping with the nature of this subject’s LDL 
subfraction profile. He had a predominance of the larger, less dense species which are 
known to be preferentially formed from the delipidation of VLDL2.
The transfer of apoB to IDL occured at a normal rate and this was the source of apoB 
in the IDL and LDL fractions as direct IDL and LDL synthesis was practically zero. 
The pool sizes of IDL and LDL were similar, with the relative increases as compared 
to normal being greater for IDL. In addition the transfer of apoB from IDL to LDL 
was found to be reduced despite the findings of an increased LDL pool size but 
negligible LDL direct production. This may in fact reflect a methodological error at 
the stage of ultracentrifugal separation of the lipoproteins. Due to the large amount of 
lipoprotein present in the LDL density range there is some overflow of LDL into the
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IDL density range (Marais 1996, unpublished observation). It is, therefore, possible 
that some of the measured IDL apoB is in fact LDL apoB. The fractional rate of direct 
catabolism of IDL was normal. However, the fractional catabolic rate of LDL was 
reduced below the lower limit of normal, almost to the levels seen in familial 
hypercholesterolaemia. This could perhaps be a compensatory mechanism to keep 
LDL in the plasma and so help to maintain the plasma oncotic pressure in the absence 
of albumin.
The effects of albumin on lipid synthesis, apoB secretion and LDL catabolism have 
been studied recently in HepG2 cells (Cianflone et al 1994). This study found that as 
the extracellular albumin concentration was reduced the secretion of apoB was 
increased. In addition, reductions in albumin concentration were associated with 
increased cholesterol ester synthesis but no change in triglyceride synthesis. Finally, a 
decreased albumin concentration resulted in a decrease in LDL catabolism. Although 
caution is always required when extrapolating from in vitro studies to in vivo work, 
these findings are similar to those seen in our analbuminaemic subject. In parallel with 
this is the observation that the lipoprotein compositions showed an increased 
percentage of free cholesterol with a decreased percentage of phospholipid. Increased 
free cholesterol in the lipoprotein coat stiffens the phospholipid lattice so making it 
more difficult for apolipoproteins to insert into the coat. This in turn may impede the 
lipoprotein clearance. Alternatively, the lipoproteins could be cholesterol-rich due to 
increased hepatic uptake of cholesterol-rich VLDL2 (as is seen in the increased 
catabolic rate of VLDL2) in a sense reflecting a degree of futile cycling of VLDL2. 
However, if this were the case the increase would be expected in cholesterol ester 
rather than in free cholesterol.
A very interesting aspect of this condition is that, despite gross elevations in plasma 
and LDL cholesterol, these subjects do not invariably go on to develop CHD. Indeed, 
our subject at the age of 60 years was completely asymptomatic for CHD and had no 
ECG or ultrasound findings suggestive of its development. This observation is not 
entirely explained but may be in part due to the following. Firstly, the increase in 
HDL cholesterol means that despite an elevated LDL cholesterol the LDL:HDL ratio 
was only minimally raised, in this case at 3.5, thus exerting some protective effect. 
Secondly, the nature of the LDL itself (a large, less dense species) is known to be less 
atherogenic than the small, dense species that is often seen in cases of 
hypercholesterolaemia. Thirdly, the relatively low blood pressures seen in these 
individuals may go some way to reducing the predisposition to atherosclerosis 
development.
In summary, the main kinetic findings in this subject with analbuminaemia were i). 
normal VLDL! metabolism, ii). greatly elevated VLDL2, IDL and LDL pool sizes, 
iii). grossly elevated VLDL2 production, and iv). reduced LDL catabolism. These 
findings are reflected in the elevated plasma cholesterol and apoB levels and the 
normal plasma triglyceride level.
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Thus, in hypobetalipoproteinaemia there is a reduction in apoB production, secondary 
to a defect in the apoB gene, which results in low levels of lipids and apoB containing 
lipoproteins in the plasma. By contrast, in analbuminaemia there is a greatly increased 
apoB production as part of a physiological compensatory mechanism to maintain 
plasma oncotic pressure. This in turn is associated with grossly elevated levels of 
plasma cholesterol and LDL apoB. Despite these extreme aberrations in apoB 
metabolism, both these conditions run a relatively benign course but add insight into 
apoB metabolism in normolipidaemia. The kinetic findings are summarised in 
Figure 5.3.
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Chapter 6 Stable Isotope Turnovers in
Mixed Hyperlipidaemia.
6.1 Introduction.
Mixed hyperlipidaemia is perhaps one of the more common forms of hyperlipidaemia 
to present at Lipoprotein Clinics. Typically the patient has moderate elevations in both 
cholesterol and triglycerides, giving a Fredrickson type lib or occasionally type III 
pattern, often with an associated reduction in HDL cholesterol. ApoB may also be 
elevated. The aetiology of mixed hyperlipidaemia is multifactorial. The 
hypercholesterolaemia may be inherited in a polygenic fashion, with the 
hypertriglyceridaemia being secondary to, for example, obesity, insulin resistance or 
alcohol excess. Alternatively, it may be inherited as familial combined 
hyperlipidaemia (FCHL) as described by Goldstein et al in 1973. This condition is 
thought to affect 0.5-2.0% of the population in the Western world and is found in up 
to 10% of those with premature CHD. The presenting phenotype may be a pure 
hypercholesterolaemia, a pure hypertriglyceridaemia or a mixed hyperlipidaemia. In 
addition, more than one phenotype is present within a family and an affected 
individual’s phenotype may change during his lifetime. It was originally suggested 
that the mode of inheritance of FCHL was autosomal dominant with reduced 
penetrance, but it now appears that the genetic basis is more complex. FCHL is 
difficult to diagnose due to its lack of clinical marker, so requiring family studies for 
true identification. However, in a clinical setting this is not necessarily relevant as 
treatment strategies remain the same and not all patients with mixed hyperlipidaemia 
will have FCHL. The treatment of mixed hyperlipidaemia is discussed in the 
following chapter.
Much of the kinetic work on mixed hyperlipidaemia has been performed using 
subjects with FCHL. The most consistent finding is that of increased hepatic VLDL 
apoB production (Janus et al 1980, Kissebah et al 1981, Cortner et al 1991, 
Venkatesan et al 1993) with the VLDL composition being normal. In addition, some 
workers have found an increase in the formation of LDL from VLDL (Janus et al 
1980, Kissebah et al 1981). Other metabolic findings include reduced lipoprotein 
lipase activity (Babirak et al 1992), reduced chylomicron remnant clearance (Cabezas 
et al 1993) and impaired fatty acid metabolism (Cabezas et al 1993). This chapter 
aims to characterise the apoB kinetics in subjects with mixed hyperlipidaemia.
6.2 Subject Selection.
Seven subjects (six males and one post-menopausal female) with mixed 
hyperlipidaemia (cholesterol 6.0-9.0 mmol/1, triglyceride 2.0-4.0 mmol/1) were 
recruited from the Lipoprotein Clinic at Glasgow Royal Infirmary. Secondary causes 
for the hyperlipidaemia were excluded by the relevant biochemical and 
haematological tests. In addition, no subject had the apoE 2/2 phenotype. All lipid- 
lowering medication was stopped four weeks prior to the commencement of the study 
and no subject was taking medication known to affect lipoprotein metabolism. The 
characteristics and lipid profiles of the seven subjects are given in Tables 6.1 and 6.2.
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These subjects were not classified as FCHL as family studies proved impractical - 
many of the subjects had fewer than 3 first degree relatives in the area available for 
screening. Each subject gave signed informed consent and the study was approved by 
the Ethical Committee of Glasgow Royal Infirmary.
Table 6.1 Mixed Hyperlipidaemic Subject Characteristics.
Subject Age
(years)
Sex Weight
(kg)
Body Mass 
Index
ApoE
Phenotype
RA 50 M 74 25.6 3/3
PS 37 M 72 23.9 3/3
JC 45 M 70 25.4 4/3
RS 39 M 90 27.8 4/3
DM 40 M 84 29.1 3/3
LB 52 F 73 31.2 4/4
PC 53 M 91 28.1 3/3
Table 6.2 Mixed Hyperlipidaemic Subject Lipid Profiles.
Subject Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
VLDL-choI.
(mmol/1)
LDL-chol.
(mmol/1)
HDL-chol.
(Mmol/1)
RA 6.20 2.90 0.85 3.95 1.40
PS 6.45 2.60 0.80 4.60 1.05
JC 6.40 2.25 0.75 4.70 0.95
RS 6.35 2.60 1.15 4.55 0.70
DM 7.90 3.55 1.90 5.10 0.90
LB 6.60 2.95 1.25 4.45 0.90
PC 7.00 3.60 1.45 4.60 0.95
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6.3 Methods.
Following a ten hour overnight fast each individual underwent a turnover study of 
apoB kinetics using a bolus of tri-deuterated leucine at a dose of 7mg/kg body weight. 
Subjects remained fasting throughout the day and venous blood samples were taken 
according to the protocol as described in Chapter 2. The methodology for sample 
preparation, GC-MS measurement of isotopic enrichment and kinetic analysis by 
multicompartmental modelling is as given previously. The results obtained were 
compared to those of a similar study of 15 normal individuals (cholesterol 
<6.0mmol/l, triglyceride <2.0mmol/l) carried out previously in this laboratory using 
the same methodology (Packard, unpublished data). Comparisons between the mixed 
hyperlipidaemic and normal subjects were performed using the two sample t-test.
6.4 Results.
1. Lipids and Lipoproteins.
As would be expected due to the sample selection, there were significant elevations in 
the cholesterol (pO.OOOl), triglyceride (p<0.0001), VLDL cholesterol (p=0.006) and 
LDL cholesterol (pO.OOOl) levels of the seven mixed hyperlipidaemic subjects as 
compared to those of the normal subjects. In addition, HDL cholesterol was 
significantly lower (p=0.0005). The lipoprotein compositions (Table 6.3, a & b) were 
compared to the results of the study of eighty normolipaemic subjects (cholesterol 
<6.0mmol/l and triglyceride <2.0mmol/l) reported in Chapter 3 as compositional 
analysis of the 15 normal subjects used for the kinetic comparisons was not available. 
Percentage free cholesterol was significantly (p<0.05) increased in VLDL! and 
VLDL2, but decreased in IDL and LDL. The esterified cholesterol content of VLDL! 
was increased, with reductions in the protein content. The percentage phospholipid in 
IDL and LDL was elevated. Analysis of the triglyceride :protein and 
cholesterol :protein ratios in VLDLj and VLDL2 showed that these lipoproteins, 
particularly VLDLb in the mixed hyperlipidaemic subjects were relatively lipid 
enriched (Table 6.4). The VLDL] triglyceride:protein, free cholesterol:protein and 
esterified cholesterol :protein ratios were all significantly increased, whilst in VLDL2 
only the free cholesterol:protein ratio was increased. In VLDL] the free 
cholesterol:phospholipid ratio is increased as compared to normal.
2. ApoB Pool Sizes (Table 6.5).
The apoB pool sizes in the seven subjects were all significantly elevated with the 
exception of IDL which narrowly missed significance (p = 0.08). The total apoB 
concentration was also elevated. The total apoB and VLDLi pool sizes all fell above 
the upper limit of the normal range. Two of the seven subjects had VLDL2 pool sizes 
within the normal range, whilst only one LDL pool size came within normal limits. 
The IDL pool sizes all fell within the normal range but most tended towards the upper 
limit.
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Table 6.3a Percentage Compositions o f VLDL} and VLDL2 - normal v mixed
hyperlipidaemic subjects.
VLDL,
EC
v l d l 2
ECProt FC TG PL Prot FC TG PL
Normal
mean 11.2 1.6 10.4 62.2 14.9 15.4 3.2 24.1 37.8 19.4
(SEM) (0.4) (0.2) (0.5) (1.4) (1.7) (0.4) (0.2) (0.7) (0.8) (1.3)
RA 6.5 2.2 10.7 65.5 15.1 12.3 3.5 18.3 47.6 18.2
PS 7.0 4.2 10.5 62.4 15.9 12.0 4.8 21.6 41.0 20.6
JC 8.3 2.8 14.8 59.0 15.0 18.0 3.5 29.1 31.2 18.2
RS 8.9 2.6 15.7 57.3 15.5 14.0 3.8 31.8 30.3 20.0
DM 6.1 4.4 15.6 58.7 15.1 11.9 4.9 33.9 30.2 19.2
LB 6.1 3.6 10.8 63.4 16.1 12.2 5.4 23.6 36.5 22.1
PC 6.5 4.2 10.9 62.8 15.6 13.9 3.2 24.9 38.2 19.9
Mixed
HLP
mean 7.1 3.4 12.7 61.3 15.5 13.5 4.2 26.2 36.4 19.7
(SEM) (0.4) (0.3) (0.9) (1.1) (0.2) (0.8) (0.3) (2.1) (2.4) (0.5)
p value <0.001 0.001 0.04 NS NS NS 0.03 NS NS NS
Prot = protein, FC = free cholesterol, EC = esterified cholesterol, TG = triglyceride, PL = 
phospholipid, Mixed HLP = mixed hyperlipidaemic subjects, SEM = standard error o f  mean, NS = not 
significant.
Table 6.3 b Percentage Compositions o f  IDL and LDL - normal v mixed
hyperlipidaemic subjects.
Prot FC
IDL — 
EC TG PL Prot FC
LDL — 
EC TG PL
Normal
mean 20.1 5.8 42.8 13.7 18.2 24.4 8.8 43.4 4.6 18.8
(SEM) (0.3) (0.2) (0.5) (0.5) (0.4) (0.2) (0.3) (0.4) (0.1) (0.4)
RA 20.4 5.2 37.2 16.5 20.7 23.7 5.9 44.5 5.4 20.5
PS 15.8 6.1 42.0 11.2 24.9 22.1 9.4 43.9 3.8 20.8
JC 24.2 4.0 44.8 8.0 18.9 27.0 7.4 42.2 3.9 19.4
RS 19.1 4.6 48.5 6.9 21.0 23.9 7.2 44.0 4.0 20.8
DM 17.7 5.3 45.7 10.6 20.7 24.6 8.1 41.8 5.7 19.8
LB 16.6 4.1 42.4 14.6 22.4 26.6 5.6 39.6 6.5 21.8
PC 19.7 4.0 42.8 12.5 20.9 26.6 5.2 42.8 5.3 20.2
Mixed
HLP
mean 19.1 4.8 43.3 11.5 21.4 24.9 7.0 42.7 4.9 20.5
(SEM) (1.1) (0.3) (1.3) (1.3) (0.7) (0.7) (0.6) (0.6) (0.4) (0.3)
p value NS 0.01 NS NS 0.003 NS 0.02 NS NS 0.002
84
Table 6.4 VLDL Composition Ratios - normal v mixed hyperlipidaemic
subjects.
VLDLj
FC:PR
v l d l 2
FC:PRTG:PR EC:PR FC:PL TG:PR EC:PR FC:PL
Normal
mean 5.8 0.14 1.00 0.16 2.5 0.21 1.61 0.29
(SEM) (0.20) (0.02) (0.07) (0.02) (0.10) (0.02) (0.06) (0.10)
RA 10.1 0.3 1.6 0.15 3.9 0.3 1.5 0.19
PS 8.9 0.6 1.5 0.26 3.4 0.4 1.8 0.23
JC 7.1 0.3 1.8 0.19 1.7 0.2 1.6 0.19
RS 6.4 0.3 1.8 0.17 2.2 0.3 2.3 0.19
DM 9.6 0.7 2.6 0.29 2.5 0.4 2.8 0.26
LB 10.4 0.6 1.8 0.22 3.0 0.4 1.9 0.24
PC 9.7 0.6 1.7 0.27 2.7 0.2 1.8 0.16
Mixed
HLP
mean 8.9 0.50 1.81 0.22 2.8 0.32 1.96 0.21
(SEM) (0.60) (0.07) (0.13) (0.02) (0.30) (0.04) (0.17) (0.01)
p value 0.002 0.002 0.0004 0.04 NS 0.03 NS NS
TG.PR = triglyceride:protein ratio, FC. PR = free cholesterol.protein ratio, EC.PR  = esterified 
cholesterol:protein ratio, FC.PL = free cholesterol:phospholipid ratio.
Table 6.5 ApoB Pool Sizes - normal v mixed hyperlipidaemic subjects.
Total ApoB 
(mg/di)
VLDL, Pool 
(mg)
VLDL2 Pool 
(mg)
IDL Pool 
(mg)
LDL Pool 
(mg)
Normal
mean (SEM) 60 (3.5) 42 (6.3) 93 (13) 269 (40) 1420 (99)
range 42-84 18-100 41-220 71-724 860-2248
RA 93 145 141 224 2236
PS 106 196 166 180 2528
JC 156 132 325 618 3276
RS 121 345 267 411 3323
DM 234 328 477 651 3977
LB 128 206 338 405 2785
PC 142 368 249 441 4118
Mixed HLP
mean (SEM) 140 (18) 246 (37) 280 (43) 419 (67) 3178 (268)
p value p=0.004 p=0.002 p=0.004 p=0.08 p=0.0005
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3. Kinetic Analysis (Table 6.6, a & b).
The kinetics of VLDLj were significantly different from normal, with an increased 
production rate and decreases in the fractional rates of direct catabolism and transfer. 
VLDL2 kinetics were mostly normal with the exception of a reduced fractional 
transfer rate. IDL showed significant decreases in production and fractional transfer 
rates with a normal fractional rate of direct catabolism. The production rate of LDL 
was reduced as compared to normal although not significantly (p=0.21). Overall, the 
total apoB production was increased (p=0.049). Finally, the fractional catabolic rate of 
LDL was significantly reduced. Thus the pertinent findings were i). an increase in 
apoB production, specifically VLDL! production, ii). a decrease in apoB transfer rate 
down the delipidation chain, and iii). decreases in the catabolism of VLDL! and LDL. 
The complete set of rate constants and calculated leucine pool sizes is given in 
Appendix 5. Figure 6.1, (a & b), shows representative tracer mass curves from a 
normolipidaemic and a mixed hyperlipidaemic subject.
To characterise further the apoB metabolism in the two groups, Pearson correlation 
coefficients (r) were calculated between apoB pool sizes and production rates and the 
plasma lipid levels and kinetic parameters. A sample size of n=7 is perhaps too small 
for certain statistical analyses and this needs to be borne in mind when interpreting the 
results. Firstly, the data was assessed for normality using the Anderson-Darling 
normality test. The following needed transformation prior to further analysis - 
VLDLi, VLDL2 and IDL apoB pool sizes (loge transformed), IDL and LDL apoB 
production rates (square root), total apoB production rate (loge), VLDLb VLDL2 and 
IDL fractional rates of direct catabolism (square root), and VLDLi and IDL fractional 
rates of transfer (loge). The correlations were then calculated separately for the two 
groups. Tables 6.7 and 6.8 show the correlations for apoB pool sizes and apoB 
production rates with total cholesterol, total triglyceride and the kinetic parameters.
To test the significance of the correlations, regression analysis was performed on 
those correlations with r values >0.5 or <-0.5. Again here the small sample size of the 
mixed HLP group may be statistically limiting with many of the correlated parameters 
not retaining significance whilst those in the normal group largely did. This may also 
reflect the degree of scatter of the values in the mixed HLP group. Those correlations 
with p values of <0.05 and <0.005 are marked in Tables 6.7 and 6.8. No correction for 
multiple comparison has been performed but those correlations with a significance of 
p<0.005 are unlikely to have occurred by chance.
In the normolipidaemic group the VLDLi and VLDL2 apoB pool sizes correlate 
positively with total triglyceride, whilst the IDL and LDL pool sizes correlate 
positively with total cholesterol. Total apoB correlates strongly with total plasma 
cholesterol. In the mixed hyperlipidaemic group, total apoB also correlates strongly 
with total plasma cholesterol but the individual subfraction apoB pools do not show 
significant correlations, perhaps due to the small sample size. However, there is a 
tendency for VLDLi to correlate with plasma triglyceride whilst VLDL2, IDL and 
LDL correlate with total cholesterol.
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In the normolipidaemic group the VLDL and IDL pool sizes showed negative 
correlations with VLDL2 and IDL fractional transfer rates. Total apoB also showed a 
significant negative correlation with VLDL2 fractional transfer rate. The apoB pool 
sizes appear to have little relation to the rates of production and direct catabolism of 
the lipoproteins in this group. In the mixed hyperlipidaemic group the negative 
correlation between VLDL and IDL pool sizes and VLDL2 and IDL fractional transfer 
rates persists, and total apoB correlates negatively with VLDL2 fractional transfer rate 
although not significantly. However, in this group the VLDL! and LDL apoB pools 
also correlate negatively with LDL fractional catabolic rate, a relationship that was not 
seen in the normolipidaemic group.
In both groups total apoB production correlated most strongly with VLDLi 
production. In the normolipidaemic group total apoB production also correlated 
positively with IDL production, the fractional rates of direct catabolism of VLDL2 and 
IDL and the fractional catabolic rate of LDL, reflecting the homeostatic balance 
between production and catabolism of lipoproteins in the normal state. The mixed 
hyperlipidaemic group showed a reciprocal relationship between the production rates 
of VLDL b VLDL2 and IDL such that VLDLj and VLDL2 production were negatively 
correlated whilst VLDL2 and IDL production were positively correlated. VLDL! 
production showed a non-significant positive correlation with VLDLi P°°l size in 
contrast to the negative correlation between VLDL2 production and VLDLi P°°l size 
(again non-significant).
Therefore, in both groups total apoB and total cholesterol correlated positively, with 
the apoB pool sizes of each lipoprotein correlating with its predominant lipid. The 
apoB pool sizes were negatively correlated with the fractional transfer rates of apoB 
down the delipidation chain. Catabolism of the lipoproteins showed little relationship 
to the apoB pool sizes except for LDL catabolism and VLDLi and LDL pool sizes in 
the mixed hyperlipidaemic group. Total apoB production was largely determined by 
VLDLi apoB production in both groups, with the mixed hyperlipidaemic group 
showing a negative correlation between VLDLi and VLDL2 production.
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Table 6.6a Kinetic Results - VLDLj and VLDL2, normal v mixed HLP subjects.
VLDL,
PROD
(mg/d)
VLDL,
FDC
(pool/d)
VLDL,
FTR
(pool/d)
v l d l 2
PROD
(mg/d)
v l d l 2
FDC
(pool/d)
v l d l 2
FTR
(pool/d)
Normal
mean 686 (84) 6.17 (1.84) 13.5 (2.00) 176 (26) 1.26 (0.33) 6.60 (0.69)
(SEM)
range 264-1508 0.05-27.2 5.81-37.7 21-358 0.06-3.90 3.6-12.7
RA 1078 2.8 4.5 176 0.8 5.2
PS 841 1.8 2.5 207 0.5 3.3
JC 993 0.06 7.6 279 0.8 3.2
RS 1349 2.8 1.1 190 0.003 2.2
DM 1098 0.8 2.6 192 0.4 1.7
LB 886 2.2 1.9 264 0.6 1.5
PC 1615 0.9 3.5 93 3.2 2.4
Mixed
HLP mean 1123 (103) 1.62 (0.40) 3.39 (0.81) 200 (23) 0.90 (0.40) 2.79 (0.48)
(SEM) 
p value p=0.006 p=0.03 p=0.0002 NS NS p=0.0002
PROD = production rate, FDC = fractional rate o f direct catabolism, FTR = fractional transfer rate, 
NS = not significant, Mixed HLP = mixed hyperlipidaemic subjects.
Table 6.6b Kinetic Results - IDL and LDL, normal v mixed HLP subjects.
IDL
PROD
(mg/d)
IDL
FDC
(pool/d)
IDL
FTR
(pool/d)
LDL
PROD
(mg/d)
LDL
FCR
(pool/d)
Total ApoB 
PROD
(mg/d)
Normal
mean 152 (31) 1.00 (0.24) 2.47 (0.36) 117 (28) 0.49 (0.04) 1131(109)
(SEM)
range 3-381 0.02-3.30 1.01-6.50 1-326 0.26-0.94 561-2209
RA 27 1.1 1.9 80 0.28 1361
PS 11 0.6 3.0 43 0.22 1102
JC 56 0.7 1.0 70 0.21 1398
RS 10 0.2 1.2 47 0.17 1596
DM 28 0.4 0.9 55 0.16 1373
LB 79 0.6 0.8 93 0.16 1322
PC 9 0.5 0.9 149 0.13 1866
Mixed
HLP mean 31 (10) 0.59 (0.11) 1.39 (0.30) 77 (28) 0.19 (0.02) 1431(91)
(SEM) 
p value p=0.002 NS p=0.03 NS pO.OOOl p=0.049
FCR = fractional catabolic rate.
Table 6.7a ApoB Pool Size Correlations - Pearson correlation coefficients (r)
fo r  normal and mixed HLP subjects.
Pools -
normal
mixed
Total
chol.
(mmol/I)
Total
trig.
(mmol/I)
VLDL,
PROD
(mg/d)
VLDL,
FDC
(pool/d)
VLDL,
FTR
(pool/d)
VLDLi
PROD
(mg/d)
V L D U
FDC
(pool/d)
VLDLi
FTR
(pool/d)
VLDL, 0.023 0.798** 0.475 -0.383 -0.513 0.155 0.349 -0.460
apoB
(mg)
0.588 0.662 0.690 0.169 -0.643 -0.632 0.020 -0.652
VLDL2 0.333 0.767** 0.336 -0.276 -0.398 0.444 0.109 -0.663*
apoB
(mg)
0.695 0.282 0.047 -0.499 -0.126 0.293 -0.128 -0.817*
IDL 0.616* 0.342 0.220 -0.215 -0.176 0.174 -0.066 -0.656*
apoB
(mg)
0.567 0.235 0.295 -0.644 0.119 0.163 0.041 -0.609
LDL 0.734** 0.346 -0.024 -0.103 -0.430 0.431 -0.060 -0.487
apoB
(mg)
0.735 0.583 0.672 -0.523 -0.041 -0.413 0.310 -0.628
Total 0.895** 0.373 -0.103 -0.046 -0.395 0.345 -0.264 -0.569*
apoB 
.(m g) _
0.907* 0.481 0.089 -0.372 0.078 0.036 0.006 -0.596
Normal group - top line o f  each row, Mixed HLP - italics, bottom line o f  each row, PROD 
production rate, FDC fractional rate o f  direct catabolism, FTR fractional transfer rate, NS = not 
significant, FCR = fractional catabolic rate, Mixed HLP = mixed hyperlipidaemic subjects.
* : p<0.05, ** p<0.005 on regression analysis (NB Uncorrected for multiple comparison).
Table 6.7b ApoB Poo! Size Correlations (continued).
Pools -
normal
mixed
IDL
PROD
(mg/d)
IDL
FDC
(pool/d)
IDL
FTR
(pool/d)
LDL
PROD
(mg/d)
LDL
FCR
(pool/d)
Total
PROD
(mg/d)
VLDL, -0.338 0.498 -0.568* -0111 -0.381 0.284
apoB
(mg)
-0.552 -0.806* -0.365 0.151 -0.793* 0.579
VLDLi -0.067 0.197 -0.626* 0.101 -0.100 0.442
apoB
(mg)
0.419 -0.525 -0.818* 0.001 -0.692 0.214
IDL 0.377 -0.091 -0.691** 0.121 -0.054 0.321
apoB
(mg)
0.350 -0.422 -0.885* 0.188 -0.610 0.489
LDL 0.033 -0.243 -0.463 -0.128 -0.433 0.106
apoB
(mg)
-0.235 -0.606 -0.673 0.332 -0.812* 0.687
Total -0.086 -0.400 -0.425 -0.076 -0.373 0.023
apoB
(mg)
0.156 -0.372 -0.581 -0.062 -0.508 0.140
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Table 6.8a Production Rate Correlations - Pearson correlation coefficients
(r) fo r  normal and mixed HLP subjects.
PR O D - Total Total VLDL, VLDL, VLDL, v l d l 2 VLDL2 VLDL2
chol. trig. PROD FDC FTR PROD FDC FTR
normal
mixed
(mmol/1) (mmol/l) (mg/d) (pool/d) (pool/d) (mg/d) (pool/d) (pool/d)
VLDL! -0.336 0.079 0.405 0.262 0.078 0.664** 0.185
PROD 0.202 0.507 -0.016 -0.125 -0.805* 0.401 -0.144
(mg/d)
VLDL, 0.051 0.107 0.078 0.352 -0.364 0.213 -0.093
PROD -0.269 -0.689 -0.805* -0.226 0.122 -0.498 -0.103
(mg/d)
IDL -0.133 -0.544* 0.414 0.427 0.482 -0.105 0.315 0.163
PROD -0.052 -0.233 -0.583 -0.259 0.290 0.782* -0.053 -0.163
(mg/d)
LDL 0.049 -0.056 -0.043 -0.219 0.257 -0.355 -0.117 -0.210
PROD 0.084 0.527 0.547 -0.162 0.314 -0.464 0.871* -0.050
(mg/d)
Total -0.244 -0.040 0.842** 0.509 0.236 0.326 0.661* 0.084
PROD 0.169 0.441 0.946** -0.127 -0.040 -0.609 -0.414 -0.229
(mg/d)
Normal group - top line o f  each row, Mixed HLP - italics, bottom line o f  each row, PROD 
production rate, FDC - fractional rate o f  direct catabolism, FTR = fractional transfer rate, NS not 
significant, FCR = fractional catabolic rate, Mixed HLP mixed hyperlipidaemic subjects.
* p<0.05, ** = p<0.005 on regression analysis (NB Uncorrected fo r multiple comparison).
Table 6.8b Production Rate Correlations (continued).
PR O D - IDL IDL IDL LDL LDL Total
PROD FDC FTR PROD FCR PROD
normal
mixed
(mg/d) (pool/d) (pool/d) (mg/d) (pool/d) (mg/d)
VLDL, 0.414 0.852 -0.062 -0.043 0.418 0.842**
PROD -0.583 -0.409 -0.370 0.547 -0.500 0.946**
(mg/d)
VLDL2 -0.105 0.051 -0.022 -0.355 -0.204 0.326
PROD 0.782* 0.147 -0.067 -0.464 0.247 -0.609
(mg/d)
IDL 0.199 -0.048 0.291 0.631* 0.598*
PROD 0.371 -0.456 0.100 0.070 -0.296
(mg/d)
LDL 0.291 0.075 -0.242 0.423 0.226
PROD 0.100 0.263 -0.491 -0.360 0.653
(mg/d)
Total 0.598* 0.702** -0.130 0.226 0.528*
PROD -0.296 -0.359 -0.606 0.653 -0.552
(mg/d)
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One correlation that remained highly significant in both groups was VLDLj apoB 
production as a predictor of total apoB production. For this reason, the relationships of 
VLDLj production with total triglyceride, VLDL! apoB pool size, LDL apoB pool 
size, LDL fractional catabolic rate and total apoB production were explored further by 
drawing regression plots. A question that must be raised when comparing these two 
groups is whether they are in fact two different populations or merely a continuum of 
the same separated by an arbitrary cut-off (cholesterol 6.0mmol/l, triglyceride 
2.0mmol/l)? Given the small sample size of the two groups this question is difficult to 
answer. However, regression plots were drawn for the parameters mentioned above, 
firstly on each group separately and then on the two groups joined. Finally, four extra 
subjects whose lipid levels overlapped both groups - cholesterol >6.0mmol/l but 
triglyceride <2.0mmol/l - were included in the total group. These ‘intermediate’ 
subjects (Table 6.9) were added to bridge the gap between the normolipidaemic and 
mixed HLP groups. Regression plots were then drawn for the complete group. The 
findings are summarised in Table 6.10. All the r values were stronger in the mixed 
hyperlipidaemic subjects than in the normal subjects. When the two groups were 
combined the r values for VLDLj production versus both triglyceride and VLDLj 
pool size increased whilst those for LDL pool size and LDL fractional catabolic rate 
decreased. This perhaps reflects the stronger relationship between VLDLj production 
and apoB metabolism in the mixed HLP group. The addition of the four 
‘intermediate’ subjects did not improve the regression fits and in fact worsened them 
suggesting that these subjects had no influence on the slope of the regression. The 
regression plot for VLDLj production v total apoB production in the normal plus 
mixed HLP subjects is shown in Figure 6.2.
Table 6.9 ‘Intermediate' Subjects - Lipid Levels.
‘Intermediate’
Subject
Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
1. 6.36 1.39
2. 6.28 1.95
3. 6.95 1.55
4. 6.95 1.60
2
Table 6.10 r (r ) values for VLDLj Production v Variables - all groups.
VLDLj Normal Mixed HLP Normal + Mixed Normal + Mixed
Production v ... Subjects Subjects HLP Subjects + Intermediate
(mg/d) (n=15) (n=7) (n=22) Subjects (n=26)
Triglyceride 0.077 (0.006) 0.507 (0.257) 0.597 (0.357) 0.545 (0.297)
(mmol/1)
VLDLj apoB 0.475 (0.225) 0.690 (0.476) 0.704 (0.496) 0.654 (0.428)
pool (mg)
LDL apoB -0.024 (0.000) 0.672 (0.452) 0.587 (0.345) 0.532 (0.283)
pool (mg)
LDL FCR 0.418(0.175) -0.500 (0.25) -0.217(0.047) -0.105 (0.011)
(pool/d)
Total apoB 0.842 (0.709) 0.946 (0.895) 0.866 (0.750) 0.863 (0.745)
Production
(mg/d)
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4. LDL Subfraction Profiles (Table 6.11).
All seven subjects had a minority of LDL in the large, least dense fraction (LDLI). In 
six subjects the majority of LDL was divided equally between LDLII and LDLIII. 
Subject LB had mostly small, dense LDL (LDLIII). Of note this subject was the only 
one with the apoE 4/4 phenotype. Figure 6.3 shows the LDL subfraction profiles of 
subjects JC and LB, JC with both LDLII and LDLIII and LB with mostly LDLIII.
Table 6.11 LDL Subfraction Profiles (%) - mixed HLP subjects.
Subject % LDLI
(d=1.025-1.034g/ml)
% LDLII
(d=l .034-1.044g/m 1)
% LDLIII 
(d=1.044-1.060g/ml)
RA 16 44 40
PS 16 40 44
JC 12 47 41
RS 7 40 53
DM 13 41 46
LB 2 26 72
PC 20 30 50
Mean (SEM) 12 (2.3) 38 (2.8) 49 (4.2)
6.5 Discussion.
The seven subjects in this study consisted of six males and one post-menopausal 
female (LB). At first glance subject LB would appear out of keeping with the rest of 
the group on three accounts - her sex, her elevated body mass index (BMI) of greater 
than 30, and her apoE 4/4 phenotype. The remaining subjects had BMI’s below 30 
and apoE phenotypes of either 3/3 or 4/3. However, analysis of the results with this 
subject excluded caused no significant change to the findings. Her apoE 4/4 
phenotype only appeared relevant in analysis of the LDL subfraction profiles.
In this study some findings were in keeping with previous work on FCHL but some 
were not. It is important to stress that the seven mixed hyperlipidaemic (HLP) 
subjects here were not classified as FCHL and may in fact have dyslipidaemia of a 
different aetiology. However, the majority of kinetic work on subjects with this type 
of lipid profile that is available for comparison has been performed in FCHL.
By virtue of selection, the mixed HLP and normal subjects did not overlap in their 
total cholesterol and triglyceride levels. In addition, the mixed HLP subjects had 
lower HDL cholesterol levels as is often seen with triglyceride elevations. The apoB 
levels were elevated in keeping with previous work on FCHL subjects. Compositional 
analysis revealed increased triglyceride:protein and cholesterol :protein ratios in 
VLDLj. This is in contrast to previous work in FCHL subjects where the composition 
of VLDL has been reported as normal. However, these studies did not separate VLDL 
into the triglyceride-rich VLDLj and the less triglyceride-rich VLDL2. An interesting 
finding was that of an increased free cholesterol:phospholipid ratio in VLDLj in the
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mixed HLP subjects. The amount of free cholesterol in the phospholipid lattice of the 
lipoprotein surface is largely responsible for the surface fluidity. Increasing amounts 
of free cholesterol in the surface make the lattice more rigid and so reducing the 
amount of protein that is able to insert into the lattice, in particular apoCII. Since 
lipoprotein lipase requires apoCII as a cofactor for lipoplysis, an increase in VLDL! 
free cholesterol could lead to a reduction in particle catabolism. A reduced rate of 
direct catabolism of VLDLj was in fact seen in the mixed HLP group. Reduced 
lipoprotein lipase activity has been previously reported in a subset of individuals with 
FCHL (Babirak et al 1992).
Total apoB production, in particular that of VLDL!, in the mixed HLP group was 
elevated. This concurs with the increased hepatic production of total VLDL apoB seen 
by other workers (Janus et al 1980, Kissebah et al 1981, Cortner et al 1991, 
Venkatesan et al 1993). In our subjects the increase was seen in the larger, 
triglyceride-rich VLDLi rather than in the smaller VLDL2 as might have been 
expected by the moderately elevated plasma cholesterol (Gaw et al 1995). However, 
the mean plasma triglyceride level in the study of Gaw et al was lower than in our 
subjects. Contrary to the findings of Janus et al (1980) and Kissebah et al (1981), the 
transfer of apoB down the delipidation chain from VLDLj to LDL in this study was 
reduced. Kissebah suggested that in FCHL there was increased production of a small, 
dense VLDL which was rapidly ‘metabolically channelled’ to LDL, hence explaining 
the increased levels of apoB seen in these individuals. The reduced transfer of apoB 
from VLDL to LDL seen in our study is more in keeping with the large, triglyceride- 
rich nature of the VLDL that is produced in increased amounts as VLDLj. This 
lipoprotein species is only slowly converted to LDL (Griffin and Packard 1994).
Comparison of the correlations in the normal and mixed HLP groups raises three 
points. Firstly, the predominant lipid within the plasma, i.e. cholesterol or triglyceride, 
is reflected in the apoB pool size of each lipoprotein - VLDL pool size is greater when 
triglyceride is relatively abundant whilst IDL and LDL pool sizes are larger when 
more cholesterol is present. Secondly, the apoB pool sizes and fractional transfer rates 
are negatively correlated in such a way to suggest that either enlarged pool sizes 
impede the passage of apoB down the delipidation chain, or that delayed passage of 
the apoB causes the enlarged pool sizes. Thirdly, although in both groups the major 
determinant of total apoB production is VLDLj, the main difference between the 
groups appears to lie in the reciprocal relationship between VLDLj, VLDL2 and IDL 
production rates seen in the mixed HLP group with the resultant effect that this has on 
VLDLj apoB pool size, plus the negative relationship seen between LDL catabolism 
and the pool sizes of VLDLj and LDL. In the mixed hyperlipidaemic group the 
production of VLDLj appears to determine both its own pool size and that of LDL, 
whilst having a negative effect on the production of VLDL2 and IDL. This, in keeping 
with the positive correlation between VLDLj and triglyceride, suggests that these 
individuals preferentially produce VLDLj, a triglyceride-rich particle which is slowly 
metabolised and adds to the size of the LDL pool. The correlations between LDL 
catabolism and VLDLj and IDL apoB pool sizes could reflect both the delayed 
metabolism of particles originating as VLDLj and the type of LDL that results i.e. 
VLDLj is predominantly metabolised to small, dense LDL (LDLIII) which is only 
slowly cleared from the plasma.
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The LDL subfraction profiles of the mixed HLP subjects showed both LDLII and 
LDLIII, as compared to normal males and post-menopausal females who mostly have 
LDLII alone (Caslake 1996). The smaller, denser LDL subfractions are cleared more 
slowly from the plasma and this in turn is reflected in the reduced LDL fractional 
catabolic rate seen here. The predominance of LDLIII in subject LB possibly reflects 
reduced clearance of LDL precursors on account of the apoE 4/4 phenotype.
The regression analyses were perhaps inconclusive when trying to determine whether 
the normal and mixed HLP groups were in fact different or merely a continuum of the 
same. However, the fact that the addition of a further group of subjects with elevated 
cholesterol levels but normal triglyceride levels did not improve the regression fits 
might suggest that it is triglyceride rather than cholesterol that has the main influence 
on apoB metabolism in this sort of individual. In the seven mixed HLP subjects the 
metabolism of apoB can be summarised as follows. An increased amount of apoB is 
being secreted by the liver, primarily in the form of VLDLj. This VLDLj is only 
slowly cleared from the plasma and relatively slowly delipidated to VLDL2, IDL and 
LDL. As a result of the increased production, reduced clearance and reduced transfer 
to LDL there is an increase in all of the lipoprotein pool sizes. This is seen clinically 
as an increase in plasma cholesterol and triglyceride levels. Due to metabolic 
channelling, VLDLj is delipidated to form mainly the small, dense subfractions of 
LDL. This LDL is in turn only slowly catabolised, further exacerbating the enlarged 
LDL pool size and adding to the elevated total plasma apoB seen in these subjects. 
That triglyceride can have such bearing on apoB metabolism has been reported before. 
Workers have found different levels of triglyceride at which the metabolism appears 
to change - l.lmmol/1 (Austin et al 1990), 1.3mmol/l (Tan et al 1995) and 1.6mmol/l 
(Superko and Krauss 1992).
Thus, the kinetics of apoB in these seven mixed hyperlipidaemic subjects showed 
some interesting differences from normolipaemic subjects and both some similarities 
and differences with FCHL. The apoB metabolism in these subjects appears to be 
more a consequence of triglyceride and the production of relatively triglyceride- 
enriched VLDL, with the resultant delayed delipidation and catabolism. The kinetic 
findings as compared to normal are summarised in Figure 6.4.
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Figure 6. la  Tracer Mass Curves for a Normal Subject (0-50 & 0-350 hours).
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Figure 6.2 VLDLI Production v Total ApoB Production
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Chapter 7 The Treatment of Mixed Hyperlipidaemia
Mechanisms of Action of Simvastatin 
and Atorvastatin. a New HMG-CoA 
Reductase Inhibitor.
7.1 Introduction.
Mixed hyperlipidaemia can be relatively difficult to treat. Standard practice is to use 
one of the fibrate class of drugs or nicotinic acid, both of which are more effective at 
lowering triglyceride elevations alone rather than mixed elevations of cholesterol and 
triglyceride. More recently combination therapy with a statin plus a fibrate has been 
used for cases not responsive to a fibrate alone. Whilst this combination is effective 
there is an increased risk of side effects, in particular myopathy, and a likelihood of 
reduced patient compliance due to the increased number of drugs being taken. To date 
statins alone have proved less beneficial for mixed hyperlipidaemia. However, 
atorvastatin, a new member of the statin class, is reputed to be effective at lowering 
both cholesterol and triglyceride levels.
The 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors, or 
statins, are a class of lipid-lowering drug derived originally from fungal metabolites 
(Endo et al 1976). Through their competitive inhibition of the rate limiting step in 
cholesterol synthesis (HMG-CoA conversion to mevalonate) they have proved 
efficacious in the lowering of plasma total cholesterol and LDL cholesterol. The 
mechanism of action responsible for this cholesterol lowering has been reported as an 
up-regulation of the LDL receptors, secondary to a reduced intrahepatic free 
cholesterol pool, thus leading to increased clearance of LDL from the plasma 
(Bilheimer et al 1983, Malmendier et al 1989). Other workers have found additional 
explanations for the cholesterol-lowering effect of statins, including reduced hepatic 
production of apoB-containing lipoproteins (Watts et al 1995), increased catabolism 
of LDL precursors (Gaw et al 1993), and reduced direct synthesis of LDL (Gaw et al 
1996).
Atorvastatin is one of the more recently developed of the statins and has a good safety 
profile in keeping with others in this class. It has been shown to be at least as potent as 
the others, with dose related reductions in plasma LDL cholesterol of 25% to 60% at 
doses of 2.5mg to 80mg per day (Nawrocki et al 1995). It also has a significant 
triglyceride lowering effect, achieving reductions of up to 45% on maximum therapy 
of 80mg per day in patients with primary hypertriglyceridaemia (Bakker-Arkema et al 
1996). It is, therefore, possible that this drug may be useful in the treatment of mixed 
hyperlipidaemia. The aim of this study was to characterise the effect of atorvastatin on 
the kinetics of apoB in a group of subjects with mixed hyperlipidaemia, and to 
compare this to the effect of simvastatin in the same group of subjects.
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7.2 Subject Selection.
The characteristics of the seven subjects used in this study are described in Chapter 6. 
All subjects underwent a baseline turnover, as described in the previous chapter, but 
two subjects withdrew from the study after completing only one treatment phase, one 
following treatment with simvastatin and one following treatment with atorvastatin. 
There were no serious adverse reactions to either drug. Each subject gave signed 
informed consent and the study was approved by the Ethical Committee of Glasgow 
Royal Infirmary.
7.3 Methods.
The subjects underwent three stable isotope turnover studies of apoB kinetics using a 
bolus of tri-deuterated leucine at a dose of 7mg/kg body weight. The methodology for 
the turnovers was the same on each occasion, as previously described in Chapter 2. 
Following the baseline turnover, subjects were randomised to receive either 
simvastatin 40mg per day or atorvastatin 40mg per day, both taken last thing at night. 
Each treatment phase lasted eight weeks after which time subjects returned for a 
second turnover, continuing on their current therapy for the two week turnover period. 
They were then switched onto the alternative therapy without a washout period. The 
study was a randomised cross-over trial, but not blinded. Lipid and lipoprotein 
measurements were taken at the beginning and end of each turnover but at no point 
during the eight week treatment phases. Liver function tests and creatine kinase levels 
were monitored throughout but no subject showed elevations in these parameters. 
Twenty-four hour medical contact was available to each subject for advice regarding 
possible side effects, but in the main this was not required. Subjects were asked not to 
change any aspect of their lifestyles during the study, in particular not to lose or gain 
large amounts of weight. Three day diet diaries were completed by the subjects during 
the two weeks of each turnover and analysed, courtesy of the Department of Dietetics 
and Nutrition in this hospital, to ensure consistency in the dietary composition from 
one turnover to the next. Each subject’s general practioner was informed of his 
patient’s involvement in the study and given a summary of the patient’s response to 
the two treatments at the end. Finally, the further management of each subject’s 
hyperlipidaemia was arranged prior to his discharge from the study.
7.4 Results.
1. Lipids and Lipoproteins.
Following treatment with both simvastatin and atorvastatin there were significant 
reductions (p<0.05) in total cholesterol, total triglyceride, LDL cholesterol and VLDL 
cholesterol. In most cases, the percentage reduction by atorvastatin was greater than 
that by simvastatin (Table 7.1), although two subjects (PS and JC) showed a 
marginally greater reduction in triglyceride whilst on simvastatin rather than 
atorvastatin. For both drugs HDL cholesterol showed an increase although this did not 
reach significance in either case. There was a significant decrease in plasma apoB on 
both drugs but no change in apoAI, Lp(a), HDL2 or HDL3 levels.
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Table 7.1 Lipids and Lipoproteins - baseline and treatment phases.
Subject Turnover Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
VLDL-chol
(mmol/1)
LDL-chol.
(mmol/1)
HDL-chol.
(mmol/1)
RA Baseline 6.20 2.90 0.85 3.95 1.40
Simvastatin 4.50 2.10 0.55 2.50 1.45
Atorvastatin 4.05 1.80 0.55 2.10 1.40
PS Baseline 6.45 2.60 0.80 4.60 1.05
Simvastatin 3.95 1.70 0.65 2.25 1.05
Atorvastatin 3.45 1.90 0.60 1.80 1.05
JC Baseline 6.40 2.25 0.75 4.70 0.95
Simvastatin 4.40 1.35 0.60 2.70 1.10
Atorvastatin 3.80 1.55 0.60 2.20 1.05
RS Baseline 6.35 2.60 1.15 4.55 0.70
Simvastatin 3.20 1.70 0.60 1.90 0.70
Atorvastatin - - - - -
DM Baseline 7.90 3.55 1.90 5.10 0.90
Simvastatin - - - - -
Atorvastatin 4.05 1.95 0.70 2.20 1.10
LB Baseline 6.60 2.95 1.25 4.45 0.90
Simvastatin 4.60 2.40 1.00 2.60 1.00
Atorvastatin 4.15 1.60 0.55 2.50 1.10
PC Baseline 7.00 3.60 1.45 4.60 0.95
Simvastatin 4.65 2.50 0.90 2.85 0.90
Atorvastatin 4.15 2.45 1.00 2.25 0.95
Mean Baseline 6.70 2.92 1.16 4.56 0.98
Simvastatin 4.22** 1.96** 0.72* 2.47** 1.03
Atorvastatin 3.95** 1.88** 0.67* 2.18** 1.11
% Simvastatin 37% 33% 38% 46% 6%
Change Atorvastatin 41% 36% 43% 52% 13%
*  =  p  <0.05, ** = p  <0.005, % change =  % increase or decrease from baseline.
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Compositional analysis revealed some differences between the two treatment phases 
(Table 7.2). VLDLi showed an increase in the triglyceride content on both drugs, but 
atorvastatin also caused a reduction in VLDLi free cholesterol whilst simvastatin did 
not. VLDL2 had a lower esterified cholesterol content on both drugs, whereas IDL 
only had lower esterified cholesterol on atorvastatin. LDL showed reduced free 
cholesterol on both drugs, with an increase in esterified cholesterol on atorvastatin. 
Thus, atorvastatin appears to have a more extreme effect than simvastatin in lowering 
the cholesterol content of the lipoproteins. Of note, there were no significant 
differences in the direct comparisons of simvastatin with atorvastatin.
Table 7.2 Subfraction Compositions - mean values (SEM), baseline and
treatment phases.
Sub­
fraction
Turnover %protein %free
cholesterol
% esterified 
cholesterol
% tri­
glyceride
% phos­
pholipid
VLDLj Baseline
Simvastatin
Atorvastatin
7.1 (0.4) 
7.5 (0.3) 
7.8 (0.2)
3.4 (0.3) 
2.6 (0.4) 
2.2 (0.3)*
13 (0.9)
10 (0.9)
11 (0.5)
61(1 .1) 
65 (0.7)* 
65(1.1)*
16(0.2) 
15 (0.9) 
14 (0.7)
v l d l 2 Baseline
Simvastatin
Atorvastatin
13 (0.80
14 (0.7)
15 (0.4)
4.2 (0.3) 
3.9 (0.4) 
3.7 (0.4)
26 (2.1) 
20(1.6)*  
21 (1.2)*
36 (2.4) 
42(1.4) 
41 (1.8)
20 (0.5) 
19(1.6) 
18 (0.4)
IDL Baseline
Simvastatin
Atorvastatin
19(1.1)
20 (0.7)
21 (0.6)
4.8 (0.3) 
4.4 (0.4) 
4.3 (0.3)
43 (1.3)
38 (2.4)
39 (0.9)*
11(1.3)
16(1.9)
16(1.5)
21 (0.7) 
22(1.6) 
20 (0.4)
LDL Baseline
Simvastatin
Atorvastatin
25 (0.7)
24 (0.5)
25 (0.4)
7.0 (0.6) 
4.4 (0.4)* 
4.6 (0.2)*
43 (0.6) 
46(1.3) 
45 (0.7)*
4.9 (0.4)
5.3 (0.6)
5.3 (0.3)
20 (0.3)
21 (0.6) 
20 (0.4)
* — p  <0.05, ** — p  <0.005, SEM = standard error o f  the mean.
2. ApoB Pool Sizes.
Neither drug caused a significant change to the VLDLj apoB pool size. VLDL2 and 
IDL pool sizes were significantly (p<0.05) reduced by both drugs, whilst the LDL 
pool sizes showed highly significant reductions on both drugs (p<0.005). Both drugs 
also significantly reduced the total apoB pool (Table 7.3). Again there were no 
significant differences in the direct comparisons of simvastatin with atorvastatin.
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Table 7.3 ApoB Pool Sizes - baseline and treatment phases.
Subject Turnover VLDLr B
(mg)
VLDLr B
(mg)
IDL-B
(mg)
LDL-B
(mg)
Total-B
(mg/dl)
RA Baseline 145 141 224 2236 93
Simvastatin 123 149 224 2020 85
Atorvastatin 137 77 160 1066 49
PS Baseline 196 166 180 2528 106
Simvastatin 131 141 353 1746 82
Atorvastatin 151 148 243 1278 63
JC Baseline 132 325 618 3276 156
Simvastatin 84 146 251 1373 64
Atorvastatin 159 163 227 1522 72
RS Baseline 345 267 411 3323 121
Simvastatin 101 138 181 1700 65
Atorvastatin - - - - -
DM Baseline 328 477 651 3977 234
Simvastatin - - - - -
Atorvastatin 147 189 281 1985 77
LB Baseline 206 338 405 2785 128
Simvastatin 99 226 193 1164 58
Atorvastatin 69 139 254 1330 62
PC Baseline 368 249 441 4118 142
Simvastatin 322 212 258 2218 83
Atorvastatin 233 229 166 1756 65
Mean Baseline 246 280 419 3178 140
Simvastatin 143 169* 243* 1703** 73*
Atorvastatin 149 158* 222* 1490** 65*
%Change Simvastatin 42% 40% 42% 46% 48%
Atorvastatin 39% 41% 47% 53% 54%
* = p  <0.05, ** = p  <0.005, % change  =  % increase or decrease from  baseline.
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3. Kinetic Analysis (Table 7.4).
Analysis of the kinetic results gave some unexpected findings, particularly in VLDLi. 
The original hypothesis was that the reductions in plasma triglyceride levels would be 
due to reduced hepatic VLDLj apoB production. In fact, the converse appeared to 
happen. Initial inspection of the tracer mass curves before and after treatment (Figure 
7.1) showed a change in the shape of the VLDL! curve with a higher peak value on 
treatment suggestive of an increase in VLDLj production and a steeper decline in the 
slope which would fit with an increased clearance rate. These observations were in 
fact borne out by the kinetic analysis. On atorvastatin there was a highly significant 
(p=0.0032) increase in VLDLi production. On simvastatin there was a tendency for 
VLDL! production to increase but this did not reach significance (p=0.24). All 
subjects showed increased VLDLj production on atorvastatin, whilst on simvastatin 
two showed a reduction in VLDLi production (RS and LB). The fractional rate of 
direct catabolism (FDC) of VLDLi increased significantly on atorvastatin (p=0.042) 
with all subjects showing an increase, whilst on simvastatin there was a trend towards 
an increased VLDLi FDC which did not quite reach significance (p=0.08), with one 
subject (RS) showing a reduced VLDLi FDC. (This subject was one of the two who 
also did not show increased VLDLi production on simvastatin). There was no 
significant effect of either drug on the fractional transfer rates of VLDLi apoB to 
VLDL2 apoB. Neither simvastatin nor atorvastatin caused any significant difference to 
the kinetics of VLDL2 or IDL apoB. On atorvastatin there was a highly significant 
increase in the fractional catabolic rate (FCR) of LDL (p=0.0015) with all patients 
showing this increase. This can be seen in the increased steepness of the LDL curve 
decline on treatment (Figure 7.2). On simvastatin there was a tendency for increased 
LDL FCR but this narrowly missed significance (p=0.052), with one patient (LB) 
showing no change in the FCR. These kinetic findings are illustrated in Figures 7.1 
and 7.2. The complete sets of rate constants and calculated leucine pool sizes on each 
treatment regime are given in appendices 6 and 7.
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Table 7.4a Kinetic Analysis - VLDLj and VLDL2, baseline and treatment
phases.
Subject Turnover -VLDLj—
FDC
(pools/d)
FTR
(pools/d)
-v l d l 2~
FDC
(pools/d)
FTR
(pools/d)
PROD
(mg/d)
PROD
(mg/d)
RA Baseline 1078 2.8 4.5 176 0.8 5.2
Simvastatin 2736 18.0 4.0 568 1.3 5.8
Atorvastatin 1760 9.0 3.5 98 0.5 6.9
PS Baseline 841 1.8 2.5 207 0.5 3.3
Simvastatin 1262 2.8 6.7 200 2.6 5.0
Atorvastatin 1468 3.9 5.7 312 2.8 5.0
JC Baseline 993 0.06 7.6 279 0.8 3.2
Simvastatin 1774 12.0 9.1 259 1.2 5.8
Atorvastatin 1556 6.0 3.8 383 0.02 5.6
RS Baseline 1349 2.8 1.1 190 0.003 2.2
Simvastatin 855 1.4 7.0 136 3.7 3.0
Atorvastatin - - - - - -
DM Baseline 1098 0.8 2.6 192 0.4 1.7
Simvastatin - - - - - -
Atorvastatin 1533 7.5 2.9 253 0.7 3.0
LB Baseline 886 2.2 1.9 264 0.6 1.5
Simvastatin 562 3.8 2.1 86 0.8 0.5
Atorvastatin 1449 20.0 1.3 434 2.9 0.9
PC Baseline 1615 0.9 3.5 93 3.2 2.4
Simvastatin 2651 6.3 2.0 437 2.2 2.7
Atorvastatin 1893 4.0 4.5 388 1.3 4.9
Mean Baseline 1123 1.62 3.39 200 0.9 2.8
(SEM) (103) (0.4) (0.8) (23) (0.4) (0.5)
Simvastatin 1640 7.38 5.15 281 2.0 3.8
(372) (2.6) (1.2) (76) (0.4) (0.9)
Atorvastatin 1610 8.40 3.62 311 1.4 4.4
(72)** (2.5)* (0.6) (50) (0.5) (0.9)
* = p  <0.05, ** = p  <0.005, SEM = standard error o f  the mean, PROD — production rate, FDC = 
fractional rate o f direct catabolism, FTR = fractional transfer rate.
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Table 7.4b Kinetic Analysis - IDL and LDL, baseline and treatment phases.
Subject Turnover __ m i LDL
PROD
(mg/d)
LDL
FCR
(pools/d)
PROD
(mg/d)
l L / J u
FDC
(pools/d)
FTR
(pools/d)
RA Baseline 27 1.1 1.9 80 0.28
Simvastatin 142 1.0 3.3 107 0.45
Atorvastatin 59 1.0 3.0 39 0.45
PS Baseline 11 0.6 3.0 43 0.22
Simvastatin 46 0.2 1.9 31 0.41
Atorvastatin 37 0.5 2.5 37 0.59
JC Baseline 56 0.7 1.0 70 0.21
Simvastatin 108 1.2 2.6 43 0.50
Atorvastatin 60 1.9 3.0 20 0.44
RS Baseline 10 0.2 1.2 47 0.17
Simvastatin 34 0.5 1.7 101 0.25
Atorvastatin - - - - -
DM Baseline 28 0.4 0.9 55 0.16
Simvastatin - - - - -
Atorvastatin 147 0.4 2.1 147 0.37
LB Baseline 79 0.6 0.8 93 0.16
Simvastatin 86 0.8 0.2 119 0.14
Atorvastatin 266 0.9 0.5 266 0.31
PC Baseline 9 0.5 0.9 149 0.13
Simvastatin 0 0.2 2.1 44 0.26
Atorvastatin 0 2.6 4.4 0 0.35
Mean Baseline 31 0.6 1.4 77 0.19
(SEM) (10) (0.1) (0.3) (14) (0.02)
Simvastatin 69 0.6 2.0 74 0.34
(21) (0.2) (0.4) (16) (0.06)
Atorvastatin 95 1.2 2.6 85 0.42
(40) (0.4) (0.5) (42) (0.04)**
* = p  <0.05, ** = p  <0.005, SEM = standard error o f  the mean, PROD = production rate, FDC = 
fractional rate o f  direct catabolism, FTR = fractional transfer rate, FCR = fractional catabolic rate.
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4. LDL Subfraction Profiles (Table 7.5).
On simvastatin there was a significant reduction in the concentrations of all three LDL 
subfraction species. On atorvastatin there was a significant reduction in LDLII and 
LDLIII concentrations, with a non-significant reduction in LDLI concentration. 
Analysis of the changes in percentage distribution of each subfraction in response to 
treatment gave some unexpected findings. Simvastatin caused no significant change to 
the percentage amounts of LDLI, LDLII and LDLIII, presumably due to its effect of 
equally lowering all three subfractions (the reductions of each subfraction were 60% 
LDLI, 49% LDLII and 56% LDLIII). Atorvastatin, on the other hand, showed a 
highly significant increase in the percentage of LDLII, with an associated but non­
significant increase in LDLI, and a significant decrease in the percentage of LDLIII. 
Thus, on atorvastatin there appears to be a shift in the distribution of the LDL 
subfractions from a predominance of small, dense species (LDLIII) to an increased 
proportion of larger, less dense lipoproteins (LDLI). In conjunction with this, there is 
an overall reduction in the total amount of LDL, with the largest reduction being in 
LDLIII concentration (69%) and a smaller, non-significant reduction in LDLI 
concentration (27%). Figure 7.3 gives a representative illustration of the changes in 
the LDL subfraction profiles in one subject.
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Table 7.5 LDL Subfraction Profiles - concentrations with percentages given in
brackets, baseline and treatment phases.
Subject Turnover LDLI cone" 
mg/dl
(percentage)
LDLII cone" 
mg/dl
(percentage)
LDLIII cone" 
mg/dl
(percentage)
RA Baseline 53(16) 150 (44) 133 (40)
Simvastatin 12 (37) 47 (37) 67 (53)
Atorvastatin 20 (23) 50 (57) 18(20)
PS Baseline 56(16) 136(40) 147 (44)
Simvastatin 30(16) 108 (58) 49 (26)
Atorvastatin 23(13) 108(61) 46 (26)
JC Baseline 50(12) 204 (47) 180(41)
Simvastatin 22 (9) 151 (63) 67 (28)
Atorvastatin 27(12) 100 (47) 87(41)
RS Baseline 24(7) 132 (40) 178 (53)
Simvastatin 14(8) 70 (40) 92 (52)
Atorvastatin - - -
DM Baseline 40(13) 130(41) 147 (46)
Simvastatin - - -
Atorvastatin 35(21) 71 (44) 58 (35)
LB Baseline 6 (2 ) 99 (26) 278 (72)
Simvastatin 7 (9 ) 19(23) 56 (68)
Atorvastatin 8 (4) 98 (50) 92 (46)
PC Baseline 45 (20) 65 (30) 114(50)
Simvastatin 10(7) 7 (5 ) 108 (78)
Atorvastatin 58 (40) 67 (47) 16(11)
Mean Baseline 40 (12) 131 (38) 168 (49)
Simvastatin 16* (10) 67* (39) 73** (51)
Atorvastatin 28 (19) 82* (51)** 53** (30)*
% change Simvastatin 60% 49% 56%
Atorvastatin 27% 37% 69%
* = p  <0.05, ** = p  <0.005, % change = % increase or decrease from baseline.
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7.5 Discussion.
The reductions seen here in lipids and lipoproteins due to simvastatin and atorvastatin 
are in keeping with those seen in a multitude of other studies on the statin class of 
drugs, including the recent large 4S and WOSCOPS trials. In general, atorvastatin 
caused greater mean percentage reductions than simvastatin, with both drugs at a daily 
dose of 40mg, but the difference was not statistically significant - total cholesterol 
41% v 37%, triglyceride 36% v 33%, VLDL cholesterol 43% v 38%, and LDL 
cholesterol 52% v 46%. The increase in HDL cholesterol has also been seen 
previously with the statins. In this study some subjects showed an increase in HDL 
cholesterol on treatment whilst some showed no change and thus the result was not 
statistically significant. In keeping with this was the lack of change in the apoAI 
levels and HDL subfractions. Compositional analysis showed a decrease in the 
cholesterol content of the lipoproteins in response to the statins, a finding which has 
been reported previously (Gaw et al 1993). Here atorvastatin appears to have a more 
significant effect than simvastatin which may reflect a slightly greater inhibition of 
HMG-CoA reductase such that the lipoproteins are being secreted by the liver with a 
lower cholesterol content. The increase in VLDLj triglyceride content was an 
unexpected finding but is in keeping with the observed kinetic changes, as will be 
discussed below.
Total apoB concentration was reduced by 48% on simvastatin and 54% on 
atorvastatin. The greatest reductions in each case were in LDL apoB pool sizes (46% 
and 53% respectively), but there were also substantial reductions in the apoB pools of 
VLDL2 (40%, 41%) and IDL (42%, 47%). Again atorvastatin caused the greater 
reductions but the difference from simvastatin was not significant. Of note, neither 
drug caused a significant reduction in VLDL] apoB pool size but again this is in 
keeping with the kinetic observations.
A highly unexpected finding in this study was the significant increase in VLDL! 
production rate of 43% that was seen on atorvastatin. This was contrary to the original 
hypothesis that atorvastatin would lower plasma triglyceride levels by a reduction in 
VLDL production. This reduced VLDL production has been previously reported in a 
kinetic study of simvastatin (Watts et al 1995). However, the study of Watts et al did 
not distinguish between the two subfractions of VLDL and used a monoexponential 
function for the analysis which is perhaps not entirely appropriate when modelling the 
kinetics of a heterogeneous class of lipoproteins such as VLDL. Of note was the fact 
that in the current study the majority of the subjects also showed an increase in 
VLDL, production on simvastatin but two showed a decrease and so there was no 
significant change overall. The fractional rate of direct clearance of VLDL, whilst on 
atorvastatin was also significantly increased with the resultant effect of no change in 
the VLDL, apoB pool size. Simvastatin largely caused a similar effect on VLDL, 
direct catabolism but again the increase was not significant. However, there was also 
no significant change in the VLDL, apoB pool size on this drug. Increased catabolism 
of VLDL has been noted before in subjects with mixed hyperlipidaemia, in this 
instance following treatment with pravastatin (Parhofer et al 1993).
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The unexpected increase in VLDLj production could possibly be explained if there 
existed a hepatic VLDL receptor. If this receptor, in addition to the LDL receptor, is 
up-regulated in response to reduced intrahepatic cholesterol there will be increased 
clearance of VLDL!, as was reflected in the increased VLDL! fractional rate of direct 
catabolism. (Atorvastatin has proved effective in homozygous familial 
hypercholesterolaemia, i.e. subjects with practically no LDL receptors available for 
up-regulation, (Marais, unpublished observation) and so the LDL receptor is not 
necessarily responsible for increased VLDLi clearance). Increased clearance of these 
triglyceride-rich lipoproteins will result in an increased triglyceride load being 
returned to the liver. Here the apoB is degraded and the triglyceride becomes available 
for re-secretion with newly synthesised apoB. The neutral lipid content of the 
hepatocyte has been suggested to determine the amount of post-translational apoB that 
is secreted relative to the amount that is degraded. This in turn could stimulate the 
production of triglyceride-rich lipoproteins i.e. VLDLb hence the observed increased 
production rate of VLDLi. The finding of increased VLDLi triglyceride in the 
compositional analysis adds weight to this concept of ‘futile cycling’ of triglyceride. 
Triglyceride turnover studies on these same subjects using deuterated glycerol have 
indicated that this futile cycling is occurring (Millar, unpublished observation).
That the kinetics of VLDL2 and IDL in this study were unaffected by either drug is in 
contrast to the work of Gaw et al (1993) who observed an increase in the catabolism 
of LDL precursors. The subjects in this study did show a tendency to increased rates 
of direct catabolism of VLDL2 and IDL but these did not reach significance. However, 
the pool sizes of these lipoproteins were significantly reduced. The other significant 
kinetic finding of this study was the increased fractional catabolic rate of LDL on both 
drugs. This is in keeping with the widely accepted mechanism of action of the statins, 
whereby a reduced intrahepatic cholesterol pool, secondary to HMG-CoA reductase 
inhibition, stimulates the up-regulation of LDL receptors and so increases LDL 
clearance from the plasma. The increased LDL catabolism, especially on atorvastatin, 
could also be a reflection of the nature of the LDL that is binding to the receptor. The 
larger, less dense LDL species (LDLI) are known to bind with greater affinity to the 
LDL receptor than the small, dense species (LDLIII). Atorvastatin appears to change 
the nature of the LDL subfraction profile such that LDLI predominates whereas this is 
not the case with simvastatin (see below). This may be one reason for the increased 
LDL fractional catabolic rate on simvastatin not quite reaching statistical significance. 
The kinetic findings are summarised in Figure 7.4.
The atorvastatin-induced change in the LDL subfraction profiles was a second 
unexpected finding in this study. Both simvastatin and atorvastatin reduced the 
concentrations of all three LDL subfractions (although the reduction in LDLI was not 
significant for atorvastatin). However, the relative proportions by which each 
subfraction is reduced differ between the two drugs. Simvastatin reduces each 
subfraction by roughly the same amount - 60% reduction in LDLI, 50% reduction in 
LDLII and a 55% reduction in LDLIII. If anything, the largest reduction is in LDLI, 
which is the subfraction with the highest affinity for the LDL receptor and so more 
likely to show increased clearance when the LDL receptors are up-regulated. In 
contrast, on atorvastatin the majority of the LDL reduction is in LDLIII. LDLI is 25% 
reduced, LDLII is 35% reduced and LDLIII is 70% reduced. Thus the LDL
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subfraction profile on atorvastatin is changed from a predominance of LDLIII to a 
predominance of the less dense species LDLI and LDLII. This shift in the LDL 
subfraction profile has been noted before with the fibrate class of drugs (Caslake 
1996) but never consistently with a statin. However, in a study of the effect of 
pravastatin in primary moderate hypercholesterolaemia Vega et al (1990) did note that 
three out of the ten patients studied converted their LDL subfraction pattern from 
pattern B to pattern A in response to treatment. The mechanism behind this was given 
as a reduction in triglyceride in these patients which is also the suggested explanation 
for the effect that fibrates have on altering the LDL subfraction profile. In this study, 
it could be that the marginally greater effect of atorvastatin than simvastatin on 
lowering triglyceride is enough to cause the observed change in the LDL subfraction 
profile.
Direct comparison of simvastatin and atorvastatin gave no significant differences 
between the two. However, on comparing each to the baseline results the general 
impression to emerge is that atorvastatin is slightly more efficacious at lowering lipid 
and lipoprotein levels than simvastatin when both drugs are used at the same dosage 
(40mg daily). Atorvastatin certainly shows more extensive effects on the apoB 
kinetics than simvastatin, in particular on VLDL] production and direct catabolism, 
and also on LDL catabolism. However, given the fact that simvastatin showed a 
tendency to similar effects, although not reaching significance, it is possible that this 
difference is merely a result of subject selection and a small sample size. Perhaps if 
larger numbers were studied simvastatin would also show significant changes in these 
parameters. The striking difference between the two lies in the effects on the LDL 
subfraction profiles. Direct comparison of the percentage of LDLIII on simvastatin as 
compared to atorvastatin is the only value that approaches a significant difference 
(p=0.07). Although both drugs lower plasma LDL concentration, atorvastatin causes a 
shift in the LDL subfraction profile to one of a less atherogenic nature whereas 
simvastatin does not. That this effect has only previously been seen with the fibrates 
points to the triglyceride-lowering action of atorvastatin as responsible. Perhaps the 
marginally greater efficacy of atorvastatin at lowering triglyceride is just enough to 
change the nature of the lipoproteins being transferred down the delipidation chain, 
such that the resultant LDL is predominantly of a large, less dense nature (LDLI and 
LDLII). It could be suggested that each subject has an individual ‘threshold’ 
triglyceride level at which hepatic apoB production will change such that LDLI and 
LDLII predominate in the plasma, and that the subjects selected for this study happen 
only to reach this threshold whilst on atorvastatin. This would require a much larger 
sample size to resolve.
To summarise, the results of this study showed an unexpected increase in VLDL] 
production and an unexpected change in the nature of the LDL subfraction profiles in 
this group of subjects when treated with atorvastatin 40mg daily, two effects not 
previously reported with a statin.
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Chapter 8 General Discussion.
By the beginning of the century the association between elevated plasma lipid levels, 
in particular plasma cholesterol, and atherosclerosis had become widely accepted. 
Since then research has moved forward from focusing primarily on the lipids 
themselves to concentrating on the lipoproteins and more recently on the 
apolipoproteins. As this century now closes, the research seems to have swung full 
circle with the realisation that intracellular lipid concentrations can influence the 
synthesis of apolipoproteins, the secretion of lipoproteins and hence the plasma lipid 
levels. To a certain extent this thesis has followed a similar pattern by first selecting 
subjects by virtue of their plasma lipid levels, studying their lipoprotein subfractions 
and then characterising their apolipoprotein B metabolism. The results were then 
discussed in the context of the effect that intrahepatic lipid levels have on the nature 
and amounts of apoB containing lipoproteins that are secreted by the liver.
The primary aim of this thesis was to characterise the kinetics of apoB containing 
lipoproteins in certain pathological states. In the main this aim was achieved. The 
secondary aim was to test the applicability of stable isotope methodology and 
multicompartmental modelling techniques, established in normolipidaemia, to non- 
physiological conditions. In reaching these aims three objectives were achieved. First, 
a non-kinetic study of a large group of normolipidaemic subjects highlighted various 
inter-relationships between lipoproteins and indices of obesity, insulin resistance and 
lipase activity that can have a bearing on apoB kinetics (chapter 3). Secondly, the 
kinetics of apoB containing lipoproteins were characterised in five dyslipidaemic 
states, namely familial hypercholesterolaemia and familial defective apoB-100 
(chapter 4), hypobetalipoproteinaemia and analbuminaemia (chapter 5), and mixed 
hyperlipidaemia (chapter 6). Finally, the mechanisms of action of two HMG-CoA 
reductase inhibitors were determined in the group of mixed hyperlipidaemic subjects, 
with particular reference to the effects on apoB kinetics (chapter 7).
Throughout, the findings were compared to those reported in the current literature, 
with both agreement and disagreement with other work. Where results appeared to 
conflict with other work explanations were sought. The nature of stable isotope work 
means that there are several limitations to its use. It is labour intensive and time 
consuming, therefore, often restricting sample populations to a small size. In a small 
sample, inter-individual variation has much more of an influence on the results than 
would be the case in a larger sample. This in turn has an effect on the significance or 
otherwise of results. In addition, there is less stable isotope kinetic work available for 
comparison than is the case for radio-isotopes. Although the two often give similar 
conclusions, differences can arise, in particular with regard to synthetic rates and 
tracer recycling. The different methods of data analysis used in the literature i.e. 
monoexponential functions, linear regression analysis and multicompartmental 
modelling, add further complications when results are being compared. Furthermore, 
a method used in this thesis that is not widely used in the literature is that of 
separating two classes of VLDL on the basis of density. These two VLDL 
subfractions behave in a metabolically distinct manner. While it is accepted in the 
literature that VLDL is a heterogeneous class of proteins, much of the kinetic work
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studies only total VLDL. This again leads to limitations when putting the current 
work into the context of other reports. With the studies of the familial defective apoB- 
100, hypobetalipoproteinaemic and analbuminaemic subjects there was very little 
other work available for comparison, both due to the rarity of the conditions and to the 
fact that stable isotope work in general is still limited. Certainly, the study of apoB 
kinetics in analbuminaemia is the first of its kind.
8.1 Methodological Considerations.
Throughout this thesis stable isotope methodology and multicompartmental modelling 
techniques have been used that were originally developed for use in normolipidaemic 
subjects (Demant et al 1996). These techniques were chosen as they are believed to be 
the ‘gold standard’ for kinetic analysis. Despite the limitations mentioned above, 
stable isotopes have great benefits over radio-isotopes - they are safe to handle, are 
administered endogenously and can be used repeatedly. Other workers have shown no 
difference in the particular isotope used (Lichtenstein et al 1990) and this study used 
tri-deuterated leucine. It is an essential amino acid, is ubiquitous in body protein and 
is minimally recycled. In addition, leucine is plentiful in apoB. The use of multiple 
labelling improves the sensitivity of mass spectrometry measurements. ApoB is an 
ideal marker for studying the metabolism of VLDL, IDL and LDL as it stays with the 
lipoproteins from their synthesis to their catabolism. The methods of lipoprotein and 
apoB separation are well established and in general required no modification for GC- 
MS analysis, but with two exceptions. In the case of the analbuminaemic subject, the 
very high apoB pool sizes possibly caused some error in the ultracentrifugal 
separation of IDL and LDL due to overflow from LDL into IDL. This in turn may 
have caused an overestimation of the IDL pool size (Marais, unpublished 
observation). This error could possibly have been avoided by using a smaller amount 
of plasma than the standard 2ml from which to separate the lipoproteins. However, 
since the main kinetic finding in this subject was one of increased VLDL2 production 
it is unlikely that the discrepancy in the IDL pool size had any adverse bearing on the 
results. In the subject with hypobetalipoproteinaemia, the very low levels of apoB 
necessitated the separation of total VLDL rather than its subfractions in order to 
obtain measurable amounts of apoB. As a consequence, the multicompartmental 
model had to modified in such a way as to model VLDL as a whole rather than as 
VLDLt and VLDL2. This resulted in a model with fewer compartments than the 
original but still provided interpretable results.
Multicompartmental modelling was used as it is probably the best method for 
analysing the complexities of the lipoprotein system, in particular accommodating the 
heterogeneous nature of the lipoproteins (Parhofer et al 1991). The model used here is 
that of Demant et al (1996) and has been developed from a combination of radio­
isotope and stable isotope studies that have identified the key elements of the 
lipoprotein system, notably the intrahepatic synthesis of apoB, the delipidation 
cascade and the direct input into and loss from each lipoprotein fraction. This model is 
particularly good at defining the production rates of the lipoproteins, especially the 
differential production of VLDLj and VLDL2. In addition, the kinetics of plasma free 
leucine are taken into account, with particular reference to its recycling and 
subsequent effect on the ‘tails’ of the lipoprotein enrichment curves. What is perhaps
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lacking in this model is the dual delipidation pathway for apoB entering the plasma 
either as VLDL! or as VLDL2, as was illustrated in the model of Packard et al (1995). 
However, use of this model requires the independent labelling of VLDL j and VLDL2 
which is not possible with endogenous stable isotope labelling techniques. Demant’s 
model could perhaps also be improved by the expansion of the LDL compartments to 
allow for a more polydisperse LDL, especially for the study of hypertriglyceridaemic 
subjects. This would necessitate the isolation of apoB in the subfractions of LDL 
rather than just LDL as a whole. One further concern with using this model was that 
the parameter constraints that were applied to make the model uniquely identifiable 
were based on known normal physiology and might therefore not be applicable in the 
non-physiological state. However, this proved not to be the case. Thus, this model was 
successfully applied for use in dyslipidaemic states.
As mentioned above, one major difference between this work and much of the kinetic 
work in the current literature is the separate modelling of two VLDL subtractions. 
VLDL has been shown in other studies to consist of a number of metabolically 
heterogeneous subfractions that are grouped together by virtue of their centrifugal 
density. That VLDLi and VLDL2 are metabolically distinct has been illustrated in this 
work. The massive overproduction of VLDL2 in the analbuminaemic subject and the 
increased VLDLi production in the mixed hyperlipidaemic subjects may not have 
been identified had VLDL been modelled as a whole. In addition, the effect of 
atorvastatin on increasing both VLDLt production and catabolism (the ‘futile cycling’ 
effect) would not have been seen. Thus, it is justifiable to determine the separate 
kinetics of VLDL! and VLDL2.
8.2 The Regulation of ApoB Metabolism in Man.
Observations from the above studies and from other work suggest that the lipid 
content of the hepatocyte is central to determining the amount and nature of the apoB 
containing lipoproteins that are secreted. ApoB-100 is synthesised in its final form 
within the hepatocyte. To this lipid is added prior to its secretion. The availabilty of 
lipid within the hepatocyte determines the relative proportion of apoB that is secreted 
as lipoprotein, as compared to the amount that is degraded. The type of lipid 
predominating within the hepatocyte determines the nature of the lipoprotein secreted 
i.e. if the hepatocyte is relatively enriched in triglyceride the main lipoprotein 
produced is VLDLi, whilst if cholesterol is predominant VLDL2 is preferentially 
produced. What determines the relative amounts of lipid in the hepatocyte was to a 
certain extent illustrated in the study of normolipidaemia. This highlighted the effect 
of insulin resistance and obesity on increasing the intrahepatic triglyceride content. 
The study of the analbuminaemic subject showed how a deficiency of albumin can 
also have an effect on intrahepatic lipid levels, in this case probably cholesterol ester, 
and so affect lipoprotein production. The hypobetalipoproteinaemic subject acted as 
an illustration of a genetic defect resulting in reduced apoB synthesis and hence 
reduced lipoprotein secretion.
VLDLi passes relatively slowly down the delipidation chain and is thus exposed to 
neutral lipid exchange. Catalysed by CETP, HDL2 donates cholesterol ester to VLDL 
and in return receives triglyceride, resulting in the formation of relatively triglyceride-
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enriched HDL2 and cholesterol ester-enriched VLDL. The action of hepatic lipase on 
this HDL2 results in the formation of HDL3, and a lowering of plasma HDL 
cholesterol levels. HDL2 is then reformed from HDL3 by the cholesterol accumulating 
action of LCAT. Continued delipidation of the VLDL by the action of hepatic lipase 
produces LDL that is predominantly of a small, dense, protein-rich nature (LDLIII). 
This type of LDL is only slowly cleared from the plasma by the LDL receptor 
(perhaps due to the conformation of the apoB on the lipoprotein surface) and so 
accumulates in the plasma. It is cleared by receptor-independent mechanisms such as 
the scavenger receptors on macrophages with the resultant foam cell formation, 
inflammatory reaction and atherosclerosis development. Due to its small size, this 
dense LDL is able to directly penetrate the arterial endothelium so leading to 
subendothelial cholesterol deposition and hence plaque formation.
In contrast, VLDL2 is rapidly delipidated and cleared from the plasma, with only a 
small proportion of its apoB reaching the LDL density range. That which does 
preferentially forms the larger, less dense species of LDL which in turn are rapidly 
cleared from the plasma by the LDL receptor. Exposure to neutral lipid exchange is 
minimised by the rapid clearance of the lipoproteins. This differential production of 
VLDL! or VLDL2 is illustrated in the studies of the normolipidaemic, CHD sufferers 
and the mixed hyperlipidaemic individuals who were preferentially producing 
increased amounts of VLDL! with the resultant consequences described above and the 
development of the atherogenic lipoprotein phenotype. The FH and FDB subjects on 
the other hand showed how a deficiency in the catabolism of LDL, either due to 
receptor deficiency or ligand abnormality, can affect apoB metabolism. Of note, was 
the ability of the FDB subjects to normally catabolise their LDL precursors so 
reducing the potential for neutral lipid exchange and the formation of small, dense 
LDL.
This overview of apoB metabolism, with the mentioned points of regulation, is 
illustrated in Figure 8.1.
8.3 Pharmacological Manipulation of ApoB Metabolism.
The study of the mechanisms of action of simvastatin and atorvastatin, two HMG- 
CoA reductase inhibitors, illustrated one method of iatrogenic modification of apoB 
metabolism, in addition to allowing a direct comparison of the two drugs. The 
subjects used were those from the mixed hyperlipidaemia study. This group of 
individuals have traditionally been treated with the fibrate class of drug but newer 
claims for the HMG-CoA reductase inhibitors suggest that they are equally as 
effective in treating such individuals, in particular at lowering moderate elevations in 
plasma triglyceride. In addition, the recent 4S and WOSCOPS have done much to 
promote the safety and efficacy of this class of drug. The inhibition of HMG-CoA 
reductase results in the decreased intracellular production of cholesterol. By way of a 
homeostatic response, there is an up-regulation of LDL receptors in an attempt to 
return the intracellular cholesterol content to normal. This is seen as an increase in the 
catabolic rate of LDL, an effect that was noted with both drugs (although not 
significantly with simvastatin).
I l l
One unexpected finding of this study was the increase in VLDL! production that 
atorvastatin in particular caused (this effect was inconsistant with simvastatin and did 
not reach statistical significance). In addition there was an increase in VLDL! direct 
catabolism with no resultant change in the VLDLi apoB pool size. These findings 
were contrary to the original hypothesis that these drugs would cause a reduction in 
VLDLi production. The results suggest that there is a degree of ‘futile cycling’ of 
VLDLi occurring, possibly involving a hepatic VLDL receptor, a finding that is in 
keeping with results of triglyceride turnover studies in these same patients (Millar, 
unpublished observation) and also with the current thinking described above that the 
lipid content of the hepatocytes can determine the nature of the lipoproteins secreted.
A second unexpected finding was the ability of atorvastatin to change the nature of the 
LDL subfraction profile such that there was a shift in the profile from a predominance 
of small, dense LDL species to a predominance of the larger, less dense species. This 
effect has previously been reported for the fibrate class of drug (Caslake 1996), but 
not for the HMG-CoA reductase inhibitors, and so lends weight to the possibility that 
it is the triglyceride-lowering action of atorvastatin that causes this shift. Atorvastatin 
must therefore have an effect on the lipoproteins such that less are channelled into the 
small, dense species of LDL. Perhaps by virtue of its greater effect on VLDLj 
catabolism (and hence its triglyceride lowering) than simvastatin a smaller proportion 
of apoB comes down the delipidation chain from VLDLi as opposed to VLDL2. The 
relationships between plasma triglyceride levels and LDL subfraction profiles have 
been reported by other workers (Tan et al 1995) with the suggestion that for any one 
individual once the plasma triglyceride falls below a certain ‘threshold’ level the LDL 
subfraction will change.
The fibrates lower plasma triglycerides by activation of lipoprotein lipase and so 
increasing the delipidation of triglyceride-rich lipoproteins. By reducing the residence 
time of these lipoproteins in the plasma they minimise their exposure to neutral lipid 
exchange and hence the development of small, dense LDL and low HDL cholesterol 
levels. Thus, they are able to cause a shift in the LDL subfraction profile by a 
reduction in intrahepatic triglyceride availability. This is an effect not classically 
characteristic of the HMG-CoA reductase inhibitors but it now appears that 
atorvastatin (and perhaps other drugs of this class) is capable of such an effect. If this 
proves to be the case, it will serve to further popularise these drugs for a broader use 
in dyslipidaemia in particular in the light of the 4S and WOSCOPS.
8.4 Future Studies.
The studies in this thesis have highlighted the synthesis and catabolism of apoB 
containing lipoproteins as points of regulation of apoB metabolism. In so doing, 
further questions have been raised. A prime area for further study is the futile cycling 
of triglyceride that appears to happen in mixed hyperlipidaemic subjects treated with 
atorvastatin. That this occurs perhaps indicates the existance of a hepatic receptor for 
VLDLi that is up-regulated in response to the inhibition of HMG-CoA reductase and 
subsequent reduction in intrahepatic cholesterol. Identification of this receptor would 
require cell culture studies, plus, for example, kinetic studies of FH homozygotes who 
were receptor negative for the LDL receptor. The recycling of triglyceride can be
112
identified by lipid turnover studies and this is already being undertaken in this 
laboratory. Triglyceride is endogenously labelled with penta-deuterated glycerol and 
its subsequent metabolism is analysed (Millar, unpublished).
The effects of atorvastatin on apoB metabolism can be further expanded both by using 
increased doses of the drug and by studying subjects with different forms of 
dyslipidaemia such as FH homozygotes (Marais, unpublished) or subjects with 
hypertriglyceridaemia secondary to, for example, lipoprotein lipase deficiency. In 
addition, the ability or otherwise of simvastatin to have similar effects on apoB 
metabolism can be determined by using an increased sample size of mixed 
hyperlipidaemic subjects and by increasing the dose of simvastatin used. Kinetic 
studies of some of the newer lipid-lowering agents currently being developed, for 
example microsomal transfer protein inhibitors, would also lead to further 
understanding of the regulation of apoB metabolism.
The further characterisation of apoB kinetics in analbuminaemia, an example of 
secondary hyperlipidaemia, would be interesting should more affected individuals be 
identified. Although itself a relatively benign condition, its clarification may help in 
the understanding of the nature of the dyslipidaemia of nephrotic syndrome, a 
condition characterised by heavy proteinuria, hypoproteinaemia and generalised 
oedema. Here studies have suggested that the increased apoB production is secondary 
to increased amounts of free fatty acids being diverted to the liver (Joven et al 1990). 
It is from ‘experiments of nature’ such as analbuminaemia that an understanding of 
more serious pathologies can be developed, with the ultimate aim of improved 
treatment or, ideally, prevention.
Thus, in meeting the aims and objectives of this thesis some questions regarding the 
metabolism of apoB containing lipoproteins have been answered but, as is always the 
case with research, more have been raised. What is most important is that the research 
should ultimately be applicable in the clinical context, in this case for the reduction in 
coronary heart disease.
“In expanding the field o f knowledge we but increase the horizon o f ignorance. ”
(Henry Miller, ‘The Wisdom o f the Heart’, 1941)
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FCHL Familial combined hyperlipidaemia
FCR Fractional catabolic rate
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HL Hepatic lipase
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HMG-CoA 3-Hydroxy-3-methylglutaryl Coenzyme A
HyperapoB Hyperapobetalipoproteinaemia
IDL Intermediate density lipoprotein
IRS Insulin resistance syndrome
LCAT Lecithin:cholesterol acyl transferase
LDL Low density lipoprotein
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LPL Lipoprotein lipase
MRFIT Multiple Risk Factor Intervention Trial
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NIDDM Non-insulin dependent diabetes mellitus
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4S Scandinavian Simvastatin Survival Study
WOSCOPS West of Scotland Coronary Prevention Study
VLDL Very low density lipoprotein
Appendix 1 - Manufacturers and Suppliers of Reagents, Hardware and 
Software.
Baker Instruments Ltd 
Rusham Park, Whitehall Lane 
Egham, Surrey 
TW20 9NW, UK
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate 
High Wycombe, Bucks 
HP 12 4JL, UK
BDH Laboratory Supplies 
McQuilkin & Co 
21 Polmadie Avenue, Glasgow 
G5 OBB, UK
Bio-Rad Laboratories 
2000 Alfred Nobel Drive 
Hercules 
CA 94547, USA
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane
Lewes, East Sussex 
BN7 1LG, UK
Chromacol Ltd 
3 Little Mundells, WGC 
Herts,
AL7 1EW, UK
Fisons Instruments 
Crewe Road
Wythenshaw, Manchester 
M23 9BE, UK
Genzyme Biochemicals 
50 Gibson Drive, Kings Hill 
West Mailing, Kent 
ME19 6HG, UK
VA Howe & Company Ltd 
Beaumont Close 
Banbury 
0X16 7RG, UK
Imed 
San Diego
CA 92131-1192, USA
Innogenetics NV 
Canadastraat 21-Haven 1009 
B-2070 Zwijndrecht 
Belgium
Isotec Inc
A Matheson USA Company 
3858 Benner Road, Miamisburg 
OH 45342, USA
Minitab Inc
3081 Enterprise Drive, State College 
PA 16801-3008, USA
Nycomed Pharma AS 
Oslo, Norway
Orion Diagnostica 
Espoo, Finland
Packard Instrument Company 
Canberra Packard Ltd 
Brook House, 14 Station Road 
Pangboume, Berks 
RG8 7DT, UK
SAAM Institute FL-20 
University of Washington, Seattle 
Washington 98195, USA
Scottish Antibody Production Unit (SAPU) 
Law Hospital 
Carluke, Lanarkshire 
ML8 5ES, UK
Sigma Chemical Company 
Fancy Road 
Poole, Dorset 
BH17 7TG, UK
Appendix 2 - Turnover Bleeding Schedule.
T im e  Point Blood Vol.(ml ED T A ) Plasm a  Use &  R otor Nos.
DayO O' 30 2* lml plasmas
+ 6.0 (yellow ) for safety 2*2ml SW40 1
3 . 5 m l  BQ& HDL subs. 3.5ml LDL subs
lml Apo’s A1,B & Lp(a)
V
5 ’
10’
15’
20’
4.5
4.5 
10
4.5 
10
2*lml plasmas
tt
" + 2ml SW40 
2* I ml plasmas 
" + 2ml SW40
3
4
30’ 14.5 2*lml plasmas + 2ml SW40 56=  I 
145’ 14.5
" spare plasma for pools
lhr 14.5 tt
1.5hr 10 t« 2
2hr 10 tt 3
3hr 10 4
3.5hr 10 tt 5
4hr 10 tt 6 = 2
5hr 10 tt 1
6hr 10 tt 2
8hr 10 tt 3
lOhr 10 tt 4
•patient given fat-free meal 
1lhr 10 tt 5
14hr 10 tt 6 = 3
Day I 24hr 10 tt 1
36hr 10 tt 2 + 3pools
Day 2 48hr 10 tt 3 = 4
Day 3 72hr 10 tt I
Day 4 96hr 10 tt 2 + 3pools
Day 5 120 10 tt 3 = 5
Day 6 144 10 tt 1
Day 7 168 10 ” + lml chol, trig, HDL 2
Day 8 192 10 tt 3
Day 9 216 10 tt 4
Day 10 240 10 tt 5
Day 11 264 10 tt 6 = 6
Day 12 288 10 1
Day 13 312 10 tt 2
Day 14 336 20 " + 3.5ml BQ 3 = 7
+6.0 (yellow),4.5 (purple), 
&2.0 (grey) for clinical
+urinalysis
Total = 397.5ml
NB All samples fasted except 1 l h r , 14hr, 36hr. 2*24hr urine samples
Appendix 3 - Rate Constants and Calculated Leucine Pool Sizes for FH and FDB
Subjects.
AC
(FH)
WT
(FH)
RM
(FH)
MM
(FH)
RH
(FH)
JR
(FDB)
NS
(FDB)
k (15,4) 0.04 0.08 0.06 2.47 0.02 0.02 0.02
d(5,15) 0.79 0.87 0.56 0.66 0.25 0.45 0.47
d(8,15) 0.11 0.06 0.20 0.20 0.59 0.18 0.33
d(ll,15) 0.08 0.00 0.20 0.14 0.04 0.16 0.12
d(13,15) 0.03 0.07 0.04 0.00 0.11 0.21 0.08
k(0,6) 1.65 0.05 4.6 1.24 0.05 0.33 1.74
k(0,7) 0.01 0.07 0.02 0.30 0.13 0.10 0.84
k(8,6) 0.56 0.59 1.36 0.40 0.29 1.55 2.35
k(0,9) 0.03 0.29 0.06 0.005 0.22 0.00 0.00
k(0,10) 0.01 0.00 0.005 0.02 0.04 0.10 0.84
k(ll,9) 0.26 0.96 0.20 0.14 1.00 0.03 0.42
k(12,9) 0.12 0.35 0.07 0.06 0.13 0.06 0.05
k(0,ll) 0.00 0.08 0.05 0.00 0.00 0.00 0.00
k(0,12) 0.01 0.04 0.01 0.01 0.01 0.06 0.01
k(13,ll) 0.07 0.20 0.17 0.20 0.06 0.03 0.13
k(0,13)
VLDL,
0.01 0.01 0.01 0.01 0.01 0.01 0.01
leucine
(mg)
v l d l 2
11.6 18.9 5.0 12.8 5.2 9.1 1.6
leucine
(mg)
IDL
29.0 32.9 22.2 21.4 86.0 24.4 6.3
leucine
(mg)
LDL
55.5 49.7 73.8 53.1 118.2 57.3 28.1
leucine
(mg)
269.8 350.7 313.0 354.0 808.8 386.4 203.9
Appendix 4 - Rate Constants and Calculated Leucine Pool Sizes for
Hypobetalipoproteinaemic and Analbuminaemic Subjects.
Hypobetalipoprotein­
aemic Subject (LR)
Analbuminaemic 
Subject (AK)
k (15,4) 0.02 0.08
d(5,15) 0.15
d(8,15) 0.81 -total VLDL 0.85
d(ll,15) 0.00 0.00
d(13,15) 0.19 0.00
k(0,6) 3.78
k(0,7) 0.002
k(8,6) 0.22
k(0,9) 0.00 -totalVLDL 0.52
k(0,10) 0.001 - total VLDL 0.01
k(ll,9) 0.44 -total VLDL 0.51
k(12,9) 0.02 -total VLDL 0.03
k(0,ll) 0.00 0.52
k(0,12) 0.004 0.003
k(13,ll) 0.38 0.16
k(0,13) 0.02 0.008
VLDL,
leucine (mg) 7.23
v l d l 2
leucine (mg) 1.94 = total VLDL 74.8
IDL leucine
(mg) 6.1 411.8
LDL leucine
(mg) 26.1 576.5
Appendix 5 - Rate Constants and Calculated Leucine Pool Sizes for Mixed
Hyperlipidaemic Subjects.
RA PS JC RS DM LB PC
k(15,4) 0.01 0.01 0.01 0.02 0.01 0.01 0.01
d(5,15) .0.79 0.77 0.71 0.85 0.80 0.67 0.87
d(8,15) 0.13 0.19 0.20 0.12 0.14 0.20 0.05
d(ll,15) 0.02 0.01 0.04 0.01 0.02 0.06 0.01
d(13,15) 0.06 0.04 0.05 0.03 0.04 0.07 0.08
k(0,6) 0.22 0.13 0.00 0.57 0.06 0.19 0.05
k(0,7) 0.01 0.01 0.02 0.01 0.00 0.00 0.00
k(8,6) 0.37 0.19 0.51 0.23 0.18 0.17 0.23
k(0,9) 0.05 0.03 0.04 0.00 0.02 0.03 0.20
k(0,10) 0.01 0.01 0.02 0.01 0.00 0.00 0.01
k(ll,9) 0.32 0.20 0.15 0.08 0.08 0.07 0.10
k(12,9) 0.04 0.02 0.01 0.01 0.02 0.02 0.05
k(0,ll) 0.05 0.03 0.04 0.00 0.02 0.03 0.01
k(0,12) 0.04 0.02 0.01 0.01 0.02 0.02 0.02
k(13,ll) 0.12 0.37 0.07 0.12 0.09 0.08 0.14
k(0,13)
VLDL,
0.01 0.01 0.01 0.01 0.01 0.01 0.01
leucine
(mg)
v l d l 2
14.4 18.9 11.6 30.1 25.3 18.4 33.1
leucine
(mg)
IDL
13.8 17.9 28.1 23.2 38.5 27.8 22.3
leucine
(n»g)
LDL
25.1 16.6 55.5 36.4 51.1 35.0 39.5
leucine
(mg)
199.9 238.3 279.6 282.8 310.8 223.5 365.2
Appendix 6 - Rate Constants and Calculated Leucine Pool Sizes for Mixed
Hyperlipidaemic Subjects - on Simvastatin.
RA PS JC RS DM LB PC
k(15,4) 0.02 0.01 0.02 0.01 - 0.01 0.02
d(5,15) 0.77 0.82 0.82 0.76 _ 0.66 0.85
d(8,15) 0.16 0.13 0.12 0.12 - 0.10 0.14
d(ll,15) 0.04 0.03 0.05 0.03 - 0.09 0.00
d(13,15) 0.03 0.02 0.02 0.09 - 0.14 0.01
k(0,6) 2.56 0.19 1.22 0.10 _ 0.50 0.57
k(0,7) 0.07 0.03 0.10 0.001 - 0.001 0.005
k(8,6) 0.58 0.49 0.95 0.53 - 0.28 0.18
k(0,9) 0.06 0.16 0.05 0.24 - 0.10 0.13
k(0,10) 0.07 0.03 0.10 0.001 - 0.001 0.005
k(ll,9 ) 0.30 0.28 0.22 0.19 - 0.06 0.15
k(12,9) 0.02 0.04 0.04 0.002 - 0.002 0.01
k(0,H) 0.06 0.00 0.05 0.03 - 0.10 0.001
k(0,12) 0.02 0.01 0.04 0.002 - 0.001 0.01
k(13,ll) 0.27 0.25 0.22 0.12 - 0.03 0.27
k(0,13)
VLDL!
0.02 0.02 0.02 0.01 0.01 0.01
leucine
(mg)
v l d l 2
10.9 11.9 7.50 9.00 10.6 27.5
leucine
(mg)
IDL
12.9 12.8 13.0 11.1 24.9 18.6
leucine
(mg)
LDL
20.4 31.9 22.8 16.7 20.5 21.9
leucine
(mg)
172.4 155.5 124.8 152.6 - 129.5 190.5
Appendix 7 - Rate Constants and Calculated Leucine Pool Sizes for Mixed
Hyperlipidaemic Subjects - on Atorvastatin.
RA PS JC RS DM LB PC
k(15,4) 0.01 0.01 0.02 - 0.01 0.01 0.01
d(5,15) 0.90 0.80 0.77 _ 0.73 0.60 0.83
d(8,15) 0.05 0.16 0.19 - 0.13 0.18 0.17
d(ll,15) 0.03 0.02 0.03 - 0.07 0.11 0.00
d(13,15) 0.02 0.02 0.01 - 0.07 0.11 0.00
k(0,6) 0.48 0.20 1.12 _ 1.71 1.60 0.26
k(0,7) 0.01 0.01 0.19 - 0.19 0.004 0.02
k(8,6) 0.18 0.29 0.70 - 0.87 0.10 0.30
k(0,9) 0.03 0.14 0.00 - 0.01 0.26 0.07
k(0,10) 0.01 0.01 0.19 - 0.06 0.004 0.02
k(ll,9) 0.27 0.23 0.34 - 0.27 0.08 0.28
k(12,9) 0.06 0.01 0.08 - 0.06 0.002 0.001
k(0,ll) 0.03 0.05 0.08 - 0.01 0.08 0.26
k(0,12) 0.06 0.01 0.08 - 0.02 0.001 0.001
k(13,ll) 0.24 0.36 0.23 - 0.28 0.05 0.45
k(0,13)
VLDLj
0.02 0.02 0.02 0.02 0.01 0.01
leucine
(mg)
v l d l 2
14.0 12.6 15.0 13.0 6.80 19.5
leucine
(mg)
IDL
7.92 12.3 16.4 16.4 14.0 20.1
leucine
(mg)
LDL
14.7 21.5 19.8 24.3 25.2 13.9
leucine
(mg)
108.8 95.8 143.9 - 171.5 132.1 176.0
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